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Iron deficiency without anemia (IDNA) is widely prevalent in China, where 
conventional methods for improving iron status are not always feasible in low-resource 
areas. IDNA has known detrimental effects on physical performance. Conversely, 
intense exercise training increases the risk of IDNA. While iron supplementation and 
aerobic exercise have been examined individually, the impact of simultaneous iron 
supplementation and aerobic training remains unclear. The goal of this study was to 
examine the individual and combined effects of supplementation (ferrous sulfate or a 
traditional Chinese herbal treatment, BaZhen KeLi, BZ) and/or aerobic training on iron 
status and physical performance.  
One hundred and nine IDNA Chinese women participated in an 8-week 
randomized trial with a 3x2 factorial design. Treatments included 42 mg elemental 
iron/day, 150 g BZ/day, or a placebo and aerobic training (5 sessions/week of 25 
minutes cycling) or no training. Iron status and physical performance were assessed at 
weeks 0, 4, and 8. Physical performance was measured as oxygen consumption at 
maximum exertion (VO2peak) and at the ventilatory threshold.  
 Training modified the serum ferritin response to iron supplementation. Both iron-
supplemented groups improving in serum ferritin, but the iron-trained group had 
significantly lower serum ferritin than the iron-untrained group at week 8.  
There were significant 2-way interactions between training and supplement for 
VO2peak and ventilatory threshold. These variables were significantly higher in the iron-
trained, iron-untrained, and placebo-trained groups compared to the placebo-untrained 
group, with no significant differences among these three groups for either variable. 
BZ treatment did not significantly improve any measure of iron status compared 
to placebo. The BZ-trained group showed improvements in physical performance of 
equal magnitude to those of the iron- and placebo-trained groups. The BZ-untrained 
group showed no improvements in physical performance compared to the placebo-
untrained group. 
Collectively, this dissertation concludes that regular aerobic training reduces the 
apparent efficacy of iron supplements in improving iron status. Additionally, iron 
supplementation taken without training improves endurance performance in sedentary 
women, while iron supplementation with simultaneous training provides no added 
benefit. Finally, prescribing BZ may not be advisable for improving iron status or 
physical performance in IDNA women.
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Chapter 1: Introduction 
1.1 Iron Deficiency 
 
Iron deficiency has persisted as the most common micronutrient deficiency in the 
world for years, affecting over 2 billion people in both developing and high-resource 
countries1. While severe iron deficiency results in roughly 800,000 deaths per year, 
according to the World Health Organization, there are also notable consequences of 
moderate iron deficiency (ID) on physical and cognitive ability that negatively impact 
daily life1–5.  
 
1.1.1 Biomarkers for Assessing Iron Status 
There are many biomarkers available for assessing iron status, each 
representing different aspects of iron metabolism. Figure 1.1 shows the most commonly 
measured biomarkers for iron assessment and their relative concentrations across 
differing levels of iron status. The most widely used biomarkers for iron status 
assessment are: hemoglobin, serum ferritin, zinc protoporphyrin, mean cell volume, and 
soluble transferrin receptor6; however, transferrin saturation, mean corpuscular volume, 
erythropoietin, and others are also reported by some studies. 
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Figure 1.1: Iron Status Indicators (Modified from Guthrie and Picciano, 1995) 
 
Hemoglobin (Hb), found in the red blood cells, binds oxygen and delivers it to 
tissues and cells. Red blood cells contain roughly 65-85% of the body’s iron in the form 
of hemoglobin7,8. Accordingly, hemoglobin is the most commonly measured biomarker 
for iron status. Anemia is often used interchangeably with iron deficiency, but this use is 
erroneous because anemia can also occur as a result of other micronutrient 
deficiencies, pregnancy, chronic disease, and other conditions. According to a recent 
paper by Petry et al, only about 37-50% of the cases of anemia are due to iron-
deficiency when defined using the current cut-offs for iron status indicators9. Therefore, 
while hemoglobin can be a good screening tool for assessing iron status and is more 
useful when severe iron deficiency is prevalent in the sample population, it is also 
necessary to measure other iron status biomarkers. 
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 Besides hemoglobin, the most frequently reported iron status marker, and the 
marker promoted by the World Health Organization, is serum ferritin (sFer)10. Ferritin is 
an iron storage protein found in every cell, but that concentrates mainly in the liver. The 
ferritin level found in serum is proportional to the amount of ferritin stored in the liver (8 
mg/L of stored iron for every 1 μg/L sFer) and is thus a good indicator for levels of 
stored iron11,12. As shown in Figure 1.1, ferritin levels decrease as iron stores diminish. 
Iron deficiency in adults is often defined as an sFer concentration less than 15 μg/L, a 
state that represents exhausted iron stores. Less severe iron deficiency, which reflects 
body iron depletion, represents lowered but not exhausted liver iron stores. Iron 
depletion varies in definition, but is typically defined as an sFer concentration between 
20 and 30 μg/L3,13,14. Both clinical iron deficiency and iron depletion impact several 
important functions of daily life that will be discussed in later sections8. If sFer values 
indicate iron deficiency or depletion, but hemoglobin remains above the clinical cutoff 
that defines anemia, this state is called iron deficiency non-anemia (IDNA). If iron stores 
continue to worsen, hemoglobin levels can also decline below the clinical cutoff for 
anemia, resulting in iron deficiency anemia.  
There are two major drawbacks of using sFer as a biomarker for iron status. 
First, sFer only represents the state of stored liver iron. Therefore, sFer is not a good 
indicator for processes such as erythropoiesis, functional iron such as myoglobin and 
Hb, or iron involved in cellular processes.  Additionally, as an acute phase protein, sFer 
is highly affected by inflammation, increasing in concentration in the presence of 
inflammatory insults, obesity, or exercise15. This response is especially detrimental to 
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the assessment of iron stores in research environments where chronic illness or obesity 
are highly prevalent and can result in a measured prevalence of iron deficiency in a 
population that is falsely low. Depending on the purpose for which iron status was 
assessed (population surveys, clinical trials, etc.), there are several suggested ways for 
dealing with the association between inflammation and sFer values including: increasing 
the cutoff for ID, dropping those subjects with inflammation, or adjusting the sFer values 
using correction factors16,17. While these corrections can reduce the influence of 
inflammation on sFer concentrations, it is also helpful to measure other indicators of iron 
status to assure accurate iron status assessment. 
In clinical research, soluble transferrin receptor (sTfR) is one of the more 
commonly measured biomarkers reported with sFer. Transferrin receptor is expressed 
on the membrane of cells and binds transferrin, the iron transport protein. Upon this 
binding, transferrin receptor facilitates the absorption of iron into the cell. sTfR 
expression increases with iron deficiency11 because cells express more of the protein to 
attempt to import more iron. sTfR is also used to assess erythropoietic activity, as it 
increases in conditions of higher erythropoietic demand or ineffective erythropoiesis    
17–19. sTfR is directly related to iron deficiency, reflects the mass of red blood cell 
precursors, and is less affected by inflammation than sFer20, collectively making it an 
excellent biomarker for iron status. However, there is currently no globally utilized 
standardized measure for sTfR. Each ELISA kit manufacturer uses its own scale, so 
quantification of sTfR is manufacturer-dependent and requires using reference intervals 
and deficiency cutoffs specific to the manufacturer. In order to standardize sTfR 
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between studies, the WHO released a reference reagent (material 07-202, made by 
NIBSC), which manufacturers can use to establish and standardize their reference 
values and deficiency definitions21,22. However, this reference standard is not yet 
frequently reported. More often, studies calculate and use manufacturer-specific 
correction values. This dissertation used the sTfR ELISA kit produced by RAMCO 
Laboratories to standardize all sTfR values from other labs. The recent Biomarkers 
Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project 
conducted by the US Center for Disease Control reported sTfR on the RAMCO scale 
(deficiency defined as sTfR > 8.3 mg/L), so this reference may become more standard 
in future reports20. 
A fourth measure of iron status is the estimation of total body iron. Total body 
Iron is an estimate that is calculated from the ratio of sTfR to sFer as shown below: 
Total Body Iron (mg/kg) =  −[log (sTfR/sFer ratio) − 2.8229]/0.1207 
 The total body iron measure was developed by Cook el al to provide a method to 
calculate absorption of iron during an intervention23.  Cook described this value as a 
“quantitative estimate of body iron” that is a more sensitive tool for assessing 
effectiveness of intervention trials that can capture a wider range of iron status than 
either sFer or sTfR alone. Positive total body iron values indicate the presence of stored 
iron, whereas negative values indicate depletion of stores and iron deficiency in the 
tissue. The total body iron equation is best used in populations with little inflammation, 
and is therefore appropriate for this dissertation subject population, in which 
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inflammation was uncommon, as assessed by C-reactive protein (CRP) < 5mg/L and α-
1-acid glycoprotein < 1mg/L (AGP). 
1.2 Iron Absorption 
Iron enters the body via the diet and is absorbed by the intestine. Iron excretion 
is constant at 1-2 mg/day and cannot be regulated by the body7. Therefore, the body’s 
iron concentration is regulated at the point of absorption. The body’s current iron status 
is a major regulator of the level of gut iron absorption. High iron stores in the body, 
indicated by high ferritin, result in lower absorption of iron in the intestine.  
Figure 1.2: Regulation of iron absorption at the enterocyte15
 
Figure 1.2 summarizes the iron absorption process. Ingested iron can be found 
in two forms: heme iron from animal products and inorganic non-heme iron from plant-
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based foods. Heme iron is absorbed more efficiently than non-heme iron, is about 50% 
bioavailable, and is minimally impacted by body Fe stores, whereas non-heme iron is 
only 0.1 to 35% bioavailable, averaging towards the lower end of this range24,25. The 
two forms enter the enterocyte cells via different import proteins. Absorption of heme 
iron is not well understood as of this writing. Some studies suggest that it is 
endocytosed after binding the brush border of the enterocyte26 or that it is taken up by 
the heme-responsive gene-1 protein27; however there does not appear to be enough 
evidence to conclusively determine the mechanism through which heme iron is 
absorbed. The main point of absorption for non-heme iron from the lumen into the 
enterocyte is through the apical membrane protein, divalent-metal transporter-1 
(DMT1). Before inorganic iron can be imported into the enterocyte, it must be reduced 
to its ferrous (Fe+2) form so it can be recognized by DMT1. One suggested reducing 
agent is the brush-border reductase, duodenal cytochrome B (DCYTB)28. Once inside 
the enterocyte, iron is either sequestered into the storage protein ferritin or exported for 
use via the export protein ferroportin in conjunction with the oxidizing protein ferroxidase 
hephaestin15,26. Unbound iron is highly reactive and can create harmful reactive oxygen 
species. Therefore, iron in the body is mainly found bound to various proteins. In the 
case of iron export to the bloodstream, it is bound to transferrin and transported 
throughout the body. If iron does not enter bloodstream, it is stored as the protein ferritin 
or hemosiderin. Ferritin is fairly ubiquitous throughout the body, but the primary location 
of iron storage is the liver.   
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1.3 Regulation of Iron Homeostasis 
Iron homeostasis is regulated by the iron regulatory proteins, oxygen tension, 
and hepcidin at the cellular and systemic levels, respectively. The iron regulatory 
proteins (IRP1 and IRP2) sense cytosolic iron. In the iron deficient state, the IRPs bind 
to iron response elements in the mRNA that control multiple proteins involved in iron 
absorption and transport, promoting iron uptake and reducing iron storage and erythroid 
heme production29. More specifically, iron deficiency causes IRP1 to repress hypoxia-
inducible factor 2α (HIF-2α) expression in the kidneys, which is responsible for several 
regulatory mechanisms controlling hypoxic response, erythropoiesis, and iron 
metabolism30. HIF-2α also stimulates iron absorption via downstream activation of 
proteins involved in absorption including DCYTB, DMT1, and ferroportin31. Furthermore, 
HIF activation also results in the expression of factors that ultimately reduce the use of 
pyruvate in the TCA cycle, limiting oxidative phosphorylation in ID conditions32. Under 
iron-replete conditions, the interactions between the IRP proteins and the various iron 
response elements do not occur, which results in the storage of iron as ferritin and 
increased erythropoiesis. 
At the systemic level, the liver-derived hormone hepcidin controls iron 
homeostasis through its interactions with the only non-heme Fe cellular export protein, 
ferroportin29. Under iron-replete conditions, hepcidin binds ferroportin, resulting in its 
internalization and subsequent degradation and limits iron export to the plasma33. Thus, 
under normal conditions, hepcidin limits iron absorption, decreases recycling of iron 
from erythrocytes, and reduces iron stores. Hepcidin production is mediated by the iron 
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stores in the liver, transferrin saturation, erythropoietic demand, and systemic 
inflammation through several signaling pathways and through the acute phase 
response33. More specifically, hepcidin is primarily regulated by an increase in 
erythropoiesis33. Under normal conditions (the absence of thalassemias, etc.), 
erythropoiesis drives the release of the cytokine erythropoietin (EPO), which then down-
regulates hepcidin production. Recent literature suggests that EPO may induce this 
inhibition via the hormone erythroferrone (ERFE), which suppresses hepcidin 
expression through a mechanism that is currently not well understood29. ERFE is 
expressed by both erythroblasts and skeletal muscle cells29, and can thus respond to 
both erythropoietic demands from low-iron or hypoxia (erythroblasts) as well as 
increased demands induced by exercise (skeletal muscle), which will be discussed 
later. The relationship between erythropoiesis and hepcidin regulation remains 
somewhat unclear, though literature suggests that both EPO and iron status have 
interdependent roles in regulating hepcidin29.  
Additionally, erythroid cell differentiation involves transferrin receptor 2, a protein 
located in the developing precursor cell. Iron deficiency results in the destabilization and 
subsequent shedding of this receptor from the progenitor cell, which increases the 
sensitivity of the bone marrow to respond to EPO, thus increasing ERFE production and 
down-regulating hepcidin 29. Collectively, these mechanisms suggest that iron 
deficiency influences several sites of erythropoietic control to reduce erythrocyte 
maturation while simultaneously increasing the amount of iron available for other, 
potentially more critical, functions. 
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1.4 Iron Status and Physical Performance 
 While impaired iron status is known to affect multiple aspects of physical 
performance, the metabolic mechanisms through which iron deficiency anemia and iron 
deficiency without anemia primarily produce these changes differ widely. This section 
will survey the literature examining first the effects of IDA on physical performance, then 
those of iron deficiency without anemia. 
1.4.1 Iron Deficiency Anemia and Performance 
Iron deficiency anemia negatively affects physical performance because the 
decreased Hb concentration in the body limits the amount of oxygen available for active 
muscles to use in aerobic respiration34. The observable outcome of this impairment is a 
lower maximal capacity to circulate and utilize oxygen, called VO2max. Studies have 
demonstrated that IDA women who receive iron supplements and achieve replete iron 
levels show increases in VO2max proportional to the measured changes in iron35–37. 
Lowered VO2max from IDA is known to worsen physical performance in laboratory 
settings and free-living environments, lower total energy levels, and decrease daily 
physical activity36,38,39. 
Muscle myoglobin also impacts physical performance and may be affected by 
anemia or iron deficiency. Myoglobin is similar to hemoglobin in that it functions as an 
oxygen binding protein, transferring oxygen from the erythrocytes to the muscle tissue. 
Currently there is limited research investigating myoglobin’s role in human physical 
performance in subjects with IDNA. However, several studies have suggested that 
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myoglobin concentration is negatively impacted by iron deficiency40,41. A review by 
Buratti et al summarizes findings from several studies that examined how myoglobin is 
affected by low oxygen conditions from high altitude or in subjects treated with low-dose 
erythropoietin32. The increased erythropoietic demand from high-altitude resulted in 
decreases in the three muscle myoglobin isoforms of 30-35%42. However, when 
subjects were chemically administered erythropoietin, which should theoretically 
stimulate erythropoiesis and inhibit hepcidin expression, there was no change in muscle 
iron content43. Buratti et al proposed that the discrepancy in muscle response is due to 
the iron demand of the stimulus, where high altitude induces a strong demand for iron 
and thus results in iron mobilization from muscle myoglobin, whereas in normal iron 
conditions, low-dose erythropoietin only induces a moderate iron demand, which can be 
met by other body iron stores in the body32. 
1.4.2 Iron Deficiency Without Anemia and Performance 
While it is well established that IDA negatively affects maximal aerobic exercise, 
IDNA is also known to affect submaximal physical performance measures and lowers 
time spent in daily voluntary physical activity3,13,44,45. The literature involving IDNA 
subjects who were given iron in conjunction with any kind of physical training will be 
explored further in section 1.5.2.  
Because iron deficiency without anemia does not, by definition, involve 
decreased levels of Hb, the metabolic explanation for the performance impairments 
seen in IDNA women are less related to oxygen delivery by Hb. For this reason, studies 
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involving only IDNA women do not typically show significant changes in VO2max from 
iron supplementation alone46–48. Rather, observed effects are related to changes in 
aerobic respiration pathways such as the Citric Acid cycle, oxidative phosphorylation, 
and β-oxidation that rely heavily on iron-containing and iron-dependent proteins and 
enzymes (see section 1.5 below). While it is well established that IDNA negatively 
impacts physical performance by reducing oxidative capacity34,49, it is not yet known 
exactly which enzymes in these processes are most affected by ID and which are 
associated with the observed impairments in submaximal exercise. It is also likely that 
these alterations in oxidative capacity compound the detrimental effect of restricted 
oxygen delivery that occurs in anemia, further impacting physical performance in this 
group. This relationship must be further clarified if we are to understand how iron 
deficiency exerts its effects on physical performance and activity.  
1.5 Exercise Training and Physical Performance 
 This section will first look at the literature that has examined the role of aerobic 
exercise training in altering physical performance outcomes. It will then explore the role 
of iron in relation to these factors. 
1.5.1 Physiological responses to aerobic training 
 
1.5.1a Changes in bioenergetic pathways 
Holloszy et al have shown that under normal, healthy conditions, exercise 
training induces metabolic changes in the bioenergetic pathways50. In his study, healthy 
rats underwent aerobic training 5 days a week for 1-6 weeks, depending on time of 
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sacrifice. Pre- and post-training muscle biopsies from both red and white tissue showed 
that the training resulted 70-140% increases in concentrations of various electron 
transport system enzymes and substrates in the trained rats. For example, cytochrome 
C increased 86% in trained rats compared to the sedentary group (p < 0.001). This 
study demonstrated that there is a strong relationship between the electron transport 
system, ATP production, and aerobic exercise training. 
Following the findings detailed above, Holloszy et al. used the same aerobic 
training program to demonstrate the effects of aerobic training on Krebs cycle 
enzymes51. In this study, Holloszy observed a 34-101% increase in Kreb’s cycle 
enzymes and substrates the gastrocnemius muscles of rats. The study concluded that 
while training affects oxidative phosphorylation more than the Kreb’s cycle, there was a 
significant training effect on both metabolic pathways. Additionally, this study showed 
that because training-induced changes in oxidative phosphorylation were greater than in 
the Kreb’s cycle, there must be some change in mitochondrial composition that is 
responsible for the increase in ATP production seen from aerobic training. This change 
is now known to be increased mitochondrial density and size, which allows for more 
oxidative phosphorylation and thus greater ATP production51. The changes observed in 
both the Kreb’s cycle and oxidative phosphorylation enzymes are not due to increased 
specific activity of these enzymes. Rather, trained muscle has both larger and more 
numerous mitochondria than untrained muscle. Thus, in a trained muscle undergoing 
aerobic exercise, there are simply more of the necessary enzymes available to make 
ATP52–54.   
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Aerobic exercise training also results in changes in fatty acid metabolism55. In a 
study by Molé et al, rats were exercised on a treadmill 5 days a week for 12 weeks. The 
results showed that trained rats had up to double the concentrations of palmityl CoA 
synthetase and palmityl CoA dehydrogenase – enzymes involved in muscle’s ability to 
oxidize various fatty acids. Additionally, the trained group had higher levels of carnitine 
palmityl transferase, which catalyzes the reaction to bring fatty acids into the 
mitochondria to undergo oxidation.  
In addition to mitochondrial enzyme changes in fatty acid metabolism, studies 
have shown that aerobic exercise training increases muscles’ ability to metabolize 
triacylglycerols and lowers the amounts of catecholamine released 56–58. The training-
induced increases in the enzymatic capacity to utilize lipid fuel sources appears to be 
complemented by an increase in the number of intramyocellular triglycerides that are 
stored in the muscle fibers, particularly the Type 1 oxidative fibers, as evidenced by 
Type 1 fibers having three-folder greater intra-muscular triglyceride content compared to 
Type 2 fibers in muscle cross-sections prior to exercise59. This increase in triglycerides 
is specifically due to a larger number of lipid droplets in the muscle, as opposed to an 
increased volume of existing droplets. An increased number of lipid droplets allows for 
easier lipolysis for use due to the increased surface area of the additional droplets59,60. 
The increases in lipolytic enzymes, as well as the improvements in overall oxidative 
capacity from the increased size and number of mitochondria discussed earlier, 
collectively result in the trained muscle being better able to rely on intramyocellular 
triglycerides for fuel during exercise. This shift ultimately has a glycogen sparing effect 
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in the muscle, allowing the trained muscle to perform aerobic work longer before 
reaching an anaerobic state. 
1.5.1b Changes in VO2max 
 Aerobic exercise training increases VO2max as a result of several training-
induced adaptations. VO2max is determined by cardiac output and the a-vO2 difference, 
which are respectively defined as the amount of blood moved with each heartbeat and 
the amount of oxygen removed by the capillaries as it circulates through the body. 
Aerobic training positively impacts both of these factors. With long-term aerobic training, 
the left ventricular cavity of the heart increases in volume by around 25%61,62. The 
capillarization of the heart muscle itself is also increased, allowing more blood flow to 
the heart tissue, which decreases the energetic cost of breathing. Further 
complementing these cardiovascular changes, aerobic training induces a roughly 10-
20% increase in plasma volume63. The expansion of plasma volume lowers blood 
viscosity, which enhances movement of blood through the capillaries and improves 
oxygen delivery to tissues64.  Together, these changes allow the heart to move more 
blood per beat, increasing the stroke volume component of cardiac output in the 
VO2max equation. Another component of VO2max, a-vO2 difference, or the amount of 
oxygen extracted into the muscles from the blood, also increases as a result of aerobic 
training65. This increase is accomplished partly by increased capillarization of the 
trained skeletal muscle, increased myoglobin concentrations in the muscle to accept 
oxygen, and the development of more aerobic (Type 1) muscle fibers, several of which 
are processes that are affected by iron bioavailability32,66. Together, these training 
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effects result in a higher overall VO2max in aerobically trained subjects.  
1.5.1c Changes in fatigue 
Aerobic training also influences rate of fatigue, or the reduced ability of a muscle 
to generate force. One cause of fatigue can be the inability of nerves to sustain a 
muscle response. In untrained subjects, nerves are unable to maintain a high-frequency 
signal to the muscle, thereby lowering the force that the muscle produces67,68. The other 
aspect of fatigue is the onset of anaerobic metabolism within the muscle fibers 
themselves. This kind of fatigue results from a lack of aerobic energy substrates and 
subsequent lactic acid production, which will be discussed in the following sections69.  
During exercise, glucose is broken into two pyruvate molecules during glycolysis. 
The resulting pyruvates then enter the Kreb’s cycle to produce ATP and high-energy 
molecules for later ATP production in oxidative phosphorylation. Both the Kreb’s cycle 
and oxidative phosphorylation are highly aerobic and cannot proceed if available 
oxygen becomes insufficient – such as during strenuous exercise. In this scenario, the 
anaerobic process of glycolysis can still occur, producing two net ATPs and 2 pyruvate 
molecules. During sustained vigorous activity, muscle glycogen is broken down to 
provide glucose for glycolysis, which occurs rapidly to provide the muscles with ATP. 
However, this also leads to a large accumulation of pyruvate. This pyruvate is then 
shunted into the anaerobic process of fermentation, producing lactic acid as a product, 
which builds up in the muscle69.  
Muscular fatigue occurs as a result of both depleted substrates for energy 
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production and increased metabolite products that inhibit muscle function. During 
strenuous exercise, oxygen is depleted first, inhibiting aerobic respiration. Muscle 
glycogen and phosphocreatine stores are then depleted, inhibiting the rate of anaerobic 
respiration. At this point, the muscle has highly restricted access to energy producing 
substrates and cannot sustain the same level of activity. Simultaneously, the buildup of 
lactic acid may also influence muscle fatigue, though this research is controversial. It 
was initially believed that lactic acid buildup was the main cause of muscle fatigue70, 
however recent literature suggests there may be multiple mechanisms involved in 
fatigue in addition to acidosis71,72. Regardless of the mechanism through which fatigue 
is induced, lactic acid concentration is an excellent proxy for muscle fatigue and the 
anaerobic threshold, or the point where anaerobic respiration begins during exercise.  
During light to moderate activity, lactic acid builds up steadily but is cleared by 
the body at the same rate at which it is produced, with no net lactic acid accumulation. 
The flat portion of the bottom line in Figure 1.3 indicates this steady state. When 
exercise intensity increases, this balance shifts towards production and lactic acid 
concentration increases. The lactate threshold is the highest level of oxygen 
consumption (exercise intensity) that does not increase blood lactate by more than     
1.0 mM from the resting level69. Blood lactate and the lactate threshold are technically 
easy to measure, but require constant sampling of blood, which can be problematic in 
practice. However, another measure, ventilatory threshold, corresponds well to the 
lactate threshold, is easily measured using expired air, and does not require blood 
sampling. The ventilatory threshold is the level of exercise where pulmonary ventilation 
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increases disproportionately to oxygen consumption (altered VE/VO2 ratio). Figure 1.3 
clearly depicts that while the ventilatory threshold occurs at higher levels of minute 
ventilation than the lactate threshold, the inflection points for the lactate threshold and 
the ventilatory threshold occur at nearly the same volume of oxygen consumption. Thus, 
ventilatory threshold can be an excellent proxy for lactate threshold. 
Figure 1.3: Lactate Threshold vs. Ventilatory Threshold (McArdle, Katch, and 
Katch 2010) 
 
Abbreviations: VE – Pulmonary Respiration; BTSP - body temperature, ambient pressure, 
saturated (used for expressing a gas volume that has been expressed as if it were saturated with 
water vapor at body temperature (37°C) and at the ambient barometric pressure; used for 
measurements of lung volumes); OBLA - Onset of blood lactate accumulation  
The onset of muscle fatigue is delayed by exercise training.  Aerobic training has 
been shown to lower lactate levels in healthy subjects after exercise and delay the 
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occurrence of the lactate threshold73. This decrease is likely due to improved lactate 
clearance in trained subjects74 as well as improved oxygen uptake and use65.  Aerobic 
training results in the muscle having a higher proportion of Type 1 muscle fibers, which 
have a greater number of the transporters needed for lactate clearance than the Type 2 
fibers. Figure 1.4 depicts the effects of training on lactate threshold.  
As discussed in 1.5.1b, VO2max increases proportionately with aerobic training. 
Therefore, as VO2max increases, the lactate threshold can occur at a higher percent of 
maximum O2 uptake.   
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Figure 1.4: Blood lactate concentration for trained and untrained subjects 
(McArdle, Katch, and Katch 2010)69 
Abbreviations: VO2max – maximal oxygen consumption  
1.5.2 Iron status, aerobic training, and physical performance 
 As discussed in section 1.4, both IDA and IDNA have been shown to negatively 
impact physical performance. IDA is primarily affected by lowered Hb concentrations 
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restricting oxygen delivery to tissues34,36, while both IDA and IDNA are affected by 
reduced oxidative capacity34,49. This section will explore the literature that examines 
changes in various physical performance outcomes in IDNA subjects who received iron 
supplementation as well as some kind of physical training. The literature on this topic 
examines all populations including trained athletes as well as untrained males and 
females. However, this dissertation involved only relatively sedentary females, therefore 
this section will focus on studies most relevant to our study population. 
Zhu et al45, gave a ferrous sulfate treatment or a placebo to IDNA women for 8 
weeks and observed changes in their performance in a 15-km time trial. The study 
observed lower energy expenditure during the time trial in iron-supplemented subjects 
compared to controls. Additionally, during the time trial, iron-supplemented subjects 
worked at 5.1% lower VO2 relative to VO2max than controls. A different study by 
Brutsaert et al observed a group of IDNA women’s maximal voluntary static muscle 
contractions during a dynamic knee extensor test before and after a 6-week iron 
supplementation (or placebo) period75. After supplementation, women in the placebo 
group showed no change in their ability to apply force during the leg-extension test, with 
force decreasing at the same rate over the 6-minute period before and after treatment. 
The iron group however, showed an attenuated rate of decrease in force – signifying an 
improved (slower) rate of muscle fatigue75. These studies and others13,76 indicate that 
iron supplementation alone is enough to elicit changes in endurance performance.  
 The combined effect of iron supplementation and aerobic training on physical 
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performance in IDNA subjects has also been studied. More recently, a study by 
DellaValle et al randomized a group of 40 female IDNA collegiate rowers to receive 
either 100 mg ferrous sulfate per day or a visually identical placebo for 6 weeks during 
their training season14. The subjects performed a 4 km rowing time trial and a VO2max 
test before and after 6 weeks of physical training.  While both groups increased their fat-
free mass and VO2peak (maximum observed VO2 during the test), the iron group 
showed significant improvements in sFer and larger improvements in energy 
expenditure and energetic efficiency than the control group. Additionally, the iron group 
had a slower lactate response during the first half of the time trial and at 5-minutes post-
test.  
Another study by Hinton et al, supplemented moderately active, IDNA women 
with either iron or a placebo for 6 weeks. All subjects also participated in 30 minutes of 
aerobic exercise training 5 days a week for the last 4 weeks of the study. Training 
ranged from a level of 75-85% of subjects’ maximum heart rate and became 
progressively more challenging each week in order to induce a training effect. This 
study observed that in a 15 km time trial, the iron supplemented women decreased their 
time to complete the time trial more than the placebo group after identical training3. 
From this same study, Brownlie et al showed that VO2max increased in all subjects after 
training, but the iron group showed a significantly greater improvement77. However, 
these findings were only seen in subjects with an elevated sTfR value (> 8.0 mg/L), 
indicating that the response was due more to a lack of available iron for cellular uptake 
and less related to iron stores. In another paper, Brownlie further showed that the iron 
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supplemented group worked at a significantly lower percent of their VO2max during the 
time trial than placebo group after training – again after accounting for baseline sTfR 
status45.  
 The role of exercise in affecting iron status has also been observed. Exercise 
training has been shown to negatively impact iron status76,78. Female soldiers who 
completed basic training displayed a 20% higher prevalence of iron deficiency than 
soldiers who had not yet completed basic training78. In a similar study, women were 
given either a placebo or iron supplementation before completing basic training. After 
training, sFer levels were significantly lower in the placebo group but not in the group 
that received iron.78  
Another study by Magazanik et al. randomized 28 iron depleted women (mean 
sFer at baseline 24 µg/L) to receive either 160 mg of ferrous sulfate per day or an 
identical placebo79. The women then completed a 7-week intensive physical training 
program. VO2max was assessed before, during, and after the treatment. At the midpoint 
of the study, the iron group had a 7.5% increase in VO2max, compared to no change in 
the placebo group. While no significant difference was ultimately found in VO2max after 
the 7-week training period, 66% of the placebo group had sFer values < 10 µg/L, 
whereas none of the iron group had such low values, suggesting that iron 
supplementation mitigated the negative impact of training on iron status.  
Finally, a study by Mielgo-Ayuso et al. randomized 22 national volleyball players 
to either a control group (no treatment) or an iron supplement group that received 325 
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mg of ferrous sulfate per day for 11 weeks while both groups performed the team’s 
usual training routines80. After the treatment, the control group had significantly lower 
serum iron, sFer, and Hb than they had at baseline. The iron group displayed significant 
positive changes in the same iron measures, again suggesting that the iron treatment 
prevented a worsening of iron status. Additionally, the iron group displayed significantly 
greater improvements from baseline to week 8 in various strength scores than those 
observed in the placebo group. Collectively, these studies suggest that exercise training 
may result in worsened iron status, but that this effect can be attenuated by concurrent 
iron supplementation. Additionally, iron supplementation with simultaneous exercise 
training enhances strength, endurance, efficiency and other submaximal exercise 
measures without changes to VO2max.  
 While numerous studies have compared the effects of iron supplementation 
versus placebo in trained women, to our knowledge, no study has used a design that 
has both iron and placebo as well was trained and untrained groups. Therefore, this 
dissertation used a 2x2 design to look at the effects of iron supplementation and aerobic 
exercise training in a manner that allowed for the examination of the independent and 
synergistic effects of iron supplementation and aerobic exercise training in a group of 
IDNA women.  
1.6 Traditional Chinese Medicine Treatment for Iron Deficiency 
Collectively, the data presented in sections 1.1 through 1.5 clearly demonstrate 
the impact that iron deficiency can have on physical performance and highlight the 
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importance of monitoring and addressing IDNA in a population. Many approaches are 
utilized to address iron deficiency in varying populations around the world, including 
dietary diversification, fortifying food products, and the use of dietary supplements. 
However, for some low-resource areas in rural China, these methods are less feasible 
due to issues of affordability and availability of supplements or fortified food products81. 
Therefore, it is critical to identify novel, sustainable, and affordable methods for 
addressing iron deficiency in these areas. One such possibility is using traditional 
Chinese medicinal herbal treatments. In many parts of China, traditional Chinese 
medicine is considered a “first line” of treatment that should be used before seeing a 
physician or using “Western” medicines82. While the majority of traditional Chinese 
herbal remedies have not been studied using rigorous scientific methodologies, a recent 
review of several Cochrane systematic reviews83 concluded that many treatments had 
evidence of a positive effect or lacked sufficient evidence to determine an effect either 
way. This conclusion supports the idea that traditional Chinese herbal remedies do have 
the potential to be beneficial and should be studied for their efficacy in improving 
medical conditions or nutritional deficiencies like IDNA. 
BaZhen KeLi (Chinese: 八珍颗粒, BZ) is a traditional Chinese medicinal 
treatment that is often consumed to address symptoms that would be considered by 
Western medicine to indicate iron deficiency or anemia, such as pallor and fatigue84. A 
Chinese medicine practitioner would assess iron deficiency as one of two types of qi 
deficiencies – generally meaning that the blood is lacking a vital “energy” called qi. BZ is 
an herbal mixture composed of 8 different plants, which when taken together, address 
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both of these two qi deficiencies. Table 1.1 lists the main ingredients of BZ and their 
functions in the body, according to Chinese medicinal theory. BZ is usually administered 
as a capsule containing various ratios of the eight components.  
 
Table 1.1: BaZhen capsule ingredients 
 
English Name  Latin Name Chinese Name g per 
capsule 
White Atractylodes 
Rhizome 
Rhizoma Atractylodis 
Macrocephalae 
Bai Zhu, 白术 10 
White Peony Root Radix Albus Paeoniae 
Lactiflorae 
Bai Shao, 白芍 10 
Szechuan Lovage Root Rhizoma Ligustici 
Chuanxiong 
Chuan Xiong, 川芎 10 
Chinese Angelica Root Radix Angelica Sinensis Dang Gui, 当归 10 
Codonopsis Root Radix Codonopsitis 
Pilosulae 
Dang Shen, 党参 10 
Poria (China Root) Scierotium Poriae 
Cocos 
Fu Ling, 茯苓 10 
Honey Fried Licorice 
Root  
Radix Glycyrrhizae Zhi Gan Cao, 炙甘草 5 
Chinese Foxglove Root Radix Rehmanniae Shi Di Huang 熟地黄 10 
 
 
 While BZ has long been used in traditional Chinese settings, recently its 
components have been examined in multiple research and clinical studies.  In 2011 
Wang et al85 conducted a quality control study tailored to traditional Chinese herbs to 
identify potentially active substances in the medicinal formula as given in a traditional 
Chinese context. The paper faults previous studies of Chinese herbal treatments for 
testing only the identified “active” ingredients in herbs. Thus, Wang et al tested several 
formulations of the treatment including: a. the traditional mixture of components as 
typically prescribed, b. each plant individually, and c. a mixture of three of the previously 
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identified BZ molecular components85 (ferulic acid, ligustilide, and senkyunolide A) to 
allow comparison of whole BZ to its various components. The group also tested two 
different manufacturers’ BZ products, to obtain an idea of variance among on-the-
market products. An absorption study was performed in the Caco-2 cell culture model 
for each of these seven BZ products or components. The absorbable components were 
then incubated with MCF-7 cells to determine and compare the gene expression profiles 
induced by each sample. The study found that in all of the repeated trials, the two 
brands of whole BZ treatments induced similar gene expression profiles - identifying 
nine differentially expressed genes from the whole treatments. None of the four 
individual herbal components or the active ingredient mixture clustered with the whole 
treatments’ gene expression profiles and none showed the same set of differentially 
expressed genes. The Wang et al study concluded that traditional herbal medicines 
should be administered in their whole form, suggesting that in vivo reactions are likely 
not simply relying on one herb or one active molecule of an herb within the whole 
formula. The study recognized that the Caco-2/MCF-7 model used is not likely 
representative of the process that occurs in humans and thus called for more research 
involving BZ in its whole form in human studies to further explore BZ’s effects on gene 
expression profiles in vivo settings. 
 A study by Li et al86 examined the effects of BZ on physical fatigue in mice. A 
group of 32 mice were given either a placebo or varying concentrations of BZ (5, 10 and 
20ml/ kg body weight) for 28 days. After supplementation, mice were subjected to a 
forced swimming test, after which blood lactate, blood urea nitrogen, and liver and 
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muscle glycogen were measured. Mice that received BZ extended their swimming time 
in a dose-dependent manner from 1.42 to 2.14 times that of the controls (p<0.05). 
Additionally, BZ mice showed lower levels of blood lactate and urea nitrogen, as well as 
higher levels of liver and muscle glycogen after the swimming test. This study suggests 
that BZ plays some role in physical performance, though more research is needed to 
clarify the mechanisms through which it does so. 
Finally, several studies by Wang et al87–89 examined the relationship between a 
polysaccharide in Dang Gui (Latin: Angelica sinensis, one of the herbs in BZ) and iron 
deficiency anemia. This series of papers showed that the Angelica sinensis 
polysaccharide (ASP) inhibits hepcidin expression. This mechanism potentially works 
through an inhibition of the STAT3/5 and SMAD488 pathways, inhibition of the JAK2 
pathway89, and increasing secretion of erythropoietin87, which further inhibits hepcidin 
expression. Though this series of papers examines only one biological component of 
the BZ treatment, they suggest a biological mechanism through which BZ may directly 
influence iron homeostasis.  
Collectively, these papers support the further examination of BZ in a more 
vigorous research setting for both its effects on iron status as well as physical 
performance outcome measures. 
1.7 Research Aims 
 
Previous research has justified the need for, but not allowed for the examination 
of the modifying effects of iron supplementation on improvements in performance from 
 42 
 
aerobic training or regular exercise on the effectiveness of iron supplementation. This 
dissertation expands upon prior research that suggests that regular aerobic training can 
worsen iron status and that IDNA can impact physical performance and physical activity 
via a mechanism unrelated to Hb. Understanding these relationships could greatly 
enhance our understanding of iron metabolism and better inform the design of iron 
interventions in physically active populations. Therefore, the primary research objective 
of this dissertation is to examine the relationships between and potential modifying 
effects of regular aerobic training and/or changes in iron status on maximal and 
submaximal physical performance. This objective will be explored in the following aims: 
1. To determine the modifying effects of exercise training on the effectiveness of 
iron supplementation in improving iron status assessed by sFer, sTfR, Hb, 
and body iron. 
2. To examine the combined and independent effects of exercise training and 
changes in iron status on physical performance assessed by maximal and 
submaximal exercise tests. 
The relationship between IDNA and physical activity and performance is directly 
related to larger public health concerns since decreased energetic efficiency and/or 
daily physical activity is associated with higher risks of obesity, diabetes and heart 
disease90–93.  Given the high prevalence of ID in the global population, and the 
increasing rates of obesity, diabetes, and heart disease in both developed countries and 
those undergoing the nutrition transition, such as China, it is becoming increasingly 
more important to fully understand the functional consequences of ID in daily physical 
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activity and physical performance. The detrimental effects of iron deficiency on physical 
performance also have implications for economic productivity in developing countries. 
For example, agricultural workers rely heavily on their ability to perform physical tasks, 
such as picking crops. Iron deficiency has the potential to lower physical performance 
capacity of a large portion of the labor force, which would result in an overall lower 
economic productivity in areas with a high prevalence of iron deficiency94,95. Similarly, if 
physical activity negatively impacts iron status or the effectiveness of iron 
supplementation, those areas with a high prevalence of iron deficiency among manual 
laborers could be doubly affected. Finally, most iron interventions target women with 
IDA at the expense of a large population of IDNA women who could benefit greatly from 
iron interventions. This dissertation will promote the inclusion of IDNA in iron 
interventions by clarifying the negative impact of IDNA in active populations, such a 
rural laborers or athletes. 
Additionally, it is imperative to identify new, sustainable and affordable methods 
for addressing IDNA in rural areas of China that cannot utilize the conventional methods 
of resolving iron deficiency. Given the popularity of traditional Chinese medicine in rural 
areas, as well as the promising literature that relates iron status and the Chinese herbal 
treatment BZ, it is possible that BZ may provide an alternative to iron supplementation. 
Therefore, this dissertation will also explore the third aim below: 
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3. To compare the effectiveness of using a traditional Chinese herbal treatment 
(BZ) to that of ferrous sulfate in improving iron status and/or physical 
performance of Chinese, IDNA women 
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Chapter 2: Methods 
 
2.1 Kunming Randomized Control Trial 
 
The objective of this study was to examine the individual and combined effects of 
an 8-week iron supplementation and aerobic exercise training program on biomarkers of 
iron status and the functional outcomes of physical performance (maximal and sub-
maximal measures). A subset of participants was also included in the main trial to 
examine the efficacy of using a traditional Chinese herbal medicine as an alternative to 
Western iron supplementation. The methods for that subset will be presented in Section 
2.2. The Consort diagram for the full study population is shown in Figure 2.1. 
2.1.1 Study Design 
 
The study for Aims 1 and 2 was a randomized, controlled, partially-blinded trial 
that took place at Kunming Medical University in Yunnan, China from February 2014 to 
July 2015. The 8-week intervention occurred in two waves, one from October to 
December of 2014 and the second from April to June 2015, referred to as waves 1 and 
2, respectively. Both waves were identical in protocol. The study used a 2x2 factorial 
design with participants being randomly assigned to receive either 100 mg of ferrous 
sulfate twice daily or an identical placebo for a total of 42.2 mg of elemental iron per 
day. Both the iron and placebo supplements were prepared by the author in the 
research lab of Dr. Bing Su at the Kunming Zoology Institute, a part of the Chinese 
Academy of Sciences. Twenty iron and placebo capsules were randomly selected every 
four weeks throughout the study and analyzed for iron content. 
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Figure 2.1: Consort diagram for full study population 
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The iron content of the ferrous sulfate and placebo capsules was determined by ICP/MS 
to be 21.1 mg and 0.0 mg elemental iron per capsule, respectively.  
Subjects were instructed to consume the capsules with their morning and 
evening meals, to do so with citrus juice to enhance absorption, and to avoid consuming 
capsules on an empty stomach. Thirty capsules were distributed to each subject in a 
bottle labeled with their unique subject ID every 2 weeks (weeks 0, 2, 4, and 6). Each 
subject received a log to record their daily capsule ingestion as well as information on 
medication use, illness, menstrual cycle status, any gastrointestinal complaints, physical 
activity, and musculoskeletal problems. Additionally, subjects were instructed to return 
their capsule bottles every two weeks with any remaining capsules, which were then 
counted to confirm the number of capsules reported as consumed on the capsule logs. 
Subjects were not told that the returned capsules would be counted to avoid their 
discarding any non-consumed capsules prior to returning their capsule bottles. Half of 
each capsule group was further randomized to receive either 8 weeks of aerobic 
exercise training or no training, resulting in a total of 4 groups in which supplement type 
was blinded but training group was not. The training protocol will be described in section 
2.1.4. 
In each wave, blood samples were taken at weeks 0, 4, and 8 as well as 
measurements of anthropometry, physical performance, dietary intake, and physical 
activity. Physical performance assessments will be described in section 2.1.5. Blood 
samples were assessed for 5 biomarkers: sFer, Hb, sTfR, alpha-1-acid glycoprotein 
(AGP), and C-reactive protein (CRP). Anthropometry included height, weight, mid-upper 
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arm circumference, and body fat as assessed by 4 caliper measurements of the bicep, 
triceps, suprailiac, and sub-scapular skinfold thicknesses (Lange calipers, Cambridge 
Scientific, Cambridge, MA). Dietary intake was assessed using a 4-day dietary record in 
which subjects were instructed to record all food and beverages they consumed, 
including water, during a specified Thursday to Sunday period. They were instructed to 
be as detailed as possible, giving volumes or weights when known and estimating 
“scoops” for the food served at the cafeterias on campus, which was served using a 
ladle. Subjects were asked not to alter their normal eating behaviors during the 
assessment.  
 
2.1.2 Study Participants 
 
 This study was conducted in an iron depleted, non-anemic, and otherwise 
healthy group of female Chinese university students in Yunnan, China. Women aged 18 
to 26 years were recruited locally for screening through in-class presentations and 
distributing flyers on campus. Inclusion criteria for the intervention trial were as follows:  
a. Ages 18-26 
b. Hb > 110g/L  
c. No current pregnancy or pregnancy within the previous year 
d. No recent infectious illness or fever 
e. No current inflammation or chronic inflammatory diseases  
f. No major musculoskeletal problems, medical conditions, or other injuries that 
would prevent them from completing the physical performance assessments 
and/or training 
g. No history of eating disorders 
h. Non-smoking 
i. BMI between 17 and 25 kg/m2 
j. No consumption of medications that may affect dietary iron intake or absorption 
or that have anticoagulant properties.  
k. No use of psychoactive drugs 
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Three hundred seventy-nine women were recruited in two waves (September-
December 2014 and March-June 2015) from the student population at Kunming Medical 
University in Yunnan, China. Of these, 98 women were identified in the fall wave, and 
281 were identified in the spring. In total, 191 were identified as iron-depleted without 
anemia, defined as Hb > 110 g/L and sFer < 25μg/L. Of the 191 women invited to 
participate, 124 agreed to enroll in the study. One hundred and nine women completed 
the full study (39 in wave 1, 70 in wave 2). In wave 1, three women dropped out citing 
the following reasons: left campus for family member’s death, outside injury prevented 
continuation, and gastrointestinal discomfort from assigned capsule (n=1 for each). In 
wave 2, 6 women dropped out before randomization and another 6 women dropped out 
citing the following reasons: too time intensive (n=3), outside injury prevented 
continuation (n=2), left campus early after finishing final exams and could not complete 
week 8 testing (n=1). The women were distributed as shown in Table 2.1. 
 
Table 2.1: Distribution of Subjects by Treatment Group, Final Count 
 Iron Placebo 
Trained 20 18 
Untrained 16 19 
 
After examining the data, seven of the participants had a baseline sFer > 25 µg/L 
and were excluded from analysis for a final sample size of 102 women. The 102 women 
who were included in the final data analyses were randomly assigned to the following 
supplement groups: 36 iron, 37 placebo, and 29 BZ (as shown in Table 2.1). Chapters 3 
and 4 describe analyses of only the iron and placebo groups (n = 73), while Chapter 5 
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examines the effects of BZ and includes all 102 subjects. The methods for the BZ 
analysis will be described in Section 2.2. Randomization occurred after screening, 
before the beginning of data collection at week 0. 
Participants received compensation in the form of a tablet computer at the 
conclusion of the study. Additionally, to increase compliance, trained subjects were 
offered incentives in the form of small gifts when they completed a target number of 
training days (25, 32, and 40 days). Informed consent was obtained individually from the 
women participating in screening and again for the intervention phase of the study 
before the screening/baseline blood samples were taken. The Institutional Review 
Boards of Cornell University and Kunming Medical University approved the study 
protocols. 
 
2.1.3 Blood Analyses 
 
Whole blood samples were collected from participants in 4 mL Anti-Coagulant 
vacutainer tubes for analysis at screening and a batch analysis of weeks 0, 4, and 8 
after the study was completed. Analyses were performed by two different labs, the First 
Affiliated Hospital of Kunming Medical University (FAH, Kunming, China) and the 
ShengSheng Logistics Life Science Supply Chain Solutions (SSLL, 上海生生物流有限公
司, Shanghai, China), in waves 1 and 2, respectively.  
In both waves, whole blood was refrigerated until transport (within 24 hours) to 
FAH. Hb was analyzed from whole blood at FAH in both waves using a Coulter LH 750 
Hematology analyzer.  
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In wave 1, the remaining whole blood from each time point was centrifuged at 
FAH to separate the serum, which was divided into 500µL aliquots and stored at -80ᵒ C 
until being analyzed at FAH for sFer, sTfR, AGP, and CRP using a Siemens Advia 2400 
automated analyzer. In wave 1, analyses were conducted within 48 hours of blood 
collection at each time point. 
In wave 2, whole blood was centrifuged at Kunming Medical University to 
separate the serum, which was divided into 500 µL aliquots and stored at -80ᵒ C. After 
completing the week 8 blood draw, the samples from weeks 0, 4, and 8, as well as 35 
samples from screening were shipped to Shanghai to be analyzed at SSLL. During 
shipping the temperature was maintained at -80ᵒ C, which was monitored hourly and 
adjusted as needed. At SSLL, serum was analyzed for sFer, sTfR, AGP, and CRP using 
a Siemens Advia 2400 automated analyzer.  
The wave 2 screening (n=35) and all baseline samples (waves 1 and 2) were 
analyzed at both FAH and SSLL to allow for comparison between the labs. Studies 
have demonstrated the stability of ferritin, CRP, and TfR in both whole blood (for less 
than 96 hours)96,97 or in plasma or serum frozen at -80ᵒ C (for up to 1 year)98. Therefore, 
the handling of the whole blood and subsequent storage before analyses in the present 
study are not likely to have had a large impact on the biomarker concentrations.   
Additionally, 35 serum samples from each time point were analyzed by the 
author in the clinical laboratory of the Yunnan University for Traditional Chinese 
Medicine Affiliated Hospital. These samples were analyzed for sFer and sTfR using 
RAMCO laboratories Spectro Ferritin and Human Transferrin Receptor ELISA kits, 
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respectively. In order to match the scale used by Cook et al. to derive the Body Iron 
equation, all TfR values from FAH and SSLL were adjusted to the RAMCO Laboratories 
TfR scale using the following prediction equation, which was derived by plotting the TfR 
values obtained from the FAH and SSLL hospitals against the TfR values obtained from 
the RAMCO Laboratories ELISA kit run by the author (LMP) and calculating a 
regression line: 
TfRRamco = (3.779*TfRlab) + 0.400, R2 = 0.93 
There was a strong, significant correlation between the screening sFer values 
from the FAH and SSLL laboratories (r = 0.86, p < 0.001). Therefore, no correction 
factor was made between the FAH and SSLL values. However, the FAH hospital 
contacted the researchers (LMP) after the initial analyses to inform us that a different 
machine was used to run the Week 0 blood analyses than the machine that was used 
for the other time points and that because no standard was run on both machines, the 
wave 1, week 0 data was not valid. Therefore, for wave 1, the values used as baseline 
sFer are those that were obtained at the screening a week prior to the start of the study. 
Iron status was defined using Hb, sFer, and sTfR. Participants were classified as iron 
depleted if they had sFer < 25 µg/L and iron deficient if sFer < 15 µg/L. Using sTfR on 
the RAMCO Laboratories scale, iron deficiency was defined as a value > 8.3 mg/L99. 
The equation by Cook et al. for body iron described in Section 1.1 was used to calculate 
total body iron for each subject at each time point23. Using this measure, stores were 
considered depleted for body iron values < 0 mg Fe/kg body weight. AGP and CRP 
were used to assess inflammation. Inflammation cutoffs were established as CRP > 5 
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mg/L and AGP > 1 g/L16. 
 
2.1.4 Aerobic Training Protocol 
 
The subjects assigned to training followed a training protocol based on that of 
Hinton et al. and adapted to an 8-week training period. Subjects trained for 8 weeks for 
5 days each week on a cycle ergometer with adaptable workloads that was equipped to 
measure heart rate, revolutions per minute (RPM), and work output in Watts. Each 
session involved 25-minutes of cycling. The 25-minute session was divided into 
workloads that allowed subjects to obtain a target heart rate of 75-85% of their age-
predicted maximum heart rate (HRmax). Time spent at the harder workload (85% 
HRmax) was increased each week to increase aerobic fitness of subjects as they 
progressed through training program. The training program is shown in Table 2.2. 
Additionally, optional training days were offered on weekends to allow subjects to 
make-up any days they had missed during the week. The maximum number of training 
days was 40 days. 
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Table 2.2: Training Schedule by Week 
 
Week 
Minutes at 75% 
max HR 
Minutes at 
85% max HR 
1 20 5 
2 19 6 
3 18 7 
4 17 8 
5 15 10 
6 13 12 
7 11 14 
8 10 15 
 
Abbreviations: max HR – maximum age-predicted heart rate (220 – age in years) 
 
2.1.5 Assessing Physical Performance 
 
 Physical performance was measured at weeks 0, 4, and 8 using a graded 
exercise (VO2max) performance test: The test was performed on a mechanically braked 
and calibrated cycle ergometer (Monark 884E). Oxygen consumption (VO2) was 
determined while cycling at levels of effort ranging from rest to 100% of subjects’ 
maximum capacity. Metabolic parameters were assessed using a portable metabolic 
measurement system (Cosmed K4B2, Cosmed, Rome, Italy), which analyzes heart 
rate, the breath-by-breath volume of respired air, and the concentrations of O2 and CO2 
in the expired air. The subjects breathed room air through a two-way valve connected to 
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a facemask worn throughout the testing periods. 
Calculated metabolic measures included oxygen consumption (VO2 in mL/min), 
oxygen consumption per kilogram body weight (VO2 mL/min/kg), pulmonary minute 
ventilation (VE in L/min), ventilatory threshold (VT, absolute in mL/min and VT as % of 
VO2max), heart rate (HR beats/min), respiratory exchange ratio (RER = VCO2/VO2) and 
carbon dioxide production (VCO2 in mL/min). 
Subjects were asked not to perform any strenuous physical activities/exercise for 
two days before the exercise tests. Additionally, subjects were told not to consume food 
or caffeinated products for 3 hours prior to performance testing. 
2.1.5a: VO2max protocol 
An exercise protocol adapted from that reported by Brownlie et al77 was used to 
measure VO2max. The test started when the subject's resting heart rate was <100 beats 
per minute. The test began with a 5-minute warm-up against only the empty weight 
basket (1 kg), cycling at 50 revolutions per minute (RPM). Workloads were then 
increased by 0.4 kg every 2 minutes, cycling at 50 RPM, until VO2 did not increase 
more than 150 mL/min from the previous workload, signifying the subject was working 
at their VO2max. If this condition could not be met (due to motivational or other factors), 
the test proceeded until the subject was unwilling or unable to continue. Subjects were 
considered to have reached VO2max if the data from their test (collapsed into 60-
second epochs) met two of the following conditions: a heart rate within 10 beats/min of 
their age-predicted maximum heart rate (220 - age in years), a blood lactate 
concentration > 8.0 mM, or a respiratory exchange ratio > 1.15. The highest measured 
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VO2 achieved during this test was designated as VO2peak. At baseline and week 8 only 
69.9% and 60.3% of subjects, respectively, met the criteria for VO2max. For subjects 
who failed to reach VO2max, an estimated VO2max (eVO2max) was calculated by 
plotting heart rate against VO2 and extrapolating to the VO2 value for the age-predicted 
maximum heart rate. Ventilatory threshold (VT) was calculated by combining the 
ventilatory equivalencies, excess CO2 production, and modified V-slope methods, as 
described by Gaskill et al100. Percent values at VT were calculated by taking the 
observed VO2 value at VT and dividing by VO2peak or eVO2max. Blood lactate was 
measured immediately after testing via finger stick using a Lactate Plus portable blood 
lactate analyzer (Nova Biomedical, Waltham, MA, USA). 
See Appendix A for data collection forms. 
2.2 Traditional Chinese Medicine Study 
 
2.2.1 Study Design 
 
 This study utilized the same protocol and subject population as the study 
described in Section 2.1, with the inclusion of 29 additional subjects who received the 
BZ treatment (13 trained and 16 untrained). It was a partially-blinded, randomized, 
controlled study. The objective of this study was to examine the effects of consuming a 
traditional Chinese herbal treatment, BaZhen KeLi, for 8 weeks on iron status and/or the 
physical performance in IDNA women (Aim 3). The BZ treatment was compared to both 
a placebo and to supplementation with ferrous sulfate. The BZ supplement was 
produced by the pharmacy of Yunnan University for Traditional Chinese Medicine. It 
was composed of the eight ingredients listed in Table 1.1. The study design was the 
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same as that described in Section 2.1.1 with the addition of a trained and untrained 
group that received BZ supplements in addition to the four treatment groups in the main 
study. 
 
2.2.2 Study Participants 
 
 The recruitment process and final study participants were identical to those 
described in Section 2.1.2 for the Randomized Supplementation Trial. The final sample 
included in the data analyses for this study had 102 women, distributed among six 
groups as shown in Table 2.3. 
 
Table 2.3: Participants in the BZ Study, By Treatment Group  
 Iron Placebo BZ 
Trained 20 19 13 
Untrained 16 18 16 
 
 
 
2.2.3 Outcomes 
 
 The blood analyses for the BZ study were identical to those described in Section 
2.1.3, which included the samples from the additional 29 women in the BZ groups. 
Physical performance was assessed using the protocol described in section 2.1.5.  
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Chapter 3: Efficacy of iron supplementation may be misinterpreted 
using conventional measures of iron status in iron depleted, non-
anemic women undergoing aerobic exercise training1 
 
3.1 Abstract 
 
Background: Despite having known detrimental effects, iron deficiency remains the 
most common micronutrient deficiency in the world. Many interventions aiming to 
improve iron status involve physically active populations. Intense aerobic exercise 
training negatively affects iron status; however, the impact of regular moderate aerobic 
exercise on the effectiveness of iron supplementation remains unclear.  
Objective: This study aimed to determine whether aerobic training modifies the 
assessment of the effectiveness of iron supplementation in improving conventional iron 
status measures. 
Design: Seventy-two iron depleted, non-anemic Chinese women (serum ferritin (sFer) < 
25 µg/L and hemoglobin >110 g/L) were included in an 8-week, partially-blinded, 
randomized control trial with a 2x2 factorial design including iron supplements (42mg 
elemental iron/day) or placebo and aerobic training (5 sessions/week of 25 minutes at 
75-85% maximum heart rate) or no training. Linear mixed models were used to evaluate 
the relationship between supplement type, training, and changes in iron status over 
time, measured by sFer, hemoglobin, transferrin receptor, and estimated total body iron. 
 
1This chapter contains the materials published in the American Journal of Clinical Nutrition 
under the same title. The chapter has not been modified from the printed edition except to 
match the Cornell University dissertation formatting requirements. The citation for this paper is 
shown below and a reprint is found in Appendix B. 
Am J Clin Nutr. 2017 Dec;106(6):1529-1538. doi: 10.3945/ajcn.117.152777. Epub 2017 Nov 1. 
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Results: After treatment, both the iron-supplemented trained and untrained groups had 
significantly improved sFer, sTfR, and body iron values than either placebo group. 
Similarly, trained subjects had a significantly higher aerobic fitness measures than 
untrained subjects. Training modified the sFer response to supplementation (training by 
supplement interaction p = 0.07), with the iron trained group having significantly lower 
sFer than the iron untrained group at week 8 (31.8 ± 13.5 µg/L and 47.6 ± 15.7µg/L, 
respectively, p = 0.042), while there was no significant difference between the placebo 
trained and untrained groups (21.3 ± 12.2 µg/L and 20.3 ± 7.0 µg/L, respectively, p = 
1.00).  
Conclusions: Regular aerobic training reduces the apparent effectiveness of iron 
supplementation in improving sFer and calls into question whether conventional 
measures of iron status accurately reflect iron metabolism in physically active, non-
anemic women.  
  
3.2 Introduction 
 
Iron deficiency anemia affects 20-34% of Chinese women of childbearing 
age101,102. This rate likely underestimates the prevalence of iron deficiency (ID) in the 
population because it does not account for ID without anemia [IDNA: hemoglobin 
>110g/L and serum ferritin < 15 μg/L] 103. ID with and without anemia have negative 
consequences on physical performance and exercise capacity 3,104. However, there is 
also evidence that aerobic training may have a negative influence on iron status that is 
potentially more concerning when considering iron interventions are frequently targeted 
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towards physically active populations 76,105,106.  
Intense physical exercise lowers several measures of iron status including serum 
ferritin (sFer) and increases soluble transferrin receptor (sTfR), indicative of either 
compromised iron status 5,76,105,106 or redistribution of iron to be used in erythropoiesis 
and/or muscle formation 32,43,107,108. Female soldiers who underwent a 9-week basic 
combat training showed declining iron status 78,105. Providing an iron supplement 78 
during basic combat training attenuated some of these changes, compared to placebo. 
While these findings occurred in highly intensive training programs, recreational 
physical activity can also negatively impact iron status. In a study by Hinton et al of 
IDNA women who underwent aerobic training, iron supplementation resulted in a 
modest increase in sFer (4.1μg/L), compared to those who received placebo3. 
Interestingly, the improvement in sFer in the iron supplemented, trained women in the 
Hinton et al study was less than half of that observed in a separate study of fit IDNA 
women who received similar iron supplementation but did not undergo training109. 
These findings suggest that improvements in sFer from iron supplementation may differ 
if women train during supplementation. This difference may be a result of an exercise-
induced prioritization of erythropoietic demands and muscle growth over storing iron in 
the liver, as reflected by sFer concentration. While recent literature supports this idea of 
iron redirection away from the stores to support more functional uses of iron, most 
interventions aiming to improve iron status or anemia measure only Hb, sFer, and 
sometimes sTfR or estimated body iron, calculated from the ratio of sTfR to sFer, and 
do not measure other body iron pools. This oversight could potentially lead to erroneous 
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conclusions of the effectiveness of the intervention. 
Further complicating the relationship between IDNA and exercise, research also 
suggests that women who are actively training perform better when given iron 
supplementation than those who train without supplementation 76,78, suggesting an 
intricate, but currently undefined, relationship between iron status, total body iron, 
exercise, and physical performance capacity. This relationship must be understood 
before we can properly design effective interventions to measure and target IDNA in 
physically active populations such as laborers, athletes, or non-athletes who want to 
benefit from improved fitness. While several studies have shown that training worsens 
traditional measures of iron status, to our knowledge no study has yet directly examined 
the interaction between training and iron supplementation to determine how training 
impacts the effectiveness of iron supplementation, as assessed by sFer and Hb 
concentrations. Therefore, the goal of this study is to determine whether 8 weeks of 
regular aerobic exercise on a cycle ergometer modifies the apparent effectiveness of 
concurrent iron supplementation in improving the traditional measures of iron status. We 
hypothesized that those women who received both iron and training would have smaller 
changes in sFer than women who did not train while taking iron.  
3.3 Subjects and Methods 
 
3.3.1 Subjects 
 
The sampling scheme for this study is shown in Figure 3.1.  
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Figure 3.1: Consort Diagram for Chapter 3 
 
1 Abbreviations: RCT: randomized control trial; sFer: serum ferritin  
 
Three hundred seventy-nine physically active, untrained 18- to 26-yr-old women 
were recruited in two waves (September-December 2014 and March-June 2015) from 
the student population at Kunming Medical University in Yunnan, China. Of these, 98 
women were identified in the fall wave, and 281 were identified in the spring. In total, 
191 were identified as iron-depleted without anemia, defined as Hb > 110 g/L and sFer 
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< 25 μg/L. Anemia was defined as <110 g/L to align with the Hb cutoff used by the First 
Affiliated Hospital of Kunming Medical University where the screening analyses were 
performed. The cutoff for iron depletion was set at 25 μg/L because prior research has 
shown that physical performance changes occur even in women who are iron depleted 
and not clinically iron deficient 8,10,110–112.  Screening, which included a medical history 
questionnaire, was conducted to identify and exclude women who met any of the 
following criteria: anemia (Hb < 110 g/L), current pregnancy or pregnancy within the 
previous year, current lactation or lactation within the previous year, recent infectious 
illness or fever, current inflammation or chronic inflammatory diseases, hemolytic 
anemia, chronic respiratory disease, musculoskeletal problems, history of eating 
disorders, smoking, BMI < 17 or > 25 kg/m2, or recent consumption of iron supplements, 
vitamin supplements, or medications that may affect dietary iron intake or absorption or 
that had anticoagulant properties. Subjects also filled out a physical activity 
questionnaire that indicated they did not participate in regular exercise or organized 
sports, were interested in increasing their level of physical fitness, and were willing to 
comply with the full 8-week training program. Of the eligible women, 124 agreed to 
participate in the trial (45 fall, 79 spring). The recruitment process for this study was 
designed to recruit for two additional arms of the study. This paper focuses on the first 
four arms of the study, which included the iron and placebo supplemented groups. The 
other arms of the study included two groups who received a Chinese herbal 
supplement. Of the 124 women in the total study, 85 were randomized to the treatments 
relevant to this study. 
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 Data from 6 women were excluded from statistical analyses because their sFer 
values at Week 0 increased above the screening cutoff of 25 µg/L, whereas their 
original screening values from two weeks prior indicated that they were iron depleted. 
Additionally, 9 women (from all six treatment arms) dropped out of the trial. The final 
sample size for this analysis was 72 women. Signed informed consent was obtained 
from each subject. The study was approved by the Cornell University Institutional 
Review Board and the Kunming Medical University Ethical Committee and registered 
under ClinicalTrials.gov #: NCT03002090. 
 
3.3.2 Study Design  
 
The experimental design of the study was a 2x2 randomized, double-blind, 
placebo-controlled intervention trial. Subjects were randomly assigned by the author 
(LMP) via a random number generator to treatment groups. Subjects received either 
100 mg of ferrous sulfate or an identical placebo capsule twice daily for 8 weeks. 
Subjects and all investigators were blinded to supplement type until after the per-
protocol analyses were completed. Sample size was based on consuming a minimum 
elemental iron concentration of 12 mg/capsule over 8 weeks. The final capsule 
concentration met this requirement. Previous work has demonstrated that iron status is 
improved after 4 weeks of iron supplementation at a similar dose of ferrous sulfate 3,113. 
The capsules were prepared by the author with the use of gelatin capsules, ferrous 
sulfate, and dextrose filler (PCCA, Houston, TX). At weeks 0, 2, 4, 6, and 8 of each 
wave of the study, 20 capsules of each type were randomly selected from the batch and 
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stored in a sealed container in a cool, dry place until analyzed post-study by ICP/MS. 
After the study, the iron concentrations of the iron and placebo capsules were 
determined from this random sample to be 21.1 mg and 0.00 mg of elemental iron, 
respectively.  
Subjects were instructed to consume the capsules with citrus juice during their 
morning and evening meals, and to avoid consuming the capsules on an empty 
stomach. Thirty capsules were distributed to each subject in a bottle labeled with their 
unique subject ID every 2 weeks (weeks 0, 2, 4, and 6). Each subject was instructed to 
complete a daily log to record capsule ingestion as well as information on medication 
use, illness, menstrual cycle status, any gastrointestinal complaints, physical activity, 
and musculoskeletal problems. Additionally, subjects were instructed to return their 
capsule bottles every two weeks with any remaining capsules, which were then counted 
as independent confirmation of the number of capsules reported as consumed on the 
daily logs.  
One half of each supplement group was further randomly assigned to an 
exercise training program or no training to create four treatment groups: iron trained 
(FeTr), iron untrained (FeUn), placebo trained (PLTr), and placebo untrained (PLUn). 
The training protocol was adapted from a protocol previously published by Hinton et al 
that has produced measurable improvements in endurance and maximal oxygen 
consumption (VO2max) 3. Intensity of training increased each week according to each 
subject’s heart rate. Training sessions were 25 minutes long and were divided into two 
target heart rates of 75% and 85% of age-estimated maximum, calculated as 220 (beats 
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per minute) minus age (years). The workload was adjusted as needed to maintain the 
target heart rate throughout the session. Minutes spent at 85% maximum heart rate 
increased each week to increase the difficultly of the training. The training protocol is 
shown in Table 3.1. Subjects trained Monday through Friday during each of the 8 
weeks of the study. Optional training days were offered on weekends to allow subjects 
to make-up any days they had missed during the week. The maximum number of 
training days was 40 days. 
 
Table 3.1: Daily training schedule, by week 
 
Week Minutes at 75% 
max heart rate 
Minutes at 85% 
max heart rate 
1 20 5 
2 19 6 
3 18 7 
4 17 8 
5 15 10 
6 13 12 
7 11 14 
8 10 15 
 
Training was performed on a stationary exercise bicycle (KangLe Exercise 
Products Company, Stationary Bicycle model B8.4E, Yunnan, China) equipped with 
digital output of work (watts) and cadence (rotations per minute). Subjects wore a T31 
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Polar heart rate monitor, which was read using a Polar A5 heart rate watch (Polar 
Electro Inc., Lake Success, NY). Trained research assistants recorded the watts, heart 
rate, and speed of each subject in a training log every 5 minutes throughout each 
session.  
 Daily physical activity, defined as minutes spent performing discretionary 
exercise, was assessed at weeks 0, 4, and 8 using the data from a daily log completed 
each day over the 56-day trial. Minutes of self-reported physical activity were totaled at 
each time point. Additionally, a physical activity frequency questionnaire was 
administered at Week 0 to assess similarity in habitual physical activity levels between 
groups. Participants were asked to maintain their normal pre-study activity patterns for 
the duration of the 8-week study period, regardless of whether they were in the trained 
or untrained groups.  
 Body composition and physical performance were measured before and after the 
study as well as at the 4-week midpoint. Dietary iron intake was assessed at Week 0 
using a 4-day diet record that spanned from Thursday-Sunday. These records were 
analyzed for daily iron, inhibitors and enhancers of iron absorption, and macronutrient 
content using Nutrition Data System for Research Software (2016, University of 
Minnesota).  
 All subjects were compensated for study participation with a gift. Additionally, to 
increase compliance to the training program, trained subjects were offered incentives in 
the form of small gifts when they completed a target number of training days (25, 32, 
and 40 days). While all subjects received the same gift for participation in the study, the 
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smaller training-based incentives were only offered to the trained group. 
3.3.3 Iron Status Measurements 
Iron status was assessed at Weeks 0, 4, and 8. Whole blood was collected from the 
antecubital vein into 4 mL anti-coagulant vacutainers by a phlebotomist at the Kunming 
Medical University campus hospital. A small sample of whole blood was removed for Hb 
analysis. The remaining samples were stored at 4°C until centrifugation at 1600g for 10 
minutes at room temperature within 24 hours. The serum was collected and separated 
into 0.5mL aliquots and frozen at -80°C until analysis. Blood was analyzed for sFer, 
sTfR, alpha-1-acid glycoprotein (AGP), and C-reactive protein (CRP) at the First 
Affiliated Hospital of Kunming Medical University in the first wave, and at the Shanghai 
Fenglin Clinical Laboratory in the second wave. Additionally, 75 samples from the 
second wave were run at both labs to allow for comparison between the labs. Hb was 
determined using a Coulter LH 750 Hematology analyzer (Beckman Coulter, Inc. Brea, 
CA). sFer, sTfR, AGP, and CRP were analyzed on a Siemens Advia 2400 automated 
analyzer (Siemens Healthcare, Erlangen, Germany). Estimated total body iron was 
derived from the ratio of sTfR to sFer using the equation reported by Cook et al 23 as:  
Total Body Iron = - [log(sTfR/sFer) - 2.8229] / 0.1207 
This equation uses sTfR values from Ramco ELISA kits (Ramco Laboratories, Stafford, 
TX). Therefore, we converted the sTfR values derived from the Chinese laboratories to 
Ramco-adjusted sTfR values with the prediction equation below, which was derived 
from 35 random duplicate samples run on Ramco Laboratories sTfR ELISA kits. 
sTfRRamco = (3.779*sTfRlab) + 0.400, R2 = 0.93 
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3.3.4 Physiological measurements 
Height and weight were measured using previously described standard protocols 114. 
Body composition was estimated from skinfold thicknesses measured with Lange 
calipers (Cambridge, MD) at the biceps, triceps, subscapular, and suprailiac sites. The 
Durnin and Womersley equation was used to calculate body density and percent body 
fat 115.  
Physical performance was assessed using a VO2max test at Weeks 0 and 8 on a 
mechanically braked and calibrated cycle ergometer (Monark 884E, Monark Exercise 
AB, Vansbro, Sweden). Oxygen consumption was determined while cycling at levels of 
effort ranging from rest to approximately 100% of subjects’ maximum level of exertion. 
Metabolic parameters were assessed with a portable metabolic measurement system 
(Cosmed K4B2, Cosmed, Rome, Italy), which analyzes heart rate, the volume of 
respiratory air, and concentrations of oxygen and carbon dioxide in expired air. The 
subjects breathed room air through a two-way valve connected to a facemask worn 
during the testing sessions. Oxygen consumption per kilogram body weight (VO2, 
mL/kg/min) was calculated from the portable metabolic unit’s internal program.  
Subjects were asked not to perform any strenuous physical activities/exercise for 
one day prior to the exercise tests, excluding daily training for the trained group. Trained 
subjects did not train on the day of their performance tests. Additionally, subjects were 
told not to consume food or caffeinated products for 3 hours prior to performance 
testing. 
The VO2max protocol was adapted from that used by Brownlie et al 77. The test 
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started when the subject's heart rate was <100 beats per minute. The test began with a 
5-minute warm-up with a workload of 1kg, cycling at 50 revolutions per minute (RPM). 
Workloads were then increased by 0.4kg every 2 minutes, cycling at 50 RPM, until VO2 
did not increase more than 150 mL/min from the previous workload, suggesting that the 
subject was working at their VO2max. If this condition could not be observed, the test 
proceeded until the subject was unwilling or unable to continue. The subject was 
considered to have achieved VO2max if 2 of the following conditions were met: subject 
reached: a respiratory exchange ratio > 1.10, a heart rate within 10 beats/min of their 
age-predicted maximum (220 – age), or blood lactate > 8.0mM. Blood lactate was 
assessed by finger stick using a Lactate Plus portable blood lactate analyzer (Nova 
Biomedical, Waltham, MA, USA) after completion of the final workload. 
 
3.3.5 Compliance Analyses 
Compliance to capsule consumption was assessed from 2 sources of documentation, 
pill counts from returned bottles and daily logs. The Pearson correlation coefficient 
between the capsules reported as missing in the daily logs and the capsules counted 
from the returned bottle was 0.39 (p=0.01), suggesting some discrepancies. In order to 
create a more reliable assessment of capsules consumed, two compliance variables 
were created: a conservative estimate and an average estimate. The conservative 
estimate was calculated by comparing the information from the capsule counts and the 
log for each two-week period and taking the higher number of missed capsules 
(reported or physically returned). The average estimate was created by taking the 
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average of the log and bottle counts. There were no group differences in number of 
capsules consumed for either the conservative or the average estimates. 
 
3.3.6 Statistical Analyses 
Sample size calculations were based on the Hinton et al3 and Hinton and Sinclair109 
studies discussed previously, which suggest that a smaller change in sFer is observed 
when iron supplementation is given to women who are training. Sample size was 
determined to require 25 subjects in each of the four groups, which was expanded to 29 
subjects per group after considering potential loss to follow-up in order to detect a 
4.1μg/L change in sFer, or an effect size of approximately 0.8 standard deviations, after 
8 weeks with 80% power and α = 0.053. Data were examined to verify normality of 
distribution using the Kolmogorov-Smirnov test, histograms, and qq-plots. Statistical 
analyses were performed on log-transformed variables for sFer and sTfR, which were 
found to have non-normal distributions. Measures of iron status at weeks 4 and 8 were 
analyzed using linear mixed models with fixed effects of supplement, training group, 
time, all 2- and 3-way interactions, and a random effect at the subject level. Baseline 
was included as a covariate for each measure of iron status. If the 3-way interaction 
was not significant in the full model, the 3-way interaction term was removed from the 
model and the model was rerun with all of the 2-way interaction terms. Any 2-way 
interaction terms that were not significant were also removed and a final model was run 
including only the significant 2-way interaction(s). Post-hoc pairwise comparisons were 
made with Bonferroni corrections made for multiple comparisons. Secondary analyses 
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were performed using linear models to test for relationships between variables. 
Residuals were examined for normality for all linear mixed models using the 
Kolmogorov-Smirnov test, histograms, and qq-plots. For a subgroup of those subjects 
who had a baseline sFer < 20 µg/L, the relative risk of resolving one’s iron depletion 
(being iron depleted at baseline and iron replete at week 8) was calculated for all 
pairwise comparisons between groups. For all analyses, an α level of 0.05 was used to 
indicate statistical significance. For each result where a Bonferroni correction is 
indicated, the original P value was multiplied by the number of comparisons made and 
considered significant if: (P value times k comparisons) < 0.05. All statistical analyses 
were performed in SAS 9.4 (SAS Institute, Cary NC). 
3.4 Results 
 
3.4.1 Subject characteristics 
 
There were 19 iron trained (FeTr), 16 iron untrained (FeUn), 18 placebo trained 
(PLTr), and 19 placebo untrained (PLUn) subjects included in the final analyses. 
Background characteristics including, age, anthropometry, and fitness level as 
assessed by VO2max at baseline, blood biomarkers, and dietary intake at baseline are 
shown in Table 3.2. 
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Table 3.2: Sample characteristics of total sample at Week 0 (n = 72)1  
Characteristic Iron Trained Iron Untrained Placebo Trained Placebo Untrained 
Age (years) 20.6 ± 1.1 20.3 ± 0.9 20.7 ± 1.2 20.5 ± 1.7 
Height (cm) 156.8± 5.7 156.9 ± 6.2 157.3 ± 4.7 157.4 ± 5.0 
Weight (kg) 51.2 ± 6.8 51.4 ± 7.9 53.5 ± 6.1 49.7 ± 5.6 
BMI (kg/m2) 20.8 ± 2.8 21.0 ± 3.5 21.6 ± 2.1 20.0 ± 2.1 
Body Fat (%) 25.2 ± 2.5 25.5 ± 3.2 26.0 ± 2.0 24.7 ± 2.0 
sFer (µg/L) 14.0 ± 5.8 17.1 ± 4.2 14.4 ± 4.7 15.2 ± 5.7 
Hb (g/L) 135 ± 10.3 141 ± 5.2 132 ± 12.8 133 ± 9.7 
sTfR (mg/L) 6.8 ± 3.2 5.3 ± 0.8 5.8 ± 1.5 6.1 ± 1.7 
Body Iron (mg/kg) 1.1 ± 2.6 2.7 ± 0.9 1.8 ± 1.8 1.7 ± 1.9 
VO2max (mL/min/kg) 42.7 ± 4.8 42.4 ± 5.6 41.4 ± 5.3 42.8 ± 5.0 
Physical activity (min)2 59.8 ± 91.1 56.1 ± 60.5 52.9 ± 71.7 49.0 ± 65.9 
AGP (g/L) 0.61 ± 0.08 0.61 ± 0.09 0.64 ± 0.10 0.59 ± 0.09 
CRP (mg/L)3 0.04 (0.00, 0.01) 0.22 (0.00, 0.01) 0.20 (0.00, 0.30) 0.10 (0.00, 0.21) 
Dietary Intake, daily     
    Calories, kcal 1536 ± 278 1573 ± 333 1609 ± 324 1582 ± 318 
    Fat, g 51.5 ± 12.6 57.2 ± 15.0 56.6 ± 13.3 54.8 ± 16.9 
    Protein, g 59.5 ± 20.3 60.2 ± 18.4 59.5 ± 17.5 58.2 ± 20.0 
    Carbohydrate, g 213.5 ± 43.5 204.3 ± 49.3 215.2 ± 47.2 216.0 ± 51.6 
    Iron, mg 11.7 ± 4.5 13.0 ± 5.8 11.5 ± 3.6 12.3 ± 3.7 
    Calcium, mg 323.4 ± 116.4 340.0 ± 145.5 322.5 ± 158.4 388.8 ± 190.2 
    Ascorbic Acid, mg 79.5 ± 40.8 60.2 ± 37.5 63.1 ± 41.8 67.0 ± 37.9 
    Phytic Acid, mg 534.0 ± 196.9 597.8 ± 251.5 519.1 ± 246.9 598.3 ± 252.5 
n 19 16 18 19 
1 Values are mean ± standard deviations 
2 Minutes of physical activity per week, defined as discretionary exercise, based on a self-reported questionnaire 
3 Value for CRP is given as mean with 1st and 3rd quartiles, due to skewed distribution 
Abbreviations: Stdev: standard deviation; sFer: serum ferritin; Hb: hemoglobin; sTfR: soluble transferrin receptor; VO2max: maximal oxygen consumption; AGP: α-
1-acid glycoprotein; CRP: c-reactive protein
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At baseline, all 72 subjects were iron depleted but not anemic. Of these 72 
women, 39 women (54.2%) were clinically iron deficient defined as sFer less than 
15.0µg/L, 5 women (6.9%) had sTfR values greater than 8.3mg/L, and 12 women 
(16.7%) had body iron less than 0 mg/kg.  Consistent with spending slightly less than 
one hour of discretionary physical exercise per week, VO2max levels indicated subjects 
were at a moderate to average fitness level, with no differences between the groups. 
There were no statistically significant differences in body weight or composition between 
the four groups before or after the study, nor were there significant changes during the 
8-week study period (data not shown). Likewise, there were no differences in reported 
symptomology between the four treatment groups at any time point. Additionally, there 
were no differences between groups for daily iron, calcium, ascorbic acid, phytic acid, 
fat, carbohydrate, protein, or total caloric intake (Table 3.2). Of the 72 subjects, 13 
women (18.1%) had a daily iron intake under the current U.S. estimated average 
requirement of 8.1 mg/day 116. There were no significant differences in inflammation, 
measured as CRP and AGP, between the four groups at any time point in the study, nor 
were there significant changes between time points during the 8-week study period 
(data not shown). During the 8-week study, there were no participants who indicated 
inflammation based on AGP > 1.0 g/L. Only one subject was determined to have 
inflammation based on CRP > 5.0 mg/L, which occurred at week 4. All models were run 
including this subject and again excluding this subject, but no differences were found in 
the results of these analyses, so the subject was included for all analyses reported here. 
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3.4.2 Compliance to treatments 
 
The iron and placebo groups returned 81% and 80% of their capsule bottles, 
respectively, and completed 96% and 92% of their daily capsule logs, respectively. 
There were no significant differences between the number of bottles returned or the 
percent of daily logs completed by the combined iron and combined placebo groups (t-
test, p = 0.87) or in the four individual treatment groups (one-way ANOVA, p = 0.31). 
Estimates of the amount of iron consumed by the two iron groups are shown in Table 
3.3.   
 
Table 3.3: Total capsules and iron consumed by iron supplemented groups over 8 
weeks1, 2 
 Iron Trained Iron Untrained 
 
Conservative 
Estimate 
Average 
Estimate 
Conservative 
Estimate 
Average 
Estimate 
Capsules 
consumed3 
95 ± 13 98 ± 11 97 ± 10 101 ± 7 
 
Iron Consumed 
(g/8 weeks) 
2.0 ± 0.3 2.1 ± 0.2 2.1 ± 0.2 2.1 ± 0.1 
n 19 19 16 16 
 
1Values are means ± standard deviations 
 
2 No group differences were observed for number of capsules consumed or total iron 
consumed for either estimate using one-way ANOVA with a p < 0.05 
 
3 Maximum possible capsules = 112 
 
 
Details of the training sessions attended by each group are shown in Table 3.4. 
The average number of training sessions attended by subjects in the FeTr and PLTr 
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groups was not statistically significantly different (t-test, p = 0.76). The FeTr and PLTr 
groups achieved an average of 90.5% ± 7.8% and 91.9% ± 5.6%, respectively, of the 
target heart rate over the 8 weeks of training, which was not significantly different (t-test, 
p = 0.52). In the combined training groups, 80% of target heart rate was achieved on 
91% of all days trained. Additionally, minutes spent in self-reported physical activity 
outside of the assigned training groups did not differ between groups at any time point. 
At baseline and week 8, 88% and 92% of subjects reached VO2max. There was no 
difference in the percent of each of the groups that reached VO2max at baseline or 
Week 8 (Chi-Square p=0.92 and p=0.13, respectively), suggesting there was equal 
compliance to the testing protocol between groups. 
 
 
Table 3.4: Training sessions attended, by group1 
 
Group N 
Days 
Trained2 
Range3 
% Attending 
≥ 30 days 
Percent 
target HR2 
Iron Trained 19 33.2 ± 5.7 21-40 73.7 (n=14) 90.5 ± 7.8 
Placebo 
Trained 
18 32.7± 3.7 28-40 77.8 (n=14) 91.9 ± 5.6 
 
1 No significant differences were observed between training groups for 
any variable using a t-test, p > 0.05. 
 
2 Values are means ± standard deviation. 
 
3 Maximum possible number of training sessions was 40 sessions. 
 
Abbreviations: HR: heart rate 
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3.4.3 Response to Iron Treatment 
 
Table 3.5 shows the week 8 values for each iron biomarker as well as VO2max 
after 8 weeks of treatment. Unadjusted means and standard deviations for each group, 
by time point can be found in Supplemental Table 1 in the online supporting materials. 
No significant 3-way interaction effects (supplement type by training group by time) 
were observed for any of the outcome measures in the linear mixed models (data not 
shown), nor were there significant interaction effects between time and training in any 
model. Significant training by supplement type interactions were observed for sFer and 
Hb, which will be discussed separately.  
There was a significant interaction effect between time and supplement type for 
sTfR (interaction p = 0.039). At week 8 the iron group had a significantly lower sTfR 
concentration than the placebo group (4.9 ± 0.9 mg/L and 5.9 ± 1.8 mg/L, respectively, 
p < 0.001). No significant two-way interaction effects were observed for Body Iron. 
However, the iron group had significantly higher body iron than the placebo group (5.7 ± 
1.9 mg/kg and 2.8 ± 2.5 mg/kg, respectively, p < 0.001). 
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Table 3.5: Effects of training and supplement type1 
Group n 
sFer 
(µg/L) 
Hb       
(g/L) 
sTfR 
(mg/L) 
Body Iron 
(mg/kg) 
VO2max 
(L/min/kg) 
   FeTr 19 31.8 ± 13.5 139.4 ± 8.0 5.3 ± 1.0 4.7 ± 1.9 43.3 ± 4.1 
   FeUn 16 47.6 ± 15.7 143.3 ± 6.7 4.4 ± 0.7 6.9 ± 1.3 40.8 ± 4.3 
   PLTr 18 21.3 ± 12.2 137.3 ± 9.4 5.9 ± 1.3 2.6 ± 2.8 42.4 ± 3.5 
   PLUn 19 20.3 ± 7.0 135.3 ± 10.3 5.9 ± 2.3 2.9 ± 2.2 38.8 ± 4.5 
   Supplement p value2  <0.001 0.003 <0.001 <0.001 0.28 
   Training p value2  0.034 0.66 0.018 0.023 <0.001 
   Interaction p value2  0.072 0.030 0.86 0.17 0.50 
Supplement Effect3       
   FeTr - PLTr P value  <0.001 1.00    
   FeUn - PLUn P value  <0.001 0.003    
Training Effect3       
   FeTr - FeUn P value  0.042 0.43    
   PLTr - PLUn P value  1.00 1.00    
 
1 Values are unadjusted means ± standard deviation, at week 8 
 
2 Results of linear mixed models, adjusted for baseline. Interaction p value represents the supplement type by training 
group interaction.  
 
3 P values of post-hoc pairwise comparisons with Bonferroni corrections, reported for measures where a significant 
training-by-supplement group interaction was observed. 
 
Abbreviations: sFer: serum ferritin; Hb: hemoglobin; sTfR: soluble transferrin receptor; VO2max: maximal oxygen capacity; 
FeTr: iron trained; FeUn: iron untrained; PLTr: placebo trained; PLUn: placebo untrained
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3.4.4 Response of VO2max to Aerobic Training 
 
There was no interaction observed between training group and supplement type 
for VO2max; however, a significant training effect was observed. The trained group had 
a significantly higher VO2max after treatment than the untrained group (42.8 ± 3.8 
mL/min/kg and 39.7 ± 4.5 mL/min/kg, respectively, linear mixed model p < 0.001). 
Within the training group, the number of training sessions attended (range: 21-40 
sessions) was not significantly associated with the 8-week change in VO2max (linear 
regression, r2 = 0.01, p = 0.42). 
 
3.4.5 Interaction of Supplement and Training 
 
Significant interaction effects between supplement type and training group were 
observed for sFer and Hb (p = 0.072 and 0.030, respectively, Table 3.5). The study was 
not powered at the 0.05 level to detect a clinically relevant 2-way interaction between 
training and supplement type, such as that observed for sFer. Additionally, the 
calculated sample size of 25 women per group was not achieved due to research 
conditions in the field. Therefore, the P value for the interaction (p = 0.07) was treated 
as being significant even though it did not reach the pre-specified 0.05 level. A reduced 
model was run including only the supplement-by-training group interaction term, where 
it retained its significance (p = 0.07). Post-hoc pairwise comparisons between 
supplement and training groups were adjusted for multiple comparisons using a 
Bonferroni correction (Table 3.5).   
In examining the training-by-supplement interaction for sFer, shown in Figure 2, 
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both the iron trained and iron untrained groups showed significantly higher sFer values 
than either of the placebo groups. However, sFer in the subjects who received training 
in addition to iron supplementation was significantly lower than that of those subjects 
who did not train. For the training-by-supplement interaction for Hb, the FeUn group had 
a significantly higher Hb after treatment than the PLUn group. There were no other 
significant post-hoc comparisons for the training-by-supplement interaction for Hb.  
Academic semester of testing was included as a covariate in all linear mixed 
models but was not statistically significant. The interaction between training and 
supplementation for the sFer model was maintained when baseline age, height, weight, 
and VO2max were included as covariates in the models predicting sFer. None of these 
covariates were significant at p < 0.05. In order to determine whether the changes 
observed in sFer were independent of Hb, a model was run including Hb as a covariate. 
The significance of the training-by-supplement interaction and all trends in the post-hoc 
comparisons were maintained when Hb was included as a covariate (interaction p = 
0.09), while Hb was not significant in the model (p = 0.81). 
To examine the biological plausibility of the main findings, several secondary 
analyses were conducted. No relationship was found between the number of days 
trained and change in sFer in either of the supplement groups. Additionally, there was 
no significant association between the number of capsules consumed and the change in 
sFer in either supplement group, even when sFer status at baseline was included as a 
covariate. The same result was seen using the more conservative compliance measure 
for the number of capsules consumed. However, when only those subjects who 
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Figure 3.2: LS means for the training by supplement type interaction for serum 
ferritin 1, 2, 3 
 
 
1 Values are post-hoc pairwise comparisons between supplement and training groups 
with 95% Confidence interval bands for the reduced model that did not include time 
point. The P value for the supplement by training group interaction was p = 0.07.  
 
2 N per group: 19 FeTr, 16 FeUn, 18 PLTr, and 19 PLUn subjects 
 
3 A, B, and C indicate that post-hoc pairwise comparisons between supplement and 
training groups had significant differences from all groups with differing letters.  
Results are from linear mixed models controlling for baseline, where Bonferroni 
corrections for multiple comparisons have been applied to the post-hoc pairwise 
comparisons between groups.  
 
Abbreviations: sFer: serum ferritin; FeTr: iron trained; FeUn: iron untrained; PLTr: 
placebo trained; PLUn: placebo untrained 
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returned 100% of their capsule bottles and daily logs were examined (n=25), there was 
a positive relationship between the number of capsules consumed and the change in 
sFer for the iron group (r2=0.39, p=0.04) but no relationship in the placebo group (data 
not shown). Subjects who had the highest sTfR concentrations at Week 0 (i.e. the 
lowest tissue iron levels) displayed the largest decreases in sTfR over the 8-week study 
period when given iron supplements, but no change was observed in those given the 
placebo (supplement by week 0 sTfR concentration interaction, linear model, p <0.001).  
This same trend was observed for body iron, with those subjects starting with the lowest 
body iron showing the largest improvements in body iron over the 8-week study 
(supplement-by-week 0 body iron concentration interaction p = 0.03). 
In a subgroup analysis of subjects with more severe iron depletion (sFer < 20 
µg/L) at baseline, 100% of the FeUn group repleted their iron stores by 4 weeks, and 
this resolution persisted until 8 weeks. Conversely, after 4 weeks only 53.5% ± 12.9% of 
the FeTr group had resolved their iron depletion and only 73.3% ± 11.4% by week 8. 
Figure 3.3 shows the prevalence of iron depletion within each group at each time point. 
Relative risk (RR) calculations were performed to determine pairwise differences in 
percent resolution between the four treatment groups.  
 
 
 
 
 
 83 
 
Figure 3.3: Percent of women with iron depletion (sFer < 20µg/L) by treatment 
group at 4 and 8 weeks 1, 2 
 
 
1 All subjects were iron depleted (sFer < 20 µg/L) at baseline. N per group: 19 FeTr, 16 
FeUn, 18 PLTr, and 19 PLUn subjects 
 
2 Values are percent, bars are standard error  
 
3 No iron-untrained subjects were depleted at Week 4 or 8; i.e. there was total resolution 
of iron depletion in this group 
 
Abbreviations: FeTr: iron trained; FeUn: iron untrained; PLTr: placebo trained; PLUn: 
placebo untrained 
 
 
At the end of the 8-week study period, the FeTr group was no more likely to be 
iron replete than the PLTr or PLUn group (FeTr/PLTr: RR=1.83, 95% CI: 0.92, 3.66,      
p = 0.51; FeTr/PLUn: RR=2.05, 95% CI 0.95, 4.42, p = 0.39); however, the FeUn group 
was 2.5 times more likely to be replete than the PLTr group and 2.8 times more likely to 
be replete than the PLUn group (RR=2.50, 95% CI: 1.35, 4.65, p<0.05, and RR=2.80, 
95% CI: 1.39, 5.65, p<0.05, respectively).  
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3.5 Discussion 
 
Improvements in iron status measures in both of the iron-supplemented groups 
demonstrate that the supplementation regimen was adequate to elicit changes in iron 
status. After 8 weeks of treatment, the iron-supplemented group had significantly higher 
sFer and body iron and significantly lower (indicating better iron status) sTfR 
concentrations than the placebo group. Previous studies have shown that 100 mg/day 
of ferrous sulfate is sufficient to cause changes in iron status markers of similar 
magnitudes as those observed in this study 3. Similarly, post-training improvements in 
VO2max in the trained groups confirm that the training program was sufficient to induce 
physiological adaptations. The high compliance to the training program (89% of subjects 
attending > 28 days) likely explains this effect, though the narrow range in the number 
of sessions attended likely limits our ability to find a dose-response effect of training on 
VO2max.  
 Aerobic training lowered the effectiveness of iron supplementation in improving 
traditional measures of iron status, as evidenced by the significant training-by-
supplement interaction in linear mixed models of sFer effects. While both iron 
supplemented groups showed significant improvements in sFer, the improvements of 
the trained subjects were significantly smaller than those of the untrained group. One 
interpretation of this finding is that subjects who trained while taking iron supplements 
did not benefit from the supplements as much as those who did not train.  
Additionally, by week 8, 100% of the FeUn group had resolved their iron 
depletion, as defined by sFer < 20 µg/L, compared to only 73% of the FeTr group. 
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These findings are consistent with those of McClung and colleagues, who found that 
participation in basic combat training decreased iron status in female soldiers 78,117.  
While the modifying effect of aerobic training on iron status is demonstrated by 
the results of this study, the physiological mechanism explaining this effect remains 
unclear.  Possible explanations include: reduced absorption of iron due to exercise-
induced inflammation, increased demand for iron in the oxidative pathways, or 
increased production of total body Hb or myoglobin, which could be supported by 
redirecting iron from iron stores toward erythropoietic processes 32,63,118,119.  
 There is currently conflicting evidence about whether long-term, moderate 
exercise results in a chronic inflammatory state that could affect iron status. Both acute 
and chronic inflammation result in increased concentrations of hepcidin, the primary 
regulator of iron absorption in the body. While studies have demonstrated a relationship 
between increased hepcidin expression and lower iron status after acute exercise 120,121, 
few studies have shown a long-term impact 121,122.  Outside of the role of hepcidin, 
several studies have shown that inflammation induced by exercise 123 or chemical 
injection 124,125 results in decreased expression of proteins required for iron absorption 
into the enterocyte. While this study did not detect inflammation using CRP or AGP, 
inflammation may still have been present in this population. This study did not measure 
hepcidin, its mediator IL-6, or proteins involved in iron absorption. Therefore, we cannot 
determine whether inflammation or absorption differed between the FeTr and FeUn 
groups. 
 There is evidence that exercise-induced increases in erythropoiesis draw iron 
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from the other iron stores in the body to meet the increased iron demand 32,126, which 
could explain the smaller increase in sFer observed in the FeTr group compared to the 
FeUn group. However, the details of muscle iron homeostasis in conditions of high 
erythropoietic demand, such as long-term aerobic training, remain unclear. Some 
studies have shown the increased iron demand for erythropoiesis draws iron from 
myoglobin 32, whereas others suggest it comes from the liver 107,126. It is possible that 
the iron entering the body in the FeTr group was used directly for erythropoiesis or 
muscle growth. In this study, the FeUn group showed significantly higher Hb after iron 
supplementation than the PLUn group; however, the FeTr group did not have 
significantly higher Hb than the other groups. This finding may support the idea that 
training increased the erythropoietic demand for iron, and the supplemented iron was 
used directly for this process rather than being stored as ferritin. However, if training 
were increasing the demand for iron for erythropoiesis, it would therefore be expected 
that the PLTr group would show decreases in their serum ferritin, which was not 
observed. It is possible that iron contained in muscle myoglobin was diverted for use in 
erythropoiesis in the PLTr group; however, this study was unable to assess myoglobin 
and thus cannot determine whether this was the case. 
Finally, it is possible that there was an increased iron demand in skeletal muscle 
mitochondrial bioenergetics pathways, as many enzymes and cofactors in energy 
production are iron dependent. It has been shown that ID impairs mitochondrial 
function32 and that aerobic exercise training in combination with iron supplementation 
improves mitochondrial function and density127–129. Therefore, it is also feasible that the 
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iron in the FeTr group was used to synthesize the enzymes needed for increased 
energy production or skeletal muscle growth known to occur with training32,130.  
One limitation of this study was its short duration, which may have been 
insufficient to observe any long-term effects. Additionally, blood and exercise data were 
not collected for women who dropped out, thus limiting our ability to perform a true 
intention-to-treat analysis. The subjects who dropped out or were excluded from 
analyses due to discrepancies in their sFer values at baseline may have been 
systematically different than those who were retained; however, there were no baseline 
differences between those subjects who dropped out or were excluded and those who 
were retained. The study may have had increased type I error due to the assessment of 
multiple biomarker variables. Additionally, the training group was not blinded, potentially 
introducing bias. Finally, this study was unable to measure other, potentially more 
appropriate measures of iron status such as those involved in inflammation, muscle 
growth, or erythropoiesis. Further investigation requires more invasive or more 
expensive analysis techniques, such as metabolomics, that would provide a more 
comprehensive view of iron metabolism. However, our results support the idea that sFer 
and Hb may not be the best biomarkers for iron status in non-anemic, physically active 
populations. 
3.6 Conclusion 
 
 We have demonstrated that regular, aerobic training diminishes the effectiveness 
of iron supplementation on improving sFer in iron-depleted, non-anemic women, 
compared to untrained women. Iron supplementation was still able to increase sFer in 
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trained women, but at a slower rate. This finding could have implications for 
interventions aiming to improve iron status in physically active populations, such as 
women who train casually to improve fitness in developed countries or in developing 
countries where heavy manual labor is necessary for economic livelihoods. Typically, 
iron supplementation interventions can run for 4-6 weeks at the dose used in this 
study3,14. This dose can be sufficient in that time frame, as evidenced by the 100% 
resolution of iron depletion in the iron untrained group. However, our study suggests 
that longer interventions may be necessary to improve iron stores of active women. 
Further research should explore whether a larger dose of iron can counteract the 
modifying effect that daily exercise has on improvements in sFer and whether this effect 
has any long-term impacts. Additionally, further research should determine an optimal 
iron intervention dose and duration for active populations and develop other, more 
appropriate biomarkers that are more indicative of iron involved in muscle metabolism 
and erythropoietic processes. 
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Chapter 4: Aerobic training and elevating iron status equally improve 
submaximal performance 
 
4.1 Abstract 
 
Introduction/Purpose: Iron deficiency persists as the most common micronutrient 
deficiency globally, despite having known detrimental effects on physical performance. 
While iron supplementation and aerobic exercise have been examined individually and 
are both known to improve physical performance, the impact of simultaneous iron 
supplementation and aerobic training remains unclear. The goal of this study was to 
examine the individual and combined effects of iron supplementation and aerobic 
training on improving maximal and submaximal physical performance measures. 
Methods: Seventy-three iron depleted, non-anemic women (serum ferritin < 25 µg/L and 
hemoglobin > 110 g/L) participated in a partially-blinded, 8-week randomized placebo-
controlled trial with a 2x2 factorial design including aerobic exercise training (5 
days/week of 25 minutes at 75-85% maximum heart rate) or no training and iron 
supplementation (42 mg elemental iron/day) or placebo. Linear models were used to 
examine relationships between training, supplement, and changes in exercise 
performance, measured as oxygen consumption (VO2) at maximal exertion (estimated 
VO2max and VO2peak) and at the ventilatory threshold (absolute VO2 and percent of 
estimated maximum VO2).  
Results: There were significant 2-way interactions between training and supplement for 
VO2peak, VO2 at the ventilatory threshold, and the percent of estimated VO2max at 
which the threshold occurred. These variables were significantly higher in the iron-
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trained, iron-untrained, and placebo-trained groups compared to the placebo-untrained 
group. However, there were no significant differences between these three groups 
themselves for any performance variable. 
Conclusions: Iron supplementation given to sedentary women resulted in increases in 
submaximal physical performance of the same magnitude as those produced by aerobic 
training. Furthermore, there was no an additive effect of supplemental iron to aerobic 
training above the effect of either treatment alone. 
 
4.2 Introduction 
 
In China, 20-34% of women of childbearing age suffer from iron deficiency 
anemia. This rate does not account for the prevalence of iron deficiency without anemia 
[IDNA, defined as Hemoglobin (Hb) > 110 g/L and serum ferritin (sFer) < 15 μg/L], 
which can be as high as double the rate of anemia in some populations131. The 
widespread prevalence of IDNA has consequences beyond basic nutritional 
deficiencies, as iron deficiency with and without anemia are also known to impair both 
endurance performance and maximal exercise capacity132–134. These functional 
consequences have implications for a wide range of women including athletes and 
those trying to increase physical performance for health reasons in high-income 
countries as well as manual laborers in developing areas. There is evidence that 
improving iron status can have positive impacts on physical performance in active 
women3,78; however, the relationship between iron status and physical performance 
when iron status and fitness level are changing simultaneously remains unclear.    
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It is well-established that the worsened physical performance (measured as 
maximal oxygen consumption, VO2max) observed in IDA is a result of impaired O2 
delivery to tissues36,49. However, IDNA is also known to negatively impact physical 
performance outside of the role Hb plays in oxygen delivery. In iron deficient animal 
models where Hb was replete, worsened endurance capacity was determined to be a 
result of impaired muscle oxidative capacity from reduced mitochondrial enzyme 
productivity, not impaired oxygen delivery34,49. This effect of IDNA has also been 
observed at the functional level in human studies of physical performance that have 
demonstrated impaired aerobic capacity, endurance, and energetic efficiency in IDNA 
women3,45,104.  When a group of IDNA women were given 100 mg/day of ferrous sulfate 
or a placebo and aerobically trained 5 days/week for six weeks, those women who were 
given iron adapted better to training than those given a placebo as demonstrated in 
performance tests, with a shorter time-to-completion, lower respiratory exchange ratios, 
and increased work rates during a 15 km time-trial on a cycle ergometer3. Untreated 
IDNA also impairs the typical adaptations to aerobic exercise training, including 
reducing endurance capacity104 and lower VO2max77 values after training compared to 
iron replete women.  
While these studies all provide evidence of the positive effects that iron 
supplementation can have on the adaptive response to aerobic training, there is 
currently little evidence of the effect that iron supplementation has on the physical 
performance of women who are not physically active. To our knowledge, no study has 
yet examined whether changing iron status from iron supplementation modifies the 
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adaptations in fitness level that occur from concurrent regular aerobic training. 
Therefore, the goals of this study were first to determine whether 8 weeks of iron 
supplementation modifies the response to aerobic exercise training in IDNA women and 
second to examine how supplemental iron impacts the physical performance of 
sedentary women who do not train, thus comparing the individual and combined effects 
of iron supplementation and aerobic training on physical performance. We hypothesized 
that women who receive iron while training will show the greatest improvements in 
physical performance outcomes compared to women who receive either treatment 
alone. Additionally, we expect that women who receive either training or iron alone will 
show improvements in physical performance measures compared with those who 
received no training and the placebo treatment.  
4.3 Subjects and Methods 
 
4.3.1 Subjects 
 
This study took place in two sessions (fall semester: September – December 2014 and 
spring semester: March – June 2015). Ninety-eight women participated in screening 
during the fall session, and another 281 were screened in the spring session (Figure 
4.1).  
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Figure 4.1: Consort Diagram for Chapter 41 
 
1 Abbreviations: RCT: randomized control trial; sFer: serum ferritin  
 
Of these women, 191 were identified as iron-depleted and non-anemic, defined 
as sFer < 25 μg/L and Hb > 110 g/L. A cutoff of 25 μg/L was used for iron depletion 
because prior literature suggests that physical performance and iron stores change can 
occur in iron-supplemented women who are not clinically iron deficient but still have 
depleted iron stores8,10,112. Anemia was defined as Hb > 110 g/L to align with the 
standards of care used by the First Affiliated Hospital of Kunming Medical University, 
where the screening blood analyses were conducted. Subjects were screened to 
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identify and exclude those women who met any of the following criteria: history of eating 
disorders, smoking, BMI < 17 or > 25 kg/m2, anemia (Hb < 110 g/L), hemolytic anemia, 
current pregnancy or pregnancy within the previous year, current lactation or lactation 
within the previous year, recent infectious illness or fever, current inflammation or 
chronic inflammatory diseases, chronic respiratory disease, musculoskeletal problems, 
or recent consumption of iron supplements, vitamin supplements, or medications that 
may affect dietary iron intake or absorption or that had anticoagulant properties. 
Additionally, subjects completed a physical activity questionnaire that indicated they 
were not participating in any organized sports or regular exercise activities, had an 
interest in increasing their current fitness level, and would be willing to comply with the 
full 8-week training regimen if randomized to a training group. Out of 191 eligible 
women, 124 agreed to participate in the study (45 fall, 79 spring). Recruitment for this 
study included selecting subjects for two arms that received a Chinese herbal 
supplement and are not included in this analysis (see Chapter 5), which includes only 
the iron and placebo supplemented groups. Out of the 124 study participants, 85 were 
randomized to the four arms relevant to this study. 
 During the study, 9 women (from all four treatment arms) dropped out of the trial 
for personal and health reasons. Another 5 women were excluded from statistical 
analyses because they were identified as having baseline sFer > 25 μg/L in final blood 
analyses, which were conducted in a single batch consisting of weeks 0 and 8 together 
after the study’s completion. Therefore, despite having been identified as iron depleted 
(sFer values 23.5 - 24.9 μg/L) at the initial screening, these subjects were excluded 
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from the final analyses. The final sample size for this analysis was 73 women. Signed 
informed consent was obtained from each subject. The study was approved by the 
Cornell University Institutional Review Board and the Kunming Medical University 
Ethical Committee and registered under ClinicalTrials.gov #: NCT03002090. 
 
4.3.2 Study Design 
 
This study used a 2x2, double-blind, randomized, placebo-controlled intervention 
design. Subjects were randomly assigned by the author (LMP) to treatment groups via a 
random number generator. Subjects were randomized to receive training or no training 
and iron or placebo capsules, creating a total of four groups: iron trained (IT), iron 
untrained (IU), placebo trained (PT), and placebo untrained (PU). A training protocol 
published by Hinton et al that has been shown to produce measurable changes in 
performance measures was adapted to meet an 8-week training schedule3. The 
adapted training protocol is shown in Table 3.1.  
Subjects were asked to train 5 days per week for 8 weeks, with the maximum 
number of training days being 40. Each training session lasted 25 minutes, which was 
divided into time spent pedaling at 60 revolutions per minute (RPM) at 75% or 85% of 
subjects’ age-predicted maximum heart rate (220 beats per minute – years of age). The 
first two minutes of the 25-minute session were considered a warm-up period and were 
conducted at the lowest workload on the training ergometer. After the first two minutes, 
the workload (in watts) was adjusted to ensure subjects were meeting their target heart 
rate throughout the session. Each week the time spent at 85% of maximum heart rate 
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was increased in order to continually challenge the subjects as their fitness level 
improved.  
 Training was performed on a stationary exercise bicycle (KangLe Exercise 
Products, Stationary Bicycle model B8.4E, Yunnan, China) equipped with digital output 
of work (watts) and cadence (RPM). Heart rate was read from a Polar A5 heart rate 
watch (Polar Electro Inc., Lake Success, NY) synced to a T31 Polar heart rate monitor 
worn around the subject’s chest. Trained research assistants recorded the watts, heart 
rate, and speed of each subject in a training log every 5 minutes throughout each 
session.  
 Additionally, according to their randomization group, all subjects received either 
100 mg of ferrous sulfate or an identical placebo capsule, twice daily throughout the 8-
week study period (200 mg total/day). Investigators and subjects were both blinded to 
capsule type until after the intent-to-treat data analyses were conducted. All capsules 
were prepared by the author (LMP) using dextrose filler, ferrous sulfate, and gelatin 
capsules (PCCA, Houston, TX).  During the study, a random selection of 20 capsules 
was taken from each supplement and placebo batch and stored in a sealed container in 
a cool, dry location until post-study analysis via ICP/MS. Sample size calculations were 
based on the assumption that subjects would consume a minimum of 12 mg of 
elemental iron per capsule over the 8 weeks. The iron concentrations of the placebo 
and iron capsules were determined to be 0.00 mg and 21.1 mg ± 1.1 mg elemental iron 
per capsule, respectively, thus meeting that requirement. Previous studies have shown 
that iron status can be increased after a 4-week course of a similar iron dose3,45. 
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 Subjects were instructed to consume the capsules with citrus juice during their 
morning and evening meals in order to avoid gastrointestinal side effects and maximize 
absorption. Every 2 weeks, beginning at week 0, 30 capsules were distributed to each 
subject in a bottle labeled with their individual subject ID number. Subjects were asked 
to record their morning and evening capsule ingestion, daily medication use, menstrual 
cycle status, illnesses, injuries, and physical activity on a daily log that was distributed 
with the capsule bottles every 2 weeks. Additionally, subjects returned their old capsule 
bottles along with any remaining capsules every two weeks. Returned capsules were 
counted as an independent confirmation of the values reported by the subjects on the 
daily logs.  
 Subjects were instructed to record the minutes and type(s) of physical activity 
they performed each day, excluding that of the training program, on their daily logs 
throughout the study period. Minutes of self-reported physical activity were tallied over 
the 8-week study period and METs were calculated from the 2011 Compendium of 
Physical Activities135. Furthermore, participants completed a physical activity frequency 
questionnaire prior to the study to assess habitual physical activity levels among 
groups. During the study, subjects were instructed to maintain their regular activity 
patterns throughout the 8-week study duration, regardless of whether they were 
participating in the training program. 
 Dietary assessments were conducted at baseline using a 4-day diet record from 
Thursday to Sunday before the study began. Records were analyzed for daily intake of: 
iron, inhibitors and enhancers of iron absorption, and macronutrient content using 
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Nutrition Data System for Research Software (2016, University of Minnesota). 
Additionally, percent body fat was estimated, and mid-upper arm circumference was 
measured before and after the study. 
 All subjects received a gift as compensation for their participation in the study. 
Trained subjects were offered additional incentives to increase compliance to the 
training program. These incentives were small gifts when they completed 25, 32, and 40 
training sessions. While all subjects received the same gift for participation in the full 
study, only trained subjects were eligible for the smaller incentive gifts. 
 
4.3.3 Physiological measurements 
 
Weight and height were measured using standard protocols that have been 
described previously114. Body composition was estimated from skinfold thicknesses 
measured in triplicate with Lange calipers (Cambridge, MD) at the triceps, biceps, 
subscapular, and suprailiac sites. The Durnin and Womersley equation was used to 
calculate body density and percent body fat115.  
A graded exercise test was performed at baseline and at week 8 using a 
mechanically braked and calibrated cycle ergometer (Monark 884E, Monark Exercise 
AB, Vansbro, Sweden). Oxygen consumption was measured during the test, which 
varied in difficulty from rest to approximately 100% of each subject’s maximal exertion 
level. A portable metabolic measurement system (Cosmed K4B2, Cosmed, Rome, Italy) 
in which subjects breathed room air via a two-way valve on a facemask was used to 
assess metabolic parameters including: volume of respired air (VE), concentrations of 
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oxygen and carbon dioxide in expired air, and heart rate (HR).  
 Subjects were instructed not to participate in any strenuous physical activity 
within 24 hours of their exercise test. Subjects in the training group attended the training 
session on the day before their test but did not train on the day of the VO2max test itself. 
Additionally, subjects were also instructed not to consume any foods or caffeinated 
products within 3 hours of their scheduled test. None of the subjects reported smoking 
during the study. 
 The testing protocol was adapted from a similar test used by Brownlie et al77. 
Testing began once the subject’s heart rate was below 100 beats per minute. After a 5-
minute warm-up where subjects pedaled at 50 RPM against a 1 kg workload, workloads 
were increased by 0.4 kg every 2 minutes until VO2 increased no more than 150 mL/min 
from the prior workload. Because attaining this level is quite challenging for most 
subjects, it was expected that many women would be unable to reach a plateau in VO2. 
Therefore, if no plateau was reached, the test proceeded until the subject could not 
continue or voluntarily ceased pedaling. Subjects were considered to have reached 
VO2max if they achieved any two of the following conditions: a heart rate within 10 
beats/min of their age-predicted maximum heart rate (220 - age), a blood lactate 
concentration > 8.0 mM, or a respiratory exchange ratio > 1.15. The highest measured 
VO2 achieved during this test was designated as VO2peak. At baseline and week 8 only 
69.9% and 60.3% of subjects, respectively, met the criteria for VO2max during exercise 
testing. Therefore, for subjects who failed to meet VO2max criteria, an estimated 
VO2max (eVO2max) was calculated by plotting heart rate against VO2 and extrapolating 
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to the VO2 value for the age-predicted maximum heart rate (220 - age). The variable 
eVO2max thus reflects the measured VO2max for those subjects who met the VO2max 
criteria and the estimated value for those subjects who did not meet the criteria. 
Ventilatory threshold (VT) was calculated by combining three methods 
(ventilatory equivalencies, excess CO2 production, and modified V-slope), as described 
by Gaskill et al100. This combined method has been shown to be appropriate for women 
of the fitness level and general healthy state as those in this study and improves the 
accuracy of the VT calculation compared to any one method alone100. Percent of 
VO2peak or eVO2max at VT was calculated by taking the observed VO2 value at VT and 
dividing by the peak or estimated VO2max value, respectively.  
Blood lactate was measured immediately after completion of the last grade of the 
performance test via finger stick using a Lactate Plus portable blood lactate analyzer 
(Nova Biomedical, Waltham, MA, USA). 
 
4.3.4 Iron status measurements 
 
Iron status was measured before and after the 8-week study period from whole 
blood that was collected from the antecubital vein into 4 mL serum collection 
vacutainers by a licensed phlebotomist at Kunming Medical University’s student 
hospital. Immediately after the blood draw, a small sample of whole blood was analyzed 
for Hb. The remaining samples were stored at 4°C for no longer than 24 hours, when 
then were centrifuged at 1600 g for 10 minutes at room temperature. After 
centrifugation, serum was separated into 0.5 mL aliquots and frozen at -80° C for later 
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analyses. Samples from weeks 0 and 8 were analyzed for sFer, sTfR, alpha-1-acid 
glycoprotein (AGP), and C-reactive protein (CRP) at the First Affiliated Hospital of 
Kunming Medical University and at the Shanghai Fenglin Clinical Laboratory in the fall 
and spring sessions, respectively. To allow for comparisons between the two labs, 75 
samples from the second wave were run at both labs and correlations between 
measures were examined using Pearson correlations (adjusted R2 = 0.86) and Bland-
Altman plots. sFer, sTfR, AGP, and CRP were all analyzed on a Siemens Advia 2400 
automated analyzer (Siemens Healthcare, Erlangen, Germany). Hb was determined 
using a Coulter LH 750 Hematology analyzer (Beckman Coulter, Inc. Brea, CA). Total 
body iron was calculated using the ratio of sTfR to sFer and the equation reported by 
Cook et al23: 
Total Body Iron (mg/kg) = - [log(sTfR/sFer) - 2.8229] / 0.1207 
Cook’s equation uses sTfR values from Ramco ELISA kits (Ramco Laboratories, 
Stafford, TX). To match these values, 35 random duplicate samples of serum analyzed 
at the Chinese laboratories were also run on Ramco Laboratories sTfR ELISA kits to 
determine the following conversion equation: 
sTfRRamco (mg/L) = (3.779 x sTfRlab) + 0.400, R2 = 0.93 
 
4.3.5 Compliance Analyses 
 
Compliance to training was assessed via a training score, calculated as the 
number of days trained multiplied by the total percent of the target heart rate achieved 
each day throughout training. This score should therefore reflect both the quantity and 
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the intensity of the training that the subject received. The highest possible training score 
was 40, which reflects both perfect attendance and 100% attainment of target heart rate 
on all training days. Additionally, percent of target RPM was used to reflect the subjects’ 
compliance to the instructions to maintain a constant speed of 60 RPM throughout the 
training program. 
 Compliance to capsule ingestion was assessed in two ways, from the daily logs 
filled out by the participants and the from actual count of capsule remaining in the 
returned bottles every two weeks. The Pearson correlation coefficient between the 
capsules returned in the capsule bottles and those reported as missing on the daily 
longs was 0.39 (p = 0.01), which indicates there were discrepancies between the two 
measurements. Therefore, in order to make a more reliable estimate of capsule 
consumption, two compliance variables were calculated: an average estimate and a 
conservative estimate. The average estimate was calculated by taking the average of 
the number of capsules returned and the number of capsules reported as taken in the 
logs. The conservative estimate was created by comparing the reported consumption to 
the returned capsule counts and taking the higher number of missed capsules (reported 
or returned physically) as the number missed. No significant group differences were 
found in the number of capsules taken using either method. Additionally, both methods 
were used in the compliance analyses and produced the same results. Therefore, only 
the conservative estimate is reported.  
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4.3.6 Statistical Analyses 
 
Sample size calculations were based on two studies that suggest that iron 
supplementation benefits unfit women participating in an aerobic training program 
similar to the program used in this study3,109. Sample size was determined to require 25 
subjects in each of the four groups, which was expanded to 29 subjects per group after 
anticipated attrition, to detect a 4.2 μg/L difference in sFer between groups, or 0.8 
standard deviations.  Change in sFer that corresponded to biologically meaningful 
changes in physical performance with 80% power and α = 0.05. Log transformations 
were made for variables found to have non-normal distributions (sFer and sTfR). Group 
differences at baseline were tested using one-way ANOVA. Physical performance 
measures at week 8 were analyzed using linear models testing for the main effects of 
supplement and training group as well as the training group by supplement 
interaction136. Baseline values were included as a covariate for each measure of 
physical performance. Semester (fall or spring session) of testing was included in all 
models. For all analyses, statistical significance was defined as p < 0.05 for single 
variables or p < 0.1 for interaction terms. Post-hoc pairwise comparisons were made 
with Tukey corrections for multiple comparisons. Secondary analyses were performed 
using linear models to test for relationships between variables with a significance level 
defined as p < 0.05. All statistical analyses were performed using SAS 9.4 (SAS 
Institute, Cary NC). 
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4.4 Results 
 
4.4.1 Subject characteristics 
 
There were 20 iron trained, 16 iron untrained, 19 placebo trained, and 18 placebo 
untrained subjects included in the final analyses. There were no statistically significant 
differences between groups for any background measure on the basis of one-way 
ANOVA (Table 4.1). All subjects began the study iron depleted, but not anemic. At 
baseline, 39 of the 73 subjects (53.4%) were clinically iron deficient, defined as sFer < 
15.0 µg/L, 12 women (16.4%) had body iron < 0 mg/kg, and 5 women (6.8%) had sTfR 
values > 8.3 mg/L.  
There were no significant group differences in body composition or weight at 
baseline, nor were there significant changes in weight or body composition during the 8-
week study in any group (data not shown). Daily dietary intake of iron, ascorbic acid, 
calcium, phytic acid, carbohydrates, fat, protein, or total caloric intake did not vary 
across groups at baseline. Additionally, there were no differences in reported 
symptomology across the four groups during the study. Inflammation, measured as 
CRP and AGP, showed no significant group differences at baseline (Table 4.1) or after 
the 8-week study period (data not shown).  During the study period, no participant 
demonstrated clinical inflammation based on AGP or CRP (AGP > 1.0 g/L or CRP > 5.0 
mg/L).  
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Table 4.1: Chapter 4 baseline characteristics, by intervention group1, 2  
 
Characteristic Iron  
Trained 
Iron 
Untrained 
Placebo 
Trained 
Placebo 
Untrained 
Anthropometry     
    Age (yr) 20.5 ± 1.0 20.2 ± 0.8 20.6 ± 1.3 20.6 ± 1.8 
    Height (cm) 157.1 ± 5.7 156.9 ± 6.2 157.3 ± 4.7 157.5 ± 5.2 
    Weight (kg) 52.2 ± 7.3 51.6 ± 7.9 53.2 ± 6.1 51.0 ± 5.5 
    BMI (kg/m2) 21.2 ± 2.9 21.0 ± 3.5 21.5 ± 2.1 20.6 ± 2.1 
    Body Fat (%) 29.3 ± 3.4 28.3 ± 5.1 29.1 ± 4.2 28.8 ± 2.3 
Blood Biomarkers     
    Hb (g/L) 135.4 ± 8.8 140.7 ± 5.2 137.2 ± 10.1 135.3 ± 6.5 
    sFer (µg/L) 14.6 ± 6.1 17.1 ± 4.2 14.2 ± 4.6 15.5 ± 5.8 
    sTfR (mg/L) 6.7 ± 3.1 5.3 ± 0.8 5.9 ± 1.5 6.0 ± 1.7 
    Body Iron (mg/kg) 1.3 ± 2.6 2.7 ± 0.9 1.7 ± 1.8 1.8 ± 1.9 
    AGP 0.62 ± 0.09 0.61 ± 0.09 0.64 ± 0.09 0.58 ± 0.09 
    CRP 0.06 ± 0.12 0.22 ± 0.77 0.21 ± 0.35 0.08 ± 0.13 
Performance Measures     
    Physical activity (min)3 59.8 ± 91.1 56.1 ± 60.5 52.9 ± 71.7 49.0s ± 65.9 
    VO2peak (mL/min/kg) 36.1 ± 4.4 37.3 ± 3.9 36.0 ± 4.2 36.0 ± 3.7 
    eVO2max (mL/min/kg) 40.4 ± 6.0  40.4 ±4.3 40.0 ± 4.5 40.2 ± 3.8 
    Peak HR (beats/min) 185.5 ± 10.0 190.5 ± 8.5  186.9 ± 9.5 185.6 ± 13.1 
    Post-test lactate (mmol) 10.4 ± 2.2 11.7 ± 2.0 11.9 ± 3.4 11.5 ± 2.1 
    VO2 at VT (mL/min/kg) 27.2 ± 4.2 28.8 ± 3.3 28.2 ± 2.9 29.4 ± 3.2 
    Percent eVO2max at VT (%) 77.0 ± 8.3 80.0 ± 5.8 81.1 ± 6.1  84.9 ± 4.1 
Daily Dietary Intake     
    Calories, kcal 1543 ± 272 1573 ± 333 1602 ± 315 1587 ± 327 
    Fat, g 52 ± 12 57 ± 15 56± 13 55 ± 17 
    Protein, g 59 ± 20  60 ± 18 59 ± 17 59 ± 21 
    Carbohydrate, g 215 ± 43 204 ± 49 216 ± 46 216 ± 53 
    Iron, mg 12 ± 4 13 ± 6 12 ± 4  12 ± 4 
    Calcium, mg 325 ± 114 340 ± 146 321 ± 154 394 ± 195 
    Ascorbic Acid, mg 94 ± 57 60 ± 38 65 ±41  83 ± 80 
    Phytic Acid, mg 544 ± 184 662 ± 340 533 ± 247 577 ± 252 
    n 20 16 19 18 
    
1 Values are means ± standard deviations 
 
2 There were no significant differences between the four treatment groups at baseline for any 
anthropometric, blood biomarker, physical performance measure, or dietary intake measure, on the basis 
of one-way ANOVA with an alpha of 0.05.  
 
3 Minutes of discretionary physical activity per week, above walking to and from classes, based on a self-
reported questionnaire 
 
Abbreviations: VO2peak: highest measured oxygen consumption, eVO2max: calculated maximal oxygen 
consumption; VT: ventilatory threshold; VCO2: volume of exhaled carbon dioxide; VE: minute ventilation; 
HR: heart rate; RER: respiratory exchange ratio; OP: oxygen pulse 
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Physical performance measures indicated that the women began the study at an 
average fitness level, with an average VO2peak of 36.8 ± 4.5 mL·min-1·kg-1 and an 
average VO2 at VT of 28.3 ± 3.5 mL·min-1·kg-1 (80.7 ± 6.8% and 66.7 ± 8.3% of 
VO2peak and eVO2max, respectively). Additionally, the four treatment groups did not 
differ in minutes of self-reported physical activity or metabolic equivalents (METs) 
expended per week during the 8-week study period, not including the exercise 
performed as part of the study’s training regimen for the trained subjects (data not 
shown, one-way ANOVA, p > 0.05).  
 
4.4.2 Compliance to Treatments 
 
 The IT and PT groups attended the same number of training days, reached the 
same percent target heart rate, and achieved the same training score during the 8-week 
period (32.9 ± 5.7 days, 90.5 ± 7.8%, and 30.3 ± 5.6 score; and 32.7 ± 3.7 days, 91.9 ± 
5.6%, and 30.6 ± 3.4 score, t-tests, p = 0.92, p = 0.52, and p = 0.83, respectively). 
 There were no differences in the percent of capsule bottles returned by each of 
the four groups or by combined supplement types (one-way ANOVA p = 0.38 and t-test 
p = 0.81, respectively, Table 4.2). Additionally, there were no differences in the percent 
of daily logs completed by group or by supplement type (one-way ANOVA p= 0.51 and 
t-test p = 0.20). The amount of iron consumed over the 8-week study period was the 
same in the iron-trained and iron-untrained groups (2.0 ± 0.3g and 2.1 ± 0.2g, 
respectively, one-way ANOVA, p=0.76).  
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4.4.3 Treatment Effects on Iron Status 
 
There was a significant interaction between training group and supplement type 
for sFer (Table 4.3, interaction p = 0.011). Post-hoc pairwise comparisons indicated that 
the IT and IU groups both had statistically significantly higher sFer concentrations than 
the PT or PU groups. Furthermore, the IT group had a significantly lower sFer 
concentration at week 8 than the IU group (p = 0.012). No interaction was observed for 
Hb (interaction p = 0.67), but a significant supplement effect was observed with the iron-
supplemented group having a higher Hb at week 8 than the placebo (141 g/L and 137 
g/L, respectively, p = 0.025).  
 
 
 
 
Table 4.2: Capsule compliance between supplement groups1, 2 
 
 Iron Placebo 
Percent capsule bottles returned (%) 82 ± 3 80 ± 3 
Percent daily logs completed (%) 96 ± 7 92 ± 20 
Capsules consumed (# capsules) 96 ± 12 99 ± 12 
Total iron consumed from supplement (g/8 weeks) 2.0 ± 0.3 0 
n 36 37 
 
 
1 Values are means ± standard deviations 
 
2 There were no differences between supplement groups for any measure on the basis of 
a t-test with an alpha of 0.05 
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Table 4.3:  Iron status at 8-weeks, by treatment group1 
Group n 
sFer 
(µg/L) 
Hb       
(g/L) 
   Iron Trained 19 33.2 ± 2.8 139.7 ± 1.8 
   Iron Untrained 16 46.9 ± 3.2 141.9 ± 2.1 
   Placebo Trained 19 21.5 ± 2.9 136.2 ± 1.8 
   Placebo Untrained 18 21.8 ± 3.0 136.7 ± 1.9 
   Effect of Supplement, p value2, 3  <0.001 0.025 
   Effect of Training, p value  0.06 0.481 
   Interaction, p value  0.011 0.67 
Post-hoc Group Comparisons4 
   IT - IU p value  0.012 1.00 
   IT - PT p value  0.027 1.00 
   IT - PU p value  0.036 1.00 
   IU - PT p value  <0.001 0.26 
   IU - PU p value  <0.001 0.45 
   PT - PU p value  1.00 1.00 
 
1 Values are unadjusted means ± standard errors, at week 8 
 
2 Details of main effect on Hb: Iron group 140.8 ± 1.4 g/L, placebo group 136.5 ± 1.3 g/L 
(mean ± standard error)  
 
3 Results of a linear model, comparing values at 8 weeks for sFer or Hb after adjusting 
for baseline value and semester; Interaction p value represents the 
supplement type by training group interaction 
 
4 P values are from post-hoc comparisons between groups with Tukey corrections for 
multiple comparisons 
 
Abbreviations: sFer: serum ferritin; Hb: hemoglobin 
 
 
4.4.4 Treatment Effects on Maximal Exercise Performance 
 
There was a significant interaction effect between training group and supplement 
type for VO2peak at 8 weeks (interaction p = 0.035, Table 4.4). Post-hoc pairwise 
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comparisons showed that the IT and PT groups had a significantly higher VO2peak at 8 
weeks than the PU (p = 0.007 and 0.002, respectively). Additionally, VO2peak in the IT 
group showed a trend of being higher than that of the PU group, though this trend did 
not reach the p < 0.05 significance level (p = 0.060).  
Despite the interaction between training group and supplement type observed for 
VO2peak, there was no interaction observed for eVO2max at week 8. However, there 
was a significant training effect for eVO2max (p < 0.001). After 8 weeks of treatment, the 
trained group had an eVO2max of 43.7 ± 3.1 mL·min-1·kg-1 while the placebo group was 
significantly lower at 40.3 ± 3.0 mL·min-1·kg-1. Additionally, there was a supplement 
effect observed for the percent of estimated VO2max attained at VO2peak. After 8 
weeks, the iron group achieved 96.6 ± 7.8% of eVO2max at peak while the placebo 
group achieved 92.2 ± 7.9% of eVO2max at peak (p=0.021).  
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1Results of linear models adjusted for baseline and semester, values are mean ± standard error, significance defined as p < 0.05 for single 
variables and p < 0.1 for interaction terms 
2 P values for main effects of supplement type (Supp P) and training group (Train P) 
3 P value for the training group by supplement type interaction 
4 P values for post-hoc pairwise comparisons for interaction terms, adjusted for multiple comparisons with a Tukey correction 
5 LS means ± standard error of post-hoc comparisons for main effects of training and supplement.  
* Indicates significant difference of main effect at a level of p < 0.05 
Abbreviations: eVO2max: estimated maximal oxygen consumption; IT: iron trained group; IU: iron untrained group; PT: placebo trained group; PU: 
placebo untrained group
Table 4.4: Physical performance measures at week 8 by intervention group 
 
Group n 
VO2 peak 
(mL/min/kg) 
eVO2max 
(mL/min/kg) 
Percent eVO2max 
at Peak  
Post-test 
lactate (mMol) 
VO2 at VT 
(mL/min/kg) 
VT as % 
VO2peak  
VT as % 
eVO2max 
IT1 20 37.7 ± 0.7 43.4 ± 0.6 94.5 ± 1.8 10.0 ± 0.8 34.0 ± 0.7 88.6 ± 1.5 76.3 ± 1.7 
IU1 16 37.0 ± 0.8 40.8 ± 0.7 98.7 ± 2.0 10.2 ± 0.8 31.8 ± 0.8 86.2 ± 1.6 76.6 ± 1.9 
PT1 18 38.1 ± 0.7 44.0 ± 0.7 92.9 ± 1.8 10.4 ± 0.7 32.4 ± 0.7 85.0 ± 1.5 76.2 ± 1.7 
PU1 19 34.2 ± 0.7 39.9 ± 0.7 91.5 ± 1.9 10.2 ± 0.7 27.3 ± 0.7 82.2 ± 1.6 69.6 ± 1.8 
Supp P2  0.12 0.84 0.021 0.77 <0.001 0.018 0.047 
Train P2  0.003 <0.001 0.47 0.97 <0.001 0.10 0.078 
Int. P3  0.035 0.30 0.14 0.80 0.048 0.91 0.059 
Post-hoc pairwise comparisons for significant interactions4 
IT-IU  0.92    0.14  1.00 
IT-PT  0.97    0.34  1.00 
IT-PU  0.007    <0.001  0.037 
IU-PT  0.71    0.94  1.00 
IU-PU  0.060    <0.001  0.043 
PT-PU  0.002    <0.001  0.050 
LS Means for training effects5 
Trained   43.7 ± 0.5* 93.7 ± 1.3   86.8 ± 1.1  
Untrained  40.3 ± 0.5 95.1 ± 1.4   84.2 ± 1.1  
LS Means for supplement effects5 
Iron   42.1 ± 0.5 96.6 ± 1.3*   87.4 ± 1.1*  
Placebo   41.9 ± 0.5 92.2 ± 1.3   83.6 ± 1.1  
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4.4.5 Treatment Effects on Submaximal Exercise Performance 
 
At week 8, there were significant interaction effects between training group 
and supplement type for both VO2 at VT and the percent of eVO2max at which VT 
occurred (Table 4.4). For each of these variables, the IT, IU, and PT groups all 
attained a significantly higher value or reached VT at a higher percent of estimated 
maximum than the PU group. Notably, while the IT, IU, and PT groups all showed 
significantly improved performance for both absolute and percent eVO2max, there 
were no statistically significant differences between the IT, IU, and PT groups 
themselves. 
 Main effects of training and supplement were examined for percent of 
VO2peak at VT, for which there was no significant interaction term. A significant 
supplement effect was observed for percent of VO2peak at VT, where the iron group 
reached VT at 87.4 ± 6.6% of VO2peak, while the placebo group reached 83.6 ± 
6.7% at VT (one-way ANOVA p = <0.001).  
 Academic semester of testing was included as a covariate in all linear 
regression models for submaximal and maximal exercise performance but was not 
statistically significant. For all variables where an interaction between training and 
supplement was observed, the interaction was maintained when baseline age and 8-
week change in weight or fat free mass were included in the models. Age and 
change in weight or fat free mass were not significant in any model. Finally, including 
8-week change in Hb as a covariate did not change the significance of the 
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interactions between training and supplement for any of the performance measures 
at 8 weeks. Change in Hb was not significant in any model except for the percent of 
estimated VO2max reached at VO2peak (change in Hb p = 0.017); however, the 
significant effect of Hb in this model did not impact the significance or size of the 
supplementation effect (p = 0.019). 
 
4.4.6 Secondary analyses 
 
Several secondary analyses were conducted in order to examine the biological 
plausibility of the main findings. There was no relationship between the number of 
training days attended or the training score achieved and any of the performance 
outcomes in the trained subjects. In the iron supplemented group there was a 
significant, positive relationship between the number of capsules consumed and 
eVO2max, controlling for baseline (data not shown, linear regression, p =0.039). 
There were no significant relationships between changes in sFer or Hb and changes 
in performance measures (data not shown).  
 
4.5 Discussion 
 
To our knowledge, this is the first study to examine the combined effects of 
simultaneous aerobic exercise training and supplemental iron on physical 
performance. The objectives were to analyze the independent effects of improved 
fitness and improved iron status on maximal and submaximal exercise performance 
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measures as well as to determine whether consumption of supplemental iron 
modifies the known physiological adaptations to aerobic training. A recent meta-
analysis conducted by Pasricha et al examined 22 existing studies that gave iron or 
placebo supplements to participants, with some studies having all subjects 
undergoing training and others having no training program. While the Pasricha review 
provides an important analysis of the impacts of iron status on aerobic fitness in 
trained or untrained subjects, none of the included studies had trained and untrained 
groups together in the same study. Therefore, it lacked the ability to directly examine 
the interaction between training and supplementation that the current study provides. 
Nevertheless, the Pasricha et al review found that in trained women, VO2max 
improved more in IDNA women who were given oral iron supplements compared to 
those who trained without additional iron134. The results of the present study partially 
agree with the Pasricha et al findings in suggesting that both iron supplementation 
and aerobic training individually improved VO2peak; however, the present study did 
not detect an additive effect of supplemental iron and concomitant aerobic training for 
VO2peak, nor did this study observe a supplement effect (main or interaction) for 
eVO2max. However, the Pasricha meta-analysis used VO2max and VO2peak data 
interchangeably in their maximal performance analyses, and no secondary analyses 
were done comparing peak to max after iron supplementation. This study examined 
both estimated VO2max and VO2peak separately and found different results for these 
two variables. Therefore, it is unclear whether results of the present study directly 
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contradict the results of the Pasricha et al analysis.  
The Pasricha et al meta-analysis also found that during submaximal exercise, 
iron supplementation in trained women resulted in a lower percent of VO2max being 
reached while exercising at a given submaximal workload, compared to those who 
received a placebo. Similarly, the present study found that iron supplementation had 
a significant impact on VO2 at VT as well as the percent of estimated maximum at 
which VT was reached, both of which reflect endurance capacity at differing exercise 
intensities. However, the present study was able to further expand upon previous 
findings by examining the interaction between simultaneous iron supplementation 
and aerobic training. The results of the present study indicate that training, iron 
supplementation, and their combination all result in statistically significant 
improvements in several measures of submaximal exercise performance, and that 
the effects of iron supplementation are of the same magnitude as those produced 
from aerobic training, with or without iron supplementation. In considering the 
biological mechanism through which iron supplementation could improve physical 
performance to the same degree as aerobic training, the impacts of both treatments 
on physical performance need to be examined.  
It is widely accepted that aerobic training results in a combination of muscular, 
cardiovascular, biochemical, and respiratory adaptations that increase aerobic 
exercise performance. Collectively, these training-induced adaptations, which have 
been reviewed extensively137,138, improve both maximal and submaximal exercise 
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performance. These adaptations include: increasing plasma volume, myoglobin 
stores, and capillarization of the heart and skeletal muscle, shifting of fast glycolytic 
to fast-oxidative glycolytic muscle fibers, increasing the number of slow oxidative 
muscle fibers, increasing stroke volume, and increasing the protein content and 
activity of enzymes involved in aerobic respiration 50,69,137,139,140. Training-induced 
adaptations allow for increased energy production and more efficient cellular 
respiration, allowing trained subjects to sustain exercise at a higher percentage of 
maximal aerobic capacity without crossing the anaerobic threshold69. In accordance 
with these adaptations, this study found that subjects who trained, regardless of 
supplementation group, had significant improvements in several measures of 
maximal and submaximal exercise performance. Consistent with the literature, these 
improvements suggest that the trained subjects had both improved maximal oxygen 
consumption and reached their anaerobic threshold later than the untrained subjects.  
Similarly, iron supplementation also resulted in improvements in both maximal 
and submaximal exercise performance. Significant supplement effects were 
observed for VO2peak, the percent of eVO2max achieved at VO2peak, VO2 at VT, 
and the percent of both VO2peak and eVO2max at which VT occurred. Interestingly, 
while a significant iron effect was observed for percent of eVO2max achieved at 
VO2peak, no change in eVO2max itself was observed between the iron and placebo 
groups. The Pasricha et al meta-analysis did not differentiate between VO2max and 
VO2peak data in their analysis of maximal performance. However, by analyzing 
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eVO2max and VO2peak separately, this study was able to expand upon the 
conclusion of the Pasricha et al analysis by suggesting that while IDNA women who 
received supplemental iron were able to attain a higher percentage of their existing 
maximal capacity, estimated maximum oxygen consumption itself was not improved 
by supplemental iron.  
There are several ways in which supplemental iron could have led to the 
observed increases in peak performance and performance at VT in the IU group. ID 
interferes with several signaling pathways required for muscle growth as well as 
shifting for mitochondria towards a heavier reliance on glycolytic activity, triggering 
mitophagy, negatively impacting the cristae and other mitochondrial structures, and 
decreasing mitochondrial ability to properly use fats as a fuel source32,141,142. Several 
enzymes in the TCA cycle and the electron transport chain also require iron to 
function, further impacting fuel oxidization40. Furthermore, iron is required to 
synthesize myoglobin, the skeletal muscle protein responsible for storing and 
providing oxygen to the mitochondria for respiration42. Providing supplemental iron 
could potentially help reverse these effects. At the functional level, providing 
supplemental iron to IDNA women could result in increased oxidative capacity and 
energy production, more efficient aerobic respiration, and increased muscle 
myoglobin. These metabolic changes would then result in VT occurring at a higher 
percentage of maximum values, as seen in the IU women in this study.  
Furthermore, as this study was conducted in non-anemic women and Hb did 
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not change greatly in any group, the changes resulting from iron supplementation 
were potentially more relevant to skeletal muscle and mitochondrial function, rather 
than oxygen circulation. These systems are responsible more for aerobic endurance 
than maximal performance, which could explain why the IU women reached a higher 
VO2peak and percent of estimated VO2max at peak but did not improve in estimated 
maximal oxygen consumption capacity itself. Therefore, while operating through 
different mechanisms, the increased muscle growth, mitochondrial productivity and 
efficiency, and increased myoglobin stores resulting from increased iron status could 
produce the same effects as the increased mitochondrial size and density associated 
with aerobic training.  
While the ergogenic effects of both iron supplementation and aerobic training 
on submaximal exercise are clearly demonstrated by the results of this study and 
corroborated by previous literature, it remains unclear as to why there was no 
additive benefit of iron supplementation and training together. The beneficial effect of 
providing iron supplementation to trained women has been reported in the 
literature3,77,78. Previous studies did not include trained and untrained subjects 
together and were therefore unable to examine the training and iron effects 
individually. However, these studies observed increases in physical performance with 
iron supplementation in the form of decreased times and better performance when 
completing various time-trials 3,14,78,104 or an attenuation of the rate of fatigue in 
dynamic knee extensions. Interestingly, while the results of the current study do not 
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support that iron supplementation during training provides additional benefit over iron 
supplementation or aerobic training alone, they also do not directly contradict the 
results of the existing literature.  
The referenced studies utilized different exercise tests than the one performed 
in this study. Specifically, the study by Brutsaert et al used a knee extension test, 
which is a more power-based exercise rather than an aerobic test. The difference in 
the primary energy system used to perform a knee extension test compared to that 
used in the VO2max test (glycolytic versus aerobic) from this protocol makes 
comparisons between the studies difficult. Similarly, the other studies that found a 
beneficial effect of iron above that of training all utilized endurance-based time trials. 
The exercise test conducted in the present study was a VO2max test, which is a test 
that increases in difficultly progressively until exhaustion. It is likely that the VO2max 
test used by this study was unable to capture the same aerobic steady-state 
produced by the time-trials used by other studies and was therefore unable to detect 
an additive effect of iron and exercise on aerobic energy production. A study by 
Perkkiö et al found that when iron deficient rats underwent aerobic training, their 
endurance capacity increased six-fold, while no change in performance was detected 
from a higher-intensity performance test in this same group143, suggesting that a 
steady-state endurance test may have been more appropriate to detect a beneficial 
effect of supplemental iron while training.  
Alternatively, it is possible that no additive effect of supplemental iron was 
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seen in the IT group because the additional iron provided was sufficient to begin 
suppressing the regulatory mechanisms meant to conserve iron in the IDNA state but 
was not sufficient to both reverse the negative impacts of iron deficiency while also 
meeting the increased physiological demands of training. While hypoxia is known to 
trigger HIF2α-mediated increases in erythropoiesis, in conditions where iron 
availability is low, the body also limits erythropoietin production through several 
signaling pathways including the IRP1 response, ultimately reducing the amount of 
iron used in erythropoiesis29,144,145, which could potentially impact the expected 
response to aerobic training. It is possible that the PT group in this study may have 
been operating under these suppressed conditions, which may have limited the 
training-induced improvements in performance that would be expected from an iron 
replete group undergoing the same training. This idea is supported by the 
observation that the IU group showed improvements in performance of equal 
magnitude as those in the PT group. It is possible that the benefits from training in 
the IDNA state, in which erythropoiesis and other metabolic processes do not 
function at their full capacity, are reduced to the point that simply improving iron 
status can elicit the same magnitude of changes in performance.  
Furthermore, the iron provided to the IT group may have been sufficient to 
reverse the restrictions on these pathways, thus increasing the erythropoietic 
demand from training, which could translate to improvements in maximal or 
submaximal performance from improved oxygen carrying-capacity. However, it is 
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possible that the amount of supplemental iron given to the IT group was insufficient to 
meet this increased erythropoietic demand while also fully meeting the needs of the 
skeletal muscle, mitochondria, and other systems impaired by the ID state. One 
potential explanation for an iron insufficiency despite supplementation would be 
decreased iron absorption due to an exercise-induced inflammatory response. The 
subsequent prioritization of available iron for erythropoiesis could come at the cost of 
negating the expected improvements in performance that result from increasing iron 
status discussed above. Such prioritization of erythropoiesis at the expense of other 
iron-dependent processes has been reported previously42. In this case, the expected 
effects of training or iron repletion would be less than those observed from either 
treatment alone, and, as seen in this study, could result in an improvement of equal 
magnitude to either treatment alone. However, because this study was not able to 
take muscle biopsies or measure other iron biomarkers, it is not possible to conclude 
what metabolic changes occurred with aerobic training, iron supplementation, or their 
combination.  
One limitation of this study is that it was unable to measure other iron 
homeostasis indicators such as myoglobin, hepcidin, or proteins involved in 
erythropoiesis or iron absorption, which could provide insight as to how the iron was 
being utilized by the IT group compared to the other groups and whether iron was 
being redistributed. Further research should investigate whether providing iron 
supplementation for a longer duration would eventually elicit a larger response from 
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the IT group. Additionally, the exercise tests used in the literature vary widely, making 
it difficult to compare the results of this study to those that have been reported in 
similar studies. This study was conducted in non-anemic women who were not 
regularly participating in intense aerobic training. Therefore, the results of this study 
cannot be extrapolated to IDA or other anemic women, or women who are more fit or 
professionally trained athletes. 
 
4.6 Conclusion 
 
We have demonstrated that iron supplementation in sedentary IDNA women 
produces improvements in submaximal exercise performance of equal magnitude to 
those created by aerobic exercise training, with or without iron supplementation. 
Additionally, providing iron supplements to women during training did not have an 
additive benefit above that of either training or iron supplementation alone. The 
improvements in submaximal performance of the IU group support the idea that 
supplemental iron is used by sedentary women to increase mitochondrial 
productivity. Further research should be conducted to understand whether the added 
stress of aerobic training redirects the iron supplied by a dietary supplement away 
from mitochondrial bioenergetics pathways, how it is subsequently being used, and 
whether it affects bioavailability of supplemental iron.  
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Chapter 5 Assessing the feasibility of using a traditional Chinese 
herbal supplement, BaZhen KeLi, to address iron deficiency in 
Chinese women 
 
5.1 Abstract  
 
Background: Iron deficiency can be treated with elemental iron supplementation; 
however, in some areas of China, supplements are not commonly used. BaZhen 
KeLi (BZ), a combination of 8 Chinese herbs, is often prescribed to treat symptoms 
that align with the Western definitions of iron deficiency. Despite the frequency of its 
use, there is currently no evidence in humans that BZ improves iron status or its 
impacts on physical performance. Objectives: This study aimed to compare the 
efficacy of using BZ to that of an iron supplement or placebo in improving iron status 
and physical performance. Design: 102 iron-depleted, non-anemic Chinese women 
(serum ferritin < 25 μg/L, hemoglobin > 110 g/L) were included in an 8-week, 
partially-blind randomized control trial with a 3x2 factorial design. Treatments 
included 42 mg elemental iron/day, 150 g BZ/day, or a placebo and aerobic training 
(5 sessions/week of 25 minutes cycling) or no training. Linear models were used to 
evaluate the relationships between supplement type, training group, and changes in 
iron status or physical performance. Results: Eight weeks of BZ treatment did not 
significantly improve any measure of iron status compared to placebo. The BZ-
trained group showed improvements in physical performance of equal magnitude to 
those of the iron- and placebo-trained groups. The BZ-untrained group showed no 
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improvements in physical performance compared to the placebo-untrained group. 
Conclusions: BZ treatment does not improve any measure of iron status in iron-
depleted women, nor does it have an ergogenic effect on physical performance when 
given alone or in combination with aerobic training. 
5.2 Introduction:  
 
Despite improvements in recent years, iron deficiency with and without anemia 
remains a large public health concern in China. Among women of childbearing age, 
between 20-34% are anemic (hemoglobin (Hb) < 110 g/L)81, a rate that likely 
underestimates the prevalence of iron deficiency in the population because it does 
not include those women who are iron deficient but not anemic103. Beyond the 
nutritional impacts of iron deficiency itself, iron deficiency without anemia [IDNA: Hb > 
110 g/L and serum ferritin < 15 μg/L] also results in decreased cognitive 
performance, impaired aerobic exercise capacity, and a reduced amount of time 
spent performing voluntary physical activity5. Collectively, IDNA and anemia not only 
result in a decreased productivity and quality of life at the individual level, but also 
impact the economic productivity of China as a whole, reducing the Chinese gross 
domestic product by between 2-3%81.  
While IDNA and its negative consequences can be treated with iron supplements 
or multivitamins and minerals, the use of Western multivitamins or iron supplements 
is not common among Chinese populations – especially those in the rural areas that 
are more at risk for IDNA81. Instead, many people rely on traditional Chinese 
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medicine (TCM) to diagnose and treat the symptoms of IDNA and anemia. In 2015, 
between 19 and 25 percent of mainland Chinese adults reported using TCM146. 
Furthermore, the popularity of these treatments is growing in the US, with 38.3% of 
American adults reporting use of at least one type of complementary health product 
or treatment in 2016147, and some reports showing usage rates as high 67% in US 
women of reproductive age148. Despite its popularity, TCM herbal treatments are not 
regulated by the US government and few rigorous scientific studies are available 
validating the efficacy or the nutritional composition of popular herbal treatments in 
their intended populations. Furthermore, little research has been done examining 
herbal supplements in their whole form, as they are consumed in TCM - compared to 
the examination of a single active chemical ingredient. 
In Western medicine, iron deficiency is defined by serum ferritin (sFer) and 
hemoglobin (Hb) concentrations in the blood. However, within TCM, IDNA and 
anemia are generally diagnosed as a “blood deficiency”, a “qi deficiency”, or a 
combination of the two149 and are usually treated with traditional herbal remedies. 
One common herbal treatment for such “deficiencies” is the traditional Chinese 
herbal treatment called BaZhen KeLi (BZ) that is comprised of 8 Chinese medicinal 
plants150. Though it is widely administered to treat a range of symptoms including 
anemia, fatigue, pale complexion, dizziness, and others, few studies have examined 
the efficacy of BZ in directly improving Hb or iron status.  
In a study using 80 anemic female mice, oral administration of BZ for 10 days 
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resulted in an increase in red blood cells, Hb, and hematocrit and also stimulated 
transcription of the erythropoietin mRNA in the kidney and liver, which stimulates 
erythropoiesis149. Other studies have examined a polysaccharide isolated from the 
traditional herb Radix Angelica Sinensis, a key ingredient in BZ, for its use in 
improving iron status in rats. These studies have shown that in a group of 36 
Sprague–Dawley rats, this polysaccharide down-regulates hepcidin expression and 
stimulates erythropoietin secretion , which could be beneficial to iron status87–89,151. 
Additionally, two studies have shown that administering this herb to exercising 
rodents improved their exercise performance by protecting against fatigue in mice152 
and improved exercise-induced anemia by increasing  red blood cell count and Hb 
concentration in rats153.   
While these studies demonstrate the potential of using BZ to treat iron deficiency 
with or without anemia or their associated detrimental effects on physical 
performance, to our knowledge, no study has ever tested the efficacy of BZ or its 
potential active ingredients in treating these conditions in humans. Therefore, the 
goal of this study was to compare the efficacy of BZ supplementation with that of 
ferrous sulfate supplements or a placebo in improving iron status in IDNA women. 
We hypothesize that BZ will increase markers of iron status compared to placebo, but 
to a lesser extent than the ferrous sulfate supplement. Additionally, we hypothesize 
that those subjects taking BZ will demonstrate a longer time necessary to reach the 
point in exercise where ventilation increases disproportionately to the amount of 
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oxygen consume (ventilatory threshold, VT) and a decreased total blood lactate 
levels during submaximal exercise than placebo subjects, but to a lesser extent than 
subjects taking ferrous sulfate supplements. Though previous studies have not tested 
the impacts of BZ or its components on improving maximal physical performance, 
they consistently showed an increase in Hb and inhibition of hepcidin. These 
changes are known to improve maximal performance, as they increase oxygen 
delivery to exercising tissues34,90. Therefore, we also hypothesize that BZ treatment 
will increase subjects’ highest achieved oxygen consumption during testing 
(VO2peak) compared to placebo, but to a lesser extent than in those who receive iron 
supplementation. 
 
5.3 Methods 
 
5.3.1 Subjects 
 
The Consort diagram for this study is shown in Figure 2.1. There were 379 
untrained but moderately active women recruited from September to December 2014 
and from March to June 2015. The women were students between the ages of 18 
and 26 years at Kunming Medical University. Of the recruited women, 124 were 
identified as IDNA (sFer < 25μg/L and Hb > 110 g/L). The cutoff for IDNA of sFer < 
25 μg/L was selected because literature supports that physical performance can 
improve in women of this sFer range, despite not being clinically iron deficient 8,112. A 
Hb cutoff of 110 g/L, which is lower than the 120 g/L cutoff used in Western medicine, 
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was used to define anemia in order to align with the cutoff used at the First Affiliated 
Hospital of Kunming Medical University, who performed the screening analyses. 
 Screening was conducted to identify and exclude women who met any of the 
following exclusion criteria: recent infectious illness or fever, current pregnancy or 
lactation or pregnancy/lactation within the previous year, hemolytic anemia, current 
inflammation or chronic inflammatory diseases, musculoskeletal problems, chronic 
respiratory disease, history of eating disorders, smoking, or regular/recent 
consumption of iron supplements, multivitamins, or medications that had 
anticoagulant properties or that could affect iron intake or absorption. Subjects 
completed a questionnaire that indicated they were not regularly participating in 
exercise or sports teams and were willing to comply with the full 8-week aerobic 
training schedule if randomized to a training group. In total, 124 women agreed to 
participate in the trial over the two semesters (45 fall, 79 spring). Of these, six women 
who had initially agreed to participate did not respond to further communications, 
leaving 118 women in the study who were randomized to the six groups. 
 During the study 9 women dropped out of the trial for personal and health 
reasons (3 iron, 4 placebo, and 2 BZ). Additionally, the data from 7 women were 
excluded from the statistical analysis because it was found that their sFer 
concentrations at study week 0 were above the cutoff of 25 µg/L, despite having 
screening values from two weeks prior indicated that they were iron depleted (23.5 - 
24.9μg/L). The final sample size for this analysis was 102 women. Signed informed 
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consent was obtained from each subject. The study was approved by the Cornell 
University Institutional Review Board and the Kunming Medical University Ethical 
Committee and registered under ClinicalTrials.gov #: NCT03002090. 
 
5.3.2 Study Design 
 
The study used a 3x2 randomized, partially-blinded, placebo-controlled 
intervention design. A random number generator was used by the author (LMP) to 
randomly assign participants to the six treatment groups. Subjects received one of 
the following three supplements: 100 mg of ferrous sulfate, an identical placebo 
capsule, or a BZ capsule containing the ingredients shown in Table 1.1. Capsules 
were consumed twice a day, one in the morning and one in the evening with meals (2 
capsules per day total). The researchers and participants were both blinded to the 
identity of the iron and placebo capsules. The BZ capsules were prepared locally by 
Dr. YuXu He at Yunnan University for Traditional Chinese Medicine and were visually 
distinct from the iron and placebo capsules. Therefore, while the participants were 
not told which group they were in, the BZ group was aware that their capsules were 
different. Blinding was maintained until after the initial per-protocol analyses were 
completed. The sample size was determined under the assumption of subjects 
consuming at least 12 mg elemental iron per capsule over the 8-week study period. 
The final iron capsule concentration met this requirement. Previous studies have 
shown that a 4-week treatment with this dose of ferrous sulfate is sufficient to 
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improve iron status as measured by the indicators used by the present study3,113. The 
iron and placebo capsules were prepared by one of the authors (LMP) using ferrous 
sulfate, dextrose filler, and gelatin capsules (PCCA, Houston, TX). Every two weeks 
during the study, 20 capsules of each type were randomly selected from the full batch 
and stored in a cool, dry place until their analysis by ICP/MS after the study was 
completed. A random sample of 20 of each of the iron, placebo, and BZ capsules 
were analyzed for iron content and found to have 21.1 mg, 0.00 mg, and 0.49 mg 
elemental iron per capsule, respectively. 
 Subjects were asked to consume the capsules along with their morning and 
evening meals and encouraged to consume them along with citrus juice to increase 
iron absorption. Every two weeks, 30 capsules were delivered to each subject in a 
bottle labeled with their subject ID. Subjects were also given a daily log on which they 
recorded capsule ingestion, menstrual cycle status, any gastrointestinal or other 
health complaints, medication use, and voluntary physical activity. On weeks 2, 4, 6, 
and 8, subjects were asked to return their capsule bottles along with any 
unconsumed capsules, which were counted as an independent confirmation of the 
capsule counts reported in the daily log. 
 Half of each of the three supplement groups were randomly assigned to an 8-
week aerobic exercise training program or no training, creating a total of six treatment 
groups: iron trained (FeTr), iron untrained (FeUn), placebo trained (PLTr), placebo 
untrained (PLUn), BZ trained (BzTr), and BZ untrained (BzUn). The training protocol 
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was adapted from a training program published by Hinton et al, which resulted in 
significant improvements in both maximal and submaximal exercise performance3. 
The training protocol is shown in Table 2.2. Each 25-minute session was divided into 
time spent at 75% and 85% of subjects’ age-predicted maximum heart rate (220 
beats per minute minus years of age). Each week the time spent at 85% maximum 
heart rate was increased to account for increasing fitness as the training program 
progressed. Training occurred every Monday through Friday in the 8 weeks of the 
study, with additional make-up days being offered on weekends if subjects missed a 
session during the week. The maximum number of training days was 40 sessions. 
Training was conducted using stationary exercise bicycles (KangLe Exercise 
Products Company, Stationary Bicycle model B8.4E, Yunnan, China) that provided a 
digital output of cadence (rotations per minute) and work (watts). Heart rate was 
monitored using T31 Polar heart rate monitors and Polar A5 heart rate watches 
(Polar Electro Inc., Lake Success, NY). Research assistants recorded heart rate, 
speed, and watts of each subject in training logs every 5 minutes throughout each 
training session. 
Minutes of self-reported voluntary/discretionary physical activity were 
measured using the daily logs collected at weeks 0, 4, and 8. Additionally, at 
baseline, habitual physical activity levels were assessed via a physical activity 
frequency questionnaire to compare similarity between groups. Participants were 
requested to maintain their typical physical activity patterns throughout the 8-week 
 
 
 
 
 
 
 
132 
study period, regardless of whether the group they were randomized to was trained 
or untrained. 
Maximal and submaximal physical performance, as well as body composition, 
were measured at study weeks 0, 4, and 8. Macronutrient content, dietary iron, and 
iron enhancers and inhibitors were assessed at week 0 using a 4-day diet record. 
Dietary analyses were conducted using Nutrition Data System for Research Software 
(2016, University of Minnesota). 
Participants were compensated for completing the study with a gift. 
Additionally, subjects randomized to the training groups were offered incentives to 
improve compliance to the training program. Small gifts were provided when subjects 
reached 25, 32, and 40 days of training. The incentives were only offered to the 
trained subjects, while all subjects received the same larger gift for their participation 
in the study. 
 
5.3.3 Iron Status Measurements 
 
At study weeks 0, 4, and 8, blood was drawn by a licensed phlebotomist from 
the antecubital vein into 4 mL Anti-Coagulant vacutainers at the Kunming Medical 
University campus hospital. A small sample of whole blood was immediately 
analyzed for Hb concentration using a Coulter LH 750 Hematology analyzer 
(Beckman Coulter, Inc. Brea, CA). The remaining blood was stored for no longer than 
24 hours at 4°C until it was centrifuged at 1600 g for 10 minutes at room 
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temperature. Serum was separated into 0.5 mL aliquots and frozen at -80°C until 
being analyzed for sFer, sTfR, alpha-1-acid glycoprotein (AGP), and C-reactive 
protein (CRP) using a Siemens Advia 2400 automated analyzer (Siemens 
Healthcare, Erlangen, Germany). Blood analyses were conducted at the First 
Affiliated Hospital of Kunming Medical University and the Shanghai Fenglin Clinical 
Laboratory in the first and second semesters, respectively. To allow for comparison 
between the labs, 75 samples from the second semester were run at both labs. 
Estimated total body iron was calculated using the ratio reported by Cook et al23 as: 
  Total Body Iron (mg/kg) = - [log(sTfR/sFer) - 2.8229] / 0.1207 
The total body iron equation uses the sTfR values from an ELISA kit produced by 
Ramco Laboratories (Stafford, TX). To align with this scale, sTfR values from this 
study were converted to the Ramco scale using the following prediction equation 
derived from 34 random duplicate samples run on Ramco Laboratories sTfR ELISA 
kits: 
sTfRRamco = (3.779 x sTfRlab) + 0.400, R2 = 0.93 
 
5.3.4 Physiological measurements 
 
 Height, weight, and body composition were measured using previously 
described standard methods114,115. Percent body fat was estimated using the Durnin 
and Womersley equation with skinfold thicknesses from the bicep, triceps, 
subscapular, and suprailiac sites measured with Lange calipers (Cambridge, MD). 
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 A maximal exercise test (VO2max test) was used to assess physical 
performance at study weeks 0 and 8. Tests were conducted on a mechanically 
braked and calibrated cycle ergometer (Monark 884E, Monark Exercise AB, Vansbro, 
Sweden). The test required subjects to cycle at efforts ranging from rest to 
approximately 100% of their maximum exertion level. During the test, a portable 
metabolic measurement system (Cosmed K4B2, Cosmed Rome, Italy) was used to 
measure volume of respired air, heart rate, and concentrations of O2 and CO2 in 
expired air. Oxygen consumption was standardized to body weight (VO2, mL/kg/min) 
to allow for comparison between subjects. For the 24 hours prior to performing the 
VO2max test, subjects were asked not to engage in strenuous physical activity. 
Subjects in the three trained groups did not participate in training sessions on the day 
of their VO2max tests. Additionally, subjects were instructed to avoid food and 
caffeinated beverages three hours before testing. 
 The VO2max testing protocol was adapted from previously published 
methods77. After allowing the subject’s resting heart rate to fall below 100 beats per 
minute, the test began with a 5-minute warm up pedaling against 1 kg at a cadence 
of 50 revolutions per minute (RPM). After the warm up period, workload was 
increased every two minutes by 0.4 kg while subjects maintained the 50 rpm 
cadence. This process continued until VO2 did not increase by more than 150 mL/min 
after the addition of weight – indicating subjects had reached their VO2max. 
However, as the subjects in this study were unaccustomed to such rigorous exercise 
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levels, it was expected that many would be unable to attain this plateau in VO2. 
Therefore, the test continued either until the plateau was reached or subjects ceased 
pedaling or were unable to continue. Subjects were considered to have achieved 
VO2peak (highest observed VO2) if any 2 of the following conditions were met: a 
heart rate within 10 beats/min of the predicted maximum heart rate for their age (220 
– age in years), a respiratory exchange ratio (ratio of expired CO2 to O2) greater than 
1.15, or a blood lactate concentration greater than 8.0 mM. Blood lactate was 
assessed immediately upon completion of the VO2max test via finger stick using a 
Lactate Plus portable blood lactate analyzer (Nova Biomedical, Waltham, MA, USA). 
 
5.3.5 Compliance Analyses 
 
Compliance to training was assessing using a training score that was 
calculated as the total percent of the target heart rate achieved each day multiplied 
by the number of days the subject trained. Additionally, the percent of the target 
training speed (60 rpm) each subject maintained was used as a separate indicator to 
estimate subjects’ compliance to the training instructions. 
Compliance to the supplementation groups was assessed by comparing the 
daily logs filled out by the subjects to the physical capsule counts obtained from the 
returned bottles. A combined estimate of capsules consumed was calculated by 
comparing the self-reported consumption to the returned capsule counts and taking 
the larger number of missed capsules (reported or returned physically) as the number 
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of capsules skipped. 
 
5.3.6 Statistical Analyses 
 
Sample size was determined to require 25 subjects per group to detect a 0.8 
standard deviation change (4.2 μg/L) in sFer that corresponded to biologically 
meaningful improvements in physical performance at an α = 0.05 with 80% 
power3,109. Variables were examined for normality of distribution using Kolmogorov-
Smirnov test, histograms, and qq-plots. For sFer and sTfR, statistical analyses were 
run using log transformations because these variables were found to have non-
normal distributions. Differences between groups at baseline were tested using one-
way ANOVA. Certain measures of iron status and physical performance at week 8 
were analyzed using linear models136. For all models, baseline values and semester 
of testing were included as covariates. Baseline age was also included in all models 
because it was found to be significantly different between groups at baseline. For all 
analyses, statistical significance was defined as p < 0.05 for single variables and       
p < 0.1 for interaction terms. For significant main and interaction effects, post-hoc 
pairwise comparisons of the week 8 values were made with a Tukey correction for 
multiple comparisons. Secondary analyses were conducted with linear models using 
a significance level of p < 0.05. Statistical analyses were conducted using SAS 9.4 
(SAS Institute, Cary, NC). 
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5.4 Results 
 
5.4.1 Subject characteristics 
 
Despite randomization, the BZTr group was significantly younger than the 
FeTr, PLTr, and PLUn groups at baseline (Table 5.1). There were no other 
differences observed in any background measure at baseline on the basis of one-
way ANOVA. At baseline (week 0), 52 of the 102 subjects (51.0%) were clinically iron 
deficient, defined as sFer < 15.0 µg/L, 18 women (17.7%) had body iron < 0 mg/kg, 9 
women (8.8%) had sTfR values > 8.3 mg/L, and 3 women had Hb < 120 g/L (2.9%). 
No change in weight or BMI was observed for any group from baseline to 
week 8; however, those women who received BZ had a significantly lower percent 
body fat at week 8 than those who received either iron or placebo, after adjusting for 
baseline body fat (28.4 ± 1.5, 29.5 ± 1.2, and 29.4 ± 1.3, respectively, linear model    
p = 0.007). At baseline, there were no differences in any dietary measure including 
daily intake of: calories (kcals), protein, carbohydrates, fat, iron, ascorbic acid, 
calcium, or phytic acid. There were also no differences in inflammation at baseline or 
during or after the 8-week study on the basis of α-1-acid glycoprotein (AGP) or C-
reactive protein (CRP). There were no subjects at week 0 or 8 with elevated AGP or 
CRP (AGP > 1 mg/L, CRP > 5 mg/L). Additionally, there were no differences between 
groups in reported symptomology during the 8-week study on the basis of symptoms 
reported in the daily log. 
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Table 5.1: Baseline characteristics by group 
Characteristic 
Iron 
Trained 
Iron 
Untrained 
Placebo 
Trained 
Placebo 
Untrained 
BZ  
Trained 
BZ  
Untrained 
Age (yr) 20.5 ± 1.0 20.2 ± 0.8 20.6 ± 1.3 20.6 ± 1.8 19.2 ± 1.0* 20.3 ± 1.3 
Height (cm) 157.1 ± 5.7 156.9 ± 6.2 157.3 ± 4.7 157.5 ± 5.2 156.3 ± 3.9 159.5 ± 5.8 
Weight (kg) 52.2 ± 7.3 51.6 ± 7.9 53.2 ± 6.1 51.0 ± 5.5 48.6 ± 4.6 50.0 ± 7.1 
BMI (kg/m2) 21.2 ± 2.9 21.0 ± 3.5 21.5 ± 2.1 20.6 ± 2.1 19.9 ± 1.7 19.6 ± 2.1 
Body Fat (%) 29.3 ± 3.4 28.3 ± 5.1 29.1 ± 4.2 28.8 ± 2.3 28.4 ± 3.5 28.4 ± 3.3 
Hb (g/L) 135.4 ± 8.8 140.7 ± 5.2 136.0 ± 10.5 135.3 ± 6.5 131.8 ± 8.9 133.9 ± 10.0 
sFer (µg/L) 14.6 ± 6.1 17.1 ± 4.2 14.2 ± 4.6 15.5 ± 5.8 14.9 ± 5.8 17.2 ± 5.8 
sTfR (mg/L) 6.7 ± 3.1 5.3 ± 0.8 5.9 ± 1.5 6.0 ± 1.7 7.0 ± 2.1 5.7 ± 1.5 
Body Iron (mg/kg) 1.3 ± 2.6 2.7 ± 0.9 1.7 ± 1.8 1.8 ± 1.9 1.2 ± 2.0 2.4 ± 1.9 
AGP (mg/L) 0.62 ± 0.09 0.61 ± 0.09 0.64 ± 0.09 0.58 ± 0.09 0.61 ± 0.08 0.58 ± 0.09 
CRP (mg/L) 0.06 ± 0.12 0.22 ± 0.77 0.21 ± 0.35 0.08 ± 0.13 0.02 ± 0.04 0.03 ± 0.05 
Daily Dietary Intake1 
Calories (kcal) 1543 ± 272 1573 ± 333 1602 ± 315 1587 ± 327 1482 ± 315 1609 ± 781 
Fat (g) 51.7 ± 12.3 57.2 ± 15.0 56.0 ± 13.1 55.3 ± 17.2 49.8 ± 15.6 51.9 ± 26.7 
Protein (g) 59.1 ± 19.9 60.2 ± 18.4 59.0 ± 17.1 58.7 ± 20.5 61.8 ± 25.5 61.4 ± 32.4 
Carbohydrate (g) 215 ± 43 204 ± 49 216 ± 46 216 ± 53 198 ± 27 224 ± 128 
Iron (mg) 11.7 ± 4.3 13.0 ± 5.8 11.6 3.5± 12.3 ± 3.8 13.6 ± 4.7 12.3 ± 7.6 
Calcium (mg) 325 ± 114 340 ± 146 321 ± 154 394 ± 195 363 ± 133 319 ± 217 
Ascorbic Acid (mg) 94.1 ± 57.3 60.2 ± 37.5 64.5 ±41.0 82.6 ± 79.5 90.1 ± 45.3 80.7 ± 66.1 
Phytic Acid (mg) 544 ± 184 662 ± 340 533 ± 247 577 ± 252 444 ± 162 545 ± 397 
Physical Performance Measures 
VO2peak (mL/min/kg) 35.3 ± 4.5 36.0 ± 3.5 35.0 ± 4.0 34.6 ± 3.3 37.8 ± 3.4 35.5 ± 7.4 
VO2 at VT (mL/min/kg) 27.2 ± 4.2 28.8 ±3.3 28.2 ± 2.9 29.4 ± 3.2 32.4 ± 3.1 29.7 ± 5.7 
Post-test lactate (mmol) 10.4 ± 2.2 11.7 ± 2.0  11.9 ± 3.4 11.5 ± 2.1 10.4 ± 2.3 10.8 ± 2.0 
n 20 16 19 18 13 16 
* Indicates significant group difference at week 0 on the basis of one-way ANOVA at p < 0.05 
1 Dietary intake data excludes nutrients from iron or BZ supplements 
Abbreviations: BZ – BaZhen KeLi; Hb – hemoglobin; sFer – serum ferritin; sTfR – soluble transferrin receptor; AGP – α-1-acid 
glycoprotein; CRP – C-reactive protein; VO2peak – maximum observed oxygen consumption; VO2 at VT – volume of oxygen 
consumed at the ventilatory threshold, or the point where the rate of respiration increases disproportionately to the amount of 
oxygen consumed  
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Participants began the study at an average level of fitness, based on a mean 
VO2peak of 35.6 ± 4.6 mL/min/kg and a mean VO2 at VT of 29.1 ± 4.0 mL/min/kg. 
The number of self-reported minutes spent doing physical activity did not differ 
between the groups, nor did the kcals expended per week over the 8-week period 
(data not shown, one-way ANOVA, p > 0.05). Across the 8-week study period, the 
average number of kcals expended per week in voluntary physical activity outside of 
the study’s training program was 271 kcal ± 377 kcal. 
 
5.4.2 Compliance to Treatments 
 
The three trained groups all attended approximately 32 training days, during 
which they achieved the same percent of target heart rate and percent of target 
pedaling speed (Table 5.2).  
There were no significant differences in the number of capsule bottles returned 
from each of the three supplement groups or the percent of the daily logs completed 
by each of the groups (Table 5.3). The amount of iron consumed from the capsules 
by the iron and BZ groups over the 8-week study period is shown in Table 5.3. The 
iron group consumed approximately 5 times the daily amount of iron required to 
prevent deficiency in 50% of the population (estimated average requirement, EAR) 
while the BZ group consumed only 12.3% of the EAR each day. 
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Table 5.2: Compliance to Training, by training group1 
 
 
Iron  
Trained 
Placebo  
Trained 
BZ 
Trained 
P  
Value2 
Days trained (out of 40) 32.9 ± 5.6 32.7 ± 3.7 32.4 ± 5.1 0.96 
Range (out of 40) 21-40 28-40 23-40  
Training Score (out of 40) 30.3 ± 5.6 30.6 ± 3.4 29.7 ± 5.5 0.89 
% Target HR 90.5 ± 7.8 91.9 ± 5.6 90.8 ± 3.8 0.76 
% Target RPM 99.0 ± 5.3 100 ± 0.0 98.3 ± 5.7 0.41 
n 18 18 13  
 
1Values are mean ± standard deviation 
 
2 P values are from one-way ANOVA 
 
Abbreviations: BZ – BaZhen KeLi; HR – heart rate; RPM – rotations per 
minute 
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Table 5.3: Capsule Compliance1 
 
  
 Iron Placebo BZ P value2 
Percent capsule bottles returned 81.9 ± 25.1 80.4 ± 28.3 87.9 ± 15.8  0.36 
Percent daily logs completed 96.1 ± 7.1 91.6 ± 19.5 90.0 ± 17.1 0.63 
Capsules consumed (#) 95.9 ± 11.9 99.3 ± 12.1 96.7 ± 11.1 0.88 
Iron consumed (g/8 weeks) 2.02 ± .25 0.0 ± 0.0 0.05 ± 0.01 <0.001 
n 36 37 29  
 
1Values are means ± standard deviation 
 
2 P values are from one-way ANOVA 
 
Abbreviations: BZ – BaZhen KeLi 
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5.4.3 Treatment Effects on Iron Status 
 
At week 8, there were no significant interactions between training group and 
supplement type for any measure of apparent iron status, controlling for baseline 
values. There were also no significant main effects of training for any iron status 
measure; however, there were significant main effects of supplement type for sFer, 
Hb, sTfR, and body iron (Table 5.4). At week 8, the iron-supplemented group had 
significantly higher sFer and body iron, and significantly lower sTfR (indicating better 
iron status), than either the placebo or BZ supplemented groups. There were no 
significant differences between the BZ group and the placebo group for any of the 
three iron measures.  
 
5.4.4 Treatment Effects on Physical Performance 
 
There were significant interaction effects between training group and 
supplement type for both VO2peak and VO2 at VT (Table 5.5). Post-hoc pairwise 
comparisons for the significant interaction effects, with corrections for multiple 
comparisons, are shown in Table 5.5. There were no significant interactions or main 
effects observed for post-test blood lactate concentration. 
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Table 5.4: BZ Study Iron Biomarkers at Week 8 
 
Group n 
sFer 
(µg/L) 
Hb       
(g/L) 
sTfR 
(mg/L) 
Body Iron 
(mg/kg) 
   Iron1 36 39.6 ± 16.5 141.1 ± 7.5 4.9 ± 0.9 5.8 ± 2.0 
   Placebo1 37 20.8 ± 9.8 136.3 ± 9.8 5.9 ± 1.9 2.8 ± 2.5 
   BZ1 29 18.5 ± 10.2 132.6 ± 8.6 5.9 ± 1.4 2.3 ± 2.4 
      
   Interaction p value2  0.43 0.61 1.00 0.55 
   Training p value2  0.07 0.78 0.11 0.053 
   Supplement p value2  <0.001 0.050 <0.001 <0.001 
      
Post-hoc Group Comparisons for Supplement Effect   
   Fe-PL P value  <0.001 0.057 <0.001 <0.001 
   Fe-BZ P value  <0.001 0.17 <0.001 <0.001 
   PL-BZ P value  0.90 0.99 0.68 0.80 
 
1 Values are unadjusted means ± standard errors, at week 8 
 
2 Results of a linear model, adjusted for baseline, comparing values at 8 weeks in 
each variable. Interaction p value represents the supplement type by 
training group interaction. 
 
3 P values are from post-hoc comparisons between groups with Tukey corrections for 
multiple comparisons 
 
Abbreviations: sFer: serum ferritin; Hb: hemoglobin, BZ: BaZhen KeLi 
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Table 5.5: BZ Study Physical Performance Measures at Week 81 
 
Group n 
VO2peak 
(mL/min/kg) 
VO2 at VT 
(mL/min/kg) 
Post-VO2 Test 
Lactate (mmol) 
  Iron Trained 20 37.8 ± 5.1 33.2 ± 5.0 9.8 ± 3.3 
  Iron Untrained 16 37.6 ± 4.4  32.2 ± 2.6 10.3 ± 3.9 
  Placebo Trained 19 37.8 ± 3.0 32.2 ± 3.9 10.6 ± 2.2 
  Placebo Untrained 18 33.9 ± 4.2 28.2 ± 3.9 10.1 ± 2.4 
  BZ Trained 13 35.3 ± 3.6 33.1 ± 3.6 9.4 ± 2.3 
  BZ Untrained 16 33.6 ± 4.9 29.3 ± 3.8 9.8 ± 2.0 
   Interact. p value2  0.047 0.093 0.95 
   Training p value3  0.016 <0.001 0.92 
   Supp. p value3  0.007 <0.001 0.66 
     
Post hoc pairwise comparisons for significant interaction terms4 
Is there a training effect in all trained groups? (Trained groups vs. true placebo) 
   FeTr vs. PLUn  0.019 <0.001  
   PLTr vs. PLUn  0.006 <0.001  
   BZTr vs. PLUn  1.00 0.044  
Does BZ impact training effect? (BZ trained vs. other trained groups) 
   BZTr vs. FeTr  0.17 0.27  
   BZTr vs. PLTr  0.07 0.92  
Does BZ have ergogenic effect alone or in addition to training?  
   BZTr vs. BZUn  1.00 0.46  
   BZUn vs. PLUn  1.00 0.77  
 
1 Results of linear models adjusted for baseline and semester, values are LS means ± standard 
errors, significance defined as p < 0.05 for single variables and p < 0.1 for interaction terms 
 
2 P value for the interaction between training group and supplement type  
 
3 P values for main effects of training group and supplement type (Supp. P)  
 
4 P values for post-hoc pairwise comparisons, corrected for multiple comparisons with a Tukey 
correction 
 
Abbreviations: VO2peak: highest observed oxygen consumption during VO2max test; VO2 at VT: 
oxygen consumption at ventilatory threshold; post- VO2 test lactate: blood lactate level at 
completion of VO2max test; BZ: BaZhen KeLi; Interact: interaction; Supp: supplement; FeTr: iron 
trained group; FeUn: iron untrained group; PLTr: placebo trained group; PLUn: placebo 
untrained group; BZTr: BaZhen KeLi trained group; BZUn: BaZhen KeLi untrained group 
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Academic semester of testing and baseline age were included as covariates in 
all linear regression models for both blood biomarkers and physical performance 
measures but were not statistically significant in any model. For variables where an 
interaction was observed between supplement type and training group, the 
interaction was maintained when change in Hb and baseline body fat were included 
in the models. Hb and body fat were not significant in any model. Additionally, 
including the number of capsules consumed as a covariate did not alter the 
relationships observed for any blood biomarker or physical performance measure. 
 
5.4.5 Secondary analyses 
 
Secondary analyses were conducted to examine the biological plausibility of 
the primary results. First, the relationship between the amount of iron consumed and 
the resulting change in apparent iron status and physical performance measures was 
examined in subjects who consumed either BZ or iron supplements. Significant 
relationships were observed between the amount of iron consumed and all measures 
of iron status at week 8, adjusting for baseline values (linear regression, sFer 
estimate 1.7 ± 0.2 µg/L, p < 0.001; Hb estimate 3.7 ± 1.0 g/L, p < 0.001; sTfR 
estimate -0.47 ± 0.12 mg/L, p < 0.001; body iron estimate 1.7 ± 0.2, p < 0.001). 
However, there were no significant relationships observed between the amount of 
iron consumed and any physical performance measure at week 8, adjusting for 
baseline (linear regression, p = 0.10, p = 0.16, and p = 0.41 for VO2peak, VO2 at VT, 
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and post-test blood lactate, respectively). Additionally, among all participants, there 
was a significant positive relationship between the 8-week change in sFer and 8-
week VO2peak, adjusting for baseline (estimate and SEM: 0.05 ± 0.02, p = 0.038). 
The same trend was seen for the relationship between 8-week change in sFer and 
VO2 at VT (estimate and SEM: 0.05 ± 0.03, p = 0.070). No significant relationships 
were observed between the baseline to 8-week change in Hb, sTfR, or body iron and 
any performance measure. 
 To examine the relationship between supplement and iron status markers in 
those women who should benefit most, we examined the effect of BZ 
supplementation in a subgroup of subjects with the most severe iron deficiency at 
baseline. Separate subgroup analyses were run in those women who began the 
study with the lowest Hb concentrations at week 0 (women below the median value, 
Hb < 136.0 g/L, n = 46) and those with clinical iron deficiency at week 0 (sFer < 15.0 
µg/L, n = 52). For both of these subgroups, when compared to the full study 
population, there were no differences found in the significance levels of the main or 
interaction effects for supplement or training group in any of the tested outcome 
measures. Additionally, there were no differences in the direction of the relationships 
between the adjusted means for any main or interaction effect (data not shown).  
 Functional anemia occurs when Hb is not below the clinical cutoff but still 
improves with iron supplementation. In this study, women who were functionally 
anemic could potentially respond to supplementation differently than those who were 
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not by directing the supplemental iron toward Hb production rather than towards 
improving iron stores or tissue iron (represented by sFer and sTfR, respectively). This 
reprioritization of iron could then alter the subjects’ response to training and impact 
the physical performance measures. To assess for the implications of functional 
anemia, a subgroup analysis was conducted in those women who did not show 
functional anemia – defined as women whose 8-week change in Hb was of a 
magnitude that was less than one standard deviation of that observed in the placebo 
untrained group, which should represent the natural variation in Hb (change in Hb     
< 9.2 g/L, n = 76). There were no differences in any of the measured biomarkers of 
iron status found in the significance levels of the main or interaction effects for 
supplement or training group for this group compared to the full study population 
(data not shown). For the physical performance measures, no differences in the 
results for maximal performance were observed between the full sample and those 
who were not functionally anemic. For submaximal performance, the interaction 
effect was no longer significant; however, there was a significant supplement effect (p 
= 0.002). Post-hoc pairwise comparisons showed that while the iron group performed 
significantly better than the placebo group, there was no effect for BZ on submaximal 
performance compared to placebo. The same results were found in those subjects 
who met the criteria for functional anemia (n=26), with no differences in significance 
level for any iron biomarker between the functionally anemic subgroup and the full 
sample (data not shown). 
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 Within the trained subjects, there was a significant relationship between the 
number of days trained and the post-test blood lactate concentration (linear 
regression, estimate -0.17, p = 0.027). However, in this model there was not a 
significant interaction effect between the number of days trained and supplement 
group, nor was there a significant main effect of supplement group. The same 
relationships were seen for the percent of target heart rate achieved during training 
and post-test blood lactate concentration (data not shown).   
5.5 Discussion  
 
To our knowledge, this is the first study to examine the efficacy of BZ in 
improving iron status (as assessed by sFer, sTfR, and Hb) or its associated impacts 
on physical performance in humans. The objectives were to analyze the efficacy of 
BZ supplements in improving several measures of iron status compared to 
conventional iron supplements or a placebo control as well as to examine whether BZ 
is effective at resolving the impaired physical performance known to occur in IDNA 
women.  
While there are no studies examining the impact that BZ has on iron status in 
humans, several studies in rodents have shown that BZ149 or a polysaccharide 
derived from Angelica Sinensis (one of its component herbs)87–89,151,153 at a dose of 
1g/kg body weight can increase hemoglobin concentration and reduce hepcidin 
expression, which help improve iron status. The results of this study contrast these 
previous findings, suggesting that BZ has no effect on any observed measure of iron 
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status. Iron supplementation significantly improved iron status as measured by sFer, 
sTfR, and body iron after 8 weeks of supplementation compared to both the placebo 
and the BZ groups. However, no significant differences were observed between the 
BZ and placebo groups for any iron biomarker, suggesting that BZ had no effect on 
either iron storage or cellular iron. A similar trend was observed for Hb, with no 
significant difference between the BZ and placebo groups.  
These findings directly contrast those of previously published studies that 
found that BZ or its components improved hemoglobin counts in iron deficient anemic 
rats151. The present study was conducted in non-anemic women, and therefore may 
have missed any effects of BZ treatment that occur only in the most severely iron 
deficient anemic women. However, the study was designed to measure iron 
deficiency at varying severities, using sFer and sTfR – biomarkers that are more 
sensitive to less severe stages of iron deficiency. If BZ were improving iron status, 
these more sensitive biomarkers would be the first to respond. However, while these 
markers all showed significant improvements from iron supplementation, there was 
no change whatsoever in any of these more sensitive biomarkers in the BZ group, 
suggesting that BZ treatment is not effective at improving apparent iron status.  
Additionally, when examining a subset of subjects who had Hb concentrations 
below the median value at baseline (Hb < 136.0 g/L, n =46) or a separate subset who 
were clinically iron deficient (sFer < 15 µg/L, n = 52), there was still no relationship 
between BZ treatment and improvement in Hb or any other iron status marker 
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measured in this study. This finding is consistent with the analysis of the BZ iron 
content, which showed that each capsule contained only 0.49 mg of iron. The 
intervention provided two capsules per day, delivering about 1 mg of iron to the 
subjects each day, an amount equivalent to only 12.5% of the iron estimated to meet 
the daily needs of 50% of adult women116. Collectively, these findings partially agree 
with the hypothesis in suggesting that BZ treatment is not as effective as iron 
supplementation in improving apparent iron status. However, contrary to the 
hypothesis, this study also found that treatment with BZ is no more effective than a 
placebo in improving apparent iron status in IDNA women. 
This study also aimed to determine whether BZ treatment is effective in 
improving physical performance or enhancing the impact of aerobic training. Several 
studies have found that various components of BZ (the previously mentioned 
Angelica Sinensis polysaccharide or a mixture of 4 of the 8 herbs in BZ called “Si Wu 
Tang”) have been shown to improve aerobic exercise performance in both iron 
replete and anemic rodents86,153. In a study by Yeh et al152, iron-replete mice given 
Angelica Sinensis and/or 6-weeks of aerobic training showed increased endurance 
during a swim test, decreased blood lactate after the test, and increased post-
exercise liver and muscle glycogen concentration. The Yeh et al study also observed 
a potential ergogenic effect of the herb when taken during training beyond that 
observed when training with placebo152. However, the present study found that 8 
weeks of aerobic training with simultaneous treatment with BZ had no significant 
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impact on maximal or submaximal performance or post-test lactate concentration in 
women. The FeTr, PLTr, and BZTr groups all showed statistically significant 
improvements in submaximal performance that are consistent with the improvements 
in physical performance observed in others studies that have used a similar training 
protocol3. As there were no significant differences among the three trained groups for 
maximal or submaximal exercise performance, it is likely that the improvements in 
performance in the BZTr group were due solely to the training program and not to 
any beneficial effect of BZ itself. 
Furthermore, the results of this study do not support that BZ treatment without 
training has any impact on maximal or submaximal physical performance or blood 
lactate concentration. While the FeUn group showed a significant improvement in 
submaximal exercise performance compared to the PLUn group, no effect of BZ was 
observed for maximal or submaximal exercise outside of the effect of training.  
Finally, there were no significant differences in physical performance 
measures between the BZTr group and the BZUn group, which somewhat contradicts 
the finding that the BZTr group had significant improvements in physical performance 
compared to the PLUn group. There are two possibilities that may explain this 
finding. First, it is possible that the BZ treatment in the BZUn group did have a small 
ergogenic effect, increasing the performance of the BZUn group slightly above that 
seen at baseline, but not by enough to be significantly different from the PLUn group 
at week 8. Alternatively, it is possible that because the BZTr group had the smallest 
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sample size (n=13), there was not enough statistical power to observe the same level 
of significance seen in the relationships between the PLTr-PLUn groups and the 
FeTr-FeUn groups. For both maximal and submaximal exercise performance 
measures, the BZTr group showed better performance measures than the BZUn 
group, suggesting that this sample size may have been a limitation for this 
comparison. 
There are several biological mechanisms that could explain why the results of 
this study contrast the previously published work. First, all of the previously reported 
studies have been conducted in mice or rats, which may limit the generalizability of 
their findings to humans. Additionally, this study gave BZ as it is generally prescribed 
by TCM practitioners – as a combination of 8 herbs consumed in a single capsule 
twice a day. The Tian et al study used a BaZhen decoction (liquid distilled from the 
BZ herbs), while all of the other cited studies used only components of BZ such as 
the four-herb combination, Si Wu Tang, or a single polysaccharide isolated from one 
of the BZ herbs. It is possible that one or more ingredients in the full herbal recipe 
may be blocking the effect seen from using the single polysaccharide or a smaller 
combination of herbs.  
It is also possible that the dosage of BZ per kg body weight used in this study 
differed from that used in previously published rodent studies. Because most prior 
studies use do not use the full BZ recipe, it is difficult to directly compare the dose per 
kg body weight; however, in the Tian et al study, between three and fifteen g of each 
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of the 8 herbs in BZ were put into 1L of distilled water to make the decoction. This 
study used five to ten g of each of the 8 herbs per pill, for a total of ten to twenty g of 
each herb consumed per day. Therefore, while the absolute concentration of the 
herbs in each dose is similar, the large difference in body weight between rats and 
humans could potentially decrease the potency of the BZ treatment in humans. 
However, because this study did not provide different dosages of BZ to the 
participants, we are unable to assess how a stronger dose or greater number of 
capsules per day could have altered the findings. 
One limitation of this study is that we were not able to fully blind the subjects to 
the capsules. Due to constraints at the TCM hospital where the BZ capsules were 
prepared, the BZ capsule shell was visually distinct from the iron and placebo 
capsule shells. Therefore, while the subjects in the BZ groups did not know what 
treatment group they were in, they were able to observe that their capsules were 
visually different than the other subjects’ capsules. However, the compliance 
analyses show that there were no significant differences in compliance to capsule 
consumption across groups.  
Additionally, the researchers were not blinded to the BZ group, which could 
potentially lead to bias in the physical performance data collection. To assess for 
potential measurement bias in the BZ group, subjects’ maximum heart rate was 
compared across week 0 and after 8 weeks of treatment, adjusting for baseline. 
There were no significant differences in maximum heart rate at baseline or week 8 
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(linear models p = 0.41 and p = 0.08). Because the p value for this secondary 
analysis was close to the significance cutoff of p < 0.05, post-hoc pairwise 
comparisons with a Tukey correction for multiple comparisons were examined to 
compare each BZ group with its placebo group counterpart. There were no significant 
differences between the BZTr and PLTr groups (mean and standard error 186.8 ± 2.0 
and 188.1 ± 1.5, respectively, p = 1.00), nor were there differences between the 
BZUn and PLUn groups (mean and standard error 190.6 ± 1.8 and 187.6 ± 1.6, p = 
0.82). Additionally, the percent of subjects achieving a heart rate within 10 beats per 
minute of their age predicted maximum heart rate (220-age) did not differ between 
groups at week 8 (Chi-square p = 0.22). There were also no significant changes in 
maximum heart rate across any treatment group from baseline to week 8. Maximum 
heart rate is predominantly determined by age and would not be expected to change 
from either aerobic training or iron supplementation154. Therefore, if there were 
differences in the maximum heart rate achieved during testing, it could be a result of 
differential treatment on behalf of the researchers. However, as no differences were 
observed between the supplement groups, there is no indication that such 
measurement bias occurred.  
Furthermore, due to limitations in the field, this study was unable to recruit the 
target number of women per group and may be limited in its statistical power to 
detect statistically significant differences between the six treatment groups. Despite 
the small sample size in the BZ groups, the primary outcomes of interest all showed 
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low variances of similar or smaller magnitude to those of the iron and placebo 
groups, which suggests that the BZ groups did not have outliers that influenced the 
mean values in a major way. Finally, this study was conducted in sedentary IDNA 
women. Therefore, the results of this study may not be as relevant to severely 
anemic women, or women who are more fit or professionally trained athletes. 
5.6 Conclusion 
 
We did not find any significant impact of BZ on any measure of iron status in 
IDNA women. Additionally, we did not find that BZ has an ergogenic effect on 
maximal or submaximal physical performance or post-exercise blood lactate 
concentration. Considering the prevalence of the use of TCM, and the popularity of 
BZ and its constituent herbs for treatment of fatigue, anemia, pallor, and other 
symptoms associated with iron deficiency, it is important that TCM and Western 
medicine practitioners be made aware that this herbal treatment does not appear to 
have any benefit for iron-depleted women and should not be prescribed for treatment 
of iron deficiency without anemia, especially at the expense of prescribing 
conventional therapeutic iron supplements. Further research should examine whether 
other preparations of the BaZhen herbs together or Angelica Sinensis alone have an 
ergogenic effect on submaximal physical performance.  
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Chapter 6: General Discussion 
 
6.1: Interplay of exercise and iron homeostasis – gaps in the literature 
 
The collective aim of Chapters 3 and 4 was to understand how iron 
homeostasis and aerobic training mutually influence each other in IDNA women. 
Chapter 3 concluded that when women train while taking iron supplements, the 
improvements in sFer in the trained group are significantly less than those observed 
in the women who received iron but did not train, suggesting that training reduces the 
apparent efficacy of supplementation. Chapter 4 then explored the ergogenic effects 
of iron supplementation on maximal and submaximal physical performance. The data 
presented in that chapter suggest that while supplemental iron improves submaximal 
physical performance as much as training without supplemental iron, there is no 
additive benefit of supplemental iron above that of training alone. Collectively, these 
findings suggest that when iron status and aerobic fitness change simultaneously, 
there is a prioritization of available iron to support key processes such as 
erythropoiesis, myoglobin production, or the bioenergetics pathways34,49,66,155–157. It is 
also possible that the iron was either not being absorbed perhaps due to exercise-
induced inflammation32, or that the exercise was increasing iron losses8. This 
dissertation was unable to determine exactly how iron was being utilized by women in 
various treatment groups, a shortcoming that will be discussed in the following 
sections. However, comparing the changes in the measured iron biomarkers in each 
treatment group could provide insight into what metabolic pathways were 
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differentially affected by training and iron supplementation.  
Unfortunately, biomarkers for assessment of iron homeostasis remain an 
imperfect tool. Section 6.2 will address some of the shortcomings of the conventional 
measures of iron status. It will also explore several potential methods for assessing 
iron homeostasis that could help provide a more comprehensive understanding of 
each of the body iron pools than that which is created with the current set of 
commonly used biomarkers. With the caveat that future research should account for 
the current limitations in iron status biomarkers, Section 6.3 will then examine how to 
address iron deficiency in active populations. This dissertation demonstrates the 
impact that regular aerobic activity can have on iron status. However, current 
recommendations for daily iron intake do not account for physical activity level. 
Section 6.4 will then broaden in scope to consider how to address the issue of iron 
deficiency in China, both in its current context where many women are predominantly 
sedentary158 as well as if Chinese women should begin to be more active, as 
recommended by the new physical activity guidelines produced by the Chinese 
government159. Section 6.5 further expands this topic by examining the potential for 
using traditional Chinese medicine to address iron deficiency in China, a topic for 
which there is currently underwhelming scientific evidence. Finally, Sections 6.6 and 
6.7 will present directions for future research and summarize the overall findings and 
concepts reported in this dissertation. 
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6.2 Biomarkers for the assessment of iron status  
 
One of the consistent problems revealed by the results reported in Chapters 3 
and 4 is the inability to decipher how the supplemental iron was being differentially 
utilized by the iron-trained group compared to the iron-untrained group.  
This dissertation was able to examine how the combination of iron 
supplementation and aerobic training impacts the outcomes of iron status and 
physical performance, but only at a somewhat superficial level. Iron homeostasis is 
an intricate and complicated balance of many hormones, cytokines, proteins, and 
other factors. This dissertation used three of the most commonly measured iron 
status biomarkers (sFer, sTfR, and Hb) as well as two measures of inflammation to 
try and create a more comprehensive picture of what was happening at the metabolic 
level. However, as indicated in the previous chapters, it is clear that this set of 
biomarkers was insufficient for deducing the exact changes that occurred in this 
study across the various iron pools.   
As mentioned in the discussions of Chapters 3 and 4, there are several 
additional biomarkers that could have provided a more thorough explanation for the 
results observed in this study. Of particular importance are those that represent 
erythropoietic activity such as erythropoietin and erythroferrone as well as hepcidin, 
which regulates iron on the systemic level via changes in absorption29. With these 
markers, we would have been better able to determine whether there was an 
exercise-induced up-regulation of erythropoiesis in the iron-trained group. Increases 
 
 
 
 
 
 
 
159 
in erythropoiesis and Hb production are known adaptations to aerobic training137, 
though it is less clear how IDNA alters this response. Because there were still 
significant improvements in submaximal performance in the placebo-trained group, it 
is clear that IDNA women still benefit from aerobic training, despite their iron 
deficiency. Similarly, the iron-untrained women showed improvements in submaximal 
physical performance from iron supplementation without any training. As explained in 
Chapter 4, these improvements in performance from training and iron 
supplementation are likely due to somewhat different metabolic mechanisms and are 
not likely due to changes in oxygen delivery from changes in Hb concentration. 
However, without markers of erythropoiesis and systemic iron homeostasis, it is not 
possible to determine whether these mechanisms were primarily due to changes in 
erythropoiesis, bioenergetics, myoglobin, or some combination of these or other 
factors for each treatment group.  
Another possible consequence of aerobic training that could have partially 
contributed to the observed changes in iron status indicators is exercise-induced 
inflammation that reduces iron absorption. As discussed in Chapter 3, the literature 
on whether long-term, moderate exercise results in a chronic inflammatory state 
shows conflicting results. In both acute and chronic inflammation, hepcidin levels in 
the body are increased, resulting in the internalization of ferroportin, and ultimately 
reducing overall iron levels in the body. While many studies have demonstrated a 
clear relationship between increased hepcidin expression and lower iron status after 
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acute bouts of exercise120,160, few studies have shown a long-term impact of exercise-
induced inflammation (increased hepcidin) on apparent iron status122,160,161. 
Dominguez et al found that while there was a direct relationship between intense 
aerobic exercise and hepcidin levels, this relationship was transient and would not 
support a chronic elevation of hepcidin from long-term exercise training. Additionally, 
in comparing hepcidin and sFer levels of athletes after a basketball training season, 
Zieman et al found that while there was increased hepcidin after the training season 
compared to before the competitive season, there was no relationship between 
hepcidin and sFer. Due to the conflicting evidence about the influence of long-term 
exercise on hepcidin-mediated changes in sFer, it remains unclear whether the lower 
sFer levels in the iron-trained group were due to decreased iron absorption resulting 
from increased hepcidin. Directly measuring hepcidin in future iron interventions with 
an exercise component could provide insight into this relationship. 
Exercise-induced inflammation may also influence iron absorption beyond the 
role of hepcidin-mediated internalization of ferroportin. Several rodent studies have 
shown that inflammation induced by exercise (5-week treadmill training with 
progressive loading)123  or by chemical injection124,125 results in decreased expression 
of DMT1 and Cytochrome B, two proteins required for absorption of iron into the 
enterocyte. These mechanisms were found to be unrelated to the role of hepcidin in 
lowering iron export from the enterocyte, suggesting that exercise may impact iron 
absorption in more than one way. This dissertation was not able to measure 
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biomarkers of inflammation and iron absorption such as hepcidin, IL-6 (the primary 
mediator of inflammation mediated changes in hepcidin), DMT-1, and duodenal 
Cytochrome B. These markers could have provided clearer insight into whether the 
training regimen was inducing inflammation or increasing hepcidin levels either 
acutely or over the full 8-week study duration. Additionally, with these measures we 
could have examined the association between hepcidin levels and sFer 
concentration.  While no inflammation was detected in any group of this study using 
CRP or AGP, it is possible that the training was inducing inflammation not captured 
by these two biomarkers.  
Furthermore, all of the above arguments for using various biomarkers are 
conditional on the assumption that those biomarkers will accurately reflect total body 
iron, stored iron, and functional iron in the tissues. However, several of the most 
commonly measured iron status biomarkers can be affected by inflammation, 
misrepresenting the apparent iron status of the affected individual(s). If the trained 
subjects were experiencing an inflammatory response, it could result in 
misinterpreting the elevated sFer levels. The iron-trained group already displayed 
significantly smaller improvements in sFer than the iron-untrained group. If 
inflammation were elevating their sFer levels, this could mean that the severity of iron 
depletion remaining in the iron-trained group was greater than what was concluded in 
Chapter 3. This would indicate that regular aerobic physical activity actually has far 
larger negative implications for both iron status and its accurate assessment than 
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concluded by this study. However, without a more comprehensive set of inflammatory 
and iron status biomarkers, it is not possible to determine whether this type of 
exercise-induced inflammation occurred and the extent to which it may have 
influenced the results. 
The inability of this study to distinguish the metabolic mechanisms explaining 
the changes observed in performance and iron status is not a flaw of its design, 
especially given the particular constraints presented by conducting research in the 
Chinese academic setting (restrictions on transporting blood, where blood draws 
could occur, etc.). Indeed, this set of biomarkers is recommended by the WHO and 
many iron supplementation studies measure only sFer, Hb, and sTfR6. One major 
reason for this potential “oversight” may be the prohibitory expense of measuring 
multiple biomarkers or the difficult logistics of measuring more than a few biomarkers 
in large, international studies. However, as technology progresses and biomarkers 
like erythroferrone, erythropoietin, and hepcidin can be easily assessed on 
automated systems rather than via individual ELISA kits, the frequency of their 
measurement may increase.  
Furthermore, technologies like metabolomics may vastly improve our ability to 
understand what is happening on the metabolic level in a much more comprehensive 
way than previously possible. Untargeted metabolomics would provide insight not 
only about the iron and inflammation biomarkers mentioned above, but also on other 
markers of bioenergetics, inflammation, and general iron homeostasis that may not 
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normally be considered. Metabolomics has already been used to study both iron 
bioenergetics162,163 and exercise physiology164–166; however, as of this writing, no 
study has yet been published that utilizes this tool to examine how changing iron 
status and fitness level mutually influence each other at the metabolic level. 
Using this technology would allow researchers to examine in far greater detail 
the biological mechanisms underlying the changes in physical performance that 
occur from changes in iron status and aerobic training. Additionally, it could 
potentially even help inform the development of new biomarkers that may be more 
representative of processes of interest. For example, because they are not frequently 
reported in the literature that examines iron status in physically active women, it is not 
clear whether erythropoietin or erythroferrone would be more indicative of what is 
happening at the cellular and systemic levels in response to simultaneous iron 
supplementation and aerobic training. By examining each of the known biomarkers in 
context of the other factors involved in erythropoiesis, iron metabolism, energy 
production, and inflammation, it may be possible to create a recommendation for a 
standard set of biomarkers that better represents iron homeostasis in active 
populations.  
6.3 Iron nutrition in physically active populations 
 
Assuming that the biomarkers measured can accurately reflect iron status in 
an intervention, clinical setting, or population study, the problem of how to address 
iron deficiency in physically active populations still remains. Collectively, the results of 
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this dissertation support the idea that iron nutrition in physically active women differs 
from that of sedentary women. These differences should be accounted for when 
planning future iron interventions in populations that are, or plan to become, 
physically active. The findings in Chapter 3 support those of the previous literature, 
showing that regular aerobic training has an apparent detrimental effect on iron 
status. This dissertation further advanced the published literature in showing that 
providing a dose of iron that falls in the upper range of a conventional intervention 
dose did not improve conventional measures of iron stores as expected in trained 
women. This response is problematic for several reasons.  
Assuming that the biomarkers measured accurately reflected iron status, the 
dose of iron provided, 42.2 mg of elemental iron per day, was not enough to fully 
resolve the iron-trained group’s iron depletion as measured by sFer within an 8-week 
time frame. Conventional iron supplementation is often administered to iron deficient 
women in similar or smaller doses than those used here3,78,109. Even in the most 
severe cases of iron deficiency, where iron deficiency anemia prevalence is quite 
high (>40%), the World Health Organization recommends providing 60 mg elemental 
iron/day iron for a duration of 3 months10. This study gave 70% of that amount for an 
8-week duration and was not able to fully resolve the iron depletion of the women 
who trained while taking iron supplements. Though it is difficult to directly compare 
the WHO recommendation to the dose used in this study due to the differences in 
duration and iron concentration as well as the severity of iron depletion or deficiency, 
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the results of this study may suggest that the WHO recommended iron 
supplementation regimen might not be sufficient to resolve iron depletion, iron 
deficiency, or iron deficiency anemia in active populations.  
Further research should investigate whether active women who receive either 
the WHO recommendation of 60 mg/day (via various iron compounds including 
ferrous fumarate, ferrous sulfate, etc.) or the 200 mg ferrous sulfate (42.2 mg 
elemental iron) used in this study are able to fully resolve their iron depletion if 
supplemented for a longer duration. However, establishing an optimal dose of iron for 
iron-depleted, physically active women may be problematic because of the potential 
negative side effects of iron supplementation, including gastric distress. The WHO 
states that: “Adherence frequently diminishes due to intolerance when more than one 
iron tablet of 60 mg is required.” Interestingly, as defined by the U.S. Institute of 
Medicine, the current tolerable upper limit of iron intake for nominally health adults is 
45 mg of elemental iron per day, based on avoiding the adverse effect of 
gastrointestinal distress116. However, this study provided 42.2 mg of elemental iron 
as ferrous sulfate per day to subjects and had only one participant, in the iron 
untrained group, report any gastrointestinal discomfort presumably attributable to 
supplementation (though another subject complained she was having GI distress as 
a result of wearing the Actigraph accelerometer belt). Based on this study, it may be 
possible that IDNA women, especially those who are physically active, can tolerate a 
higher dosage of iron than iron replete and/or sedentary women. Therefore, it is 
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important to determine a dosage regimen that provides enough elemental iron to 
resolve the physiological iron deficiency while still being tolerated by the individual.  
Additionally, it could be beneficial for the WHO to consider revising its 
guidelines for practitioners to indicate that the current recommendation may not be 
adequate for iron depleted, active populations such as manual laborers, athletes, 
people who regularly perform vigorous physical activity for general fitness purposes, 
or sedentary people who begin a regular physical activity regimen. 
This research may also have implications for iron replete individuals who are 
currently, or are planning to become, highly active. Previous literature shows that 
intense regular, physical activity significantly increases the risk of iron deficiency in 
women and that this detrimental effect of exercise may be prevented by 
supplemental iron intake78,117,167,168. However, the US Institute of Medicine’s 
Estimated Average Requirement (EAR) for iron, or the average amount of daily iron 
consumption required to meet physiological demands, fails to account for an 
individual’s physical activity level. The current recommendation only accounts for 
age, gender, and pregnancy or lactation status of the individual as well as an 
assumed bioavailability of iron of 18% in the typical omnivorous American diet116. 
Therefore, the current recommendation that menstruating women between the 19 
and 50 years of age consume 8.1 mg of dietary iron per day (which equates to 1460 
μg absorbed iron per day) may be insufficient for highly active populations. Because 
these women are at higher risk for iron deficiency due to their activity, they may 
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require a higher daily intake to maintain a healthy iron status as reflected by the 
conventional measures of sFer and sTfR. The EAR value is calculated using a 
factorial method encompassing basal iron loses, menstrual loses, and absorption. 
Both iron loses and absorption are potentially impacted by physical activity8,123,169, 
suggesting that the iron requirement should be adjusted for women who are more 
physically active. Further research should investigate whether the average daily 
physiological iron requirement is higher in regularly active women. 
Creating an iron intake recommendation for “active” women may be further 
complicated by the definition used for activity. At the time of this writing, there was 
very little published literature examining how the known effects of regular exercise on 
iron status are altered when exercise is more or less intense, or continued for a 
longer duration, than that reported in this dissertation or the published literature (5 
days per week, 25-30 minutes per day, cycling at 75-85% of maximum age-predicted 
maximum heart rate)3. Therefore, it is currently unclear how physical activity impacts 
iron homeostasis when only performed a few days a week or at a low percentage of 
age-predicted maximum heart rate in untrained women. Additionally, it is unclear 
whether a similar response would be observed in highly trained women who 
underwent longer or more intense exercise sessions. 
Similarly, there is very little published literature concerning iron status and the 
duration of exercise training, both in terms of the length of exercise performed each 
day as well as the duration of the training program undertaken. A study by Comassi 
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et al examined the effect of the duration of a single bout of intense exercise (Ironman 
or Half Ironman triathlons) in elite male athletes on inflammation and iron 
homeostasis170. The Comassi study found that the inflammatory response induced by 
the exercise was dependent on the duration of the activity. They also reported lower 
apparent iron status in those with increased duration of activity. This finding suggests 
that duration of single-bouts of exercise does play a role in iron homeostasis; 
however, the Comassi report does not indicate whether these effects are sustained 
with long-term training programs. Additionally, it only included elite male athletes, 
which make the results difficult to extrapolate to less fit individuals or to females. 
Future research should investigate the impacts of exercise regimens of 
varying duration and intensity on several measures of iron status to more fully 
understand when and how iron homeostasis is impacted by physical activity. 
Additionally, these studies should be conducted in both untrained and trained 
populations to understand how initial fitness level impacts this relationship. However, 
as discussed in Section 6.2, markers of iron status may misrepresent iron 
homeostasis in active populations. Therefore, research investigating duration and 
intensity of exercise should also account for acute and chronic changes in 
inflammation, myoglobin, and erythropoiesis to create a more comprehensive 
understanding of how these factors affect iron homeostasis. This research should be 
conducted in populations of varying fitness levels. Many reported findings on iron 
status and exercise used elite athletes or military recruits117,170,171, while there is very 
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little reported evidence for these relationships in recreationally active or sedentary 
individuals. Furthermore, there is little literature published that investigates this 
relationship in IDNA males. Except for menstruation, there is no physiological 
evidence that iron homeostasis in males differs from that of females. In order to 
create iron intake recommendations that account for physical activity and are 
applicable to the general population (male or female, US or Chinese), it must first be 
understood how intensity and duration of exercise, gender, and current fitness level 
influence the relationship between aerobic training and iron homeostasis. 
 
6.4: TCM to Address Iron Deficiency in China  
 
This dissertation focuses on the relationship between changing iron status, 
fitness level, and physical performance outcomes. The previous sections have 
highlighted the need to develop recommendations for iron supplementation regimens 
in active, iron deficient women as well as for preventing iron deficiency in healthy 
women who are highly active. However, it is also important to understand these 
relationships in the context of China and its cultural views on both exercise and 
Western medicine.  
According to the 2009 China Health and Nutrition Survey, iron deficiency 
without anemia affects 28.4% of Chinese women between 18 and 50 years of age172. 
This number does not include the additional 10.7% of women in this age group who 
have iron deficiency anemia173, bringing the collective number of Chinese women of 
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childbearing age affected by some level of iron deficiency to nearly 40%. This 
prevalence rate matches that found in both the study reported in this dissertation as 
well as an unpublished pilot study that we conducted in Shanghai in 2012, though the 
samples used in the Shanghai and dissertation studies were not necessarily 
representative of the greater Chinese population. According to the World Bank, in 
2016 there were over 321 million women in this age range. Therefore, resolving iron 
deficiency in this population could potentially impact the health of 128 million Chinese 
women.  
Improving iron status in China is not as simple as recommending that all 
affected women consume conventional “Western” iron supplements. The use of 
dietary supplements to deliver elemental iron or combined as multivitamins plus 
minerals is low in China174. Recent literature suggests that 9.2% of women use some 
form of commercially produced dietary supplement, but these are not specific to 
iron175,176. A recent study in Chinese children found that only 3.9% of children under 3 
years of age were consuming commercial iron supplements, which suggests that iron 
supplementation use is particularly low in China.  
While the use of commercial dietary supplements and multivitamins and 
minerals is low in China, the use of traditional Chinese herbal medicines is much 
higher175. These medicines should be prescribed by a Chinese medicine doctor, but 
many formulations are available over-the-counter. Both prescription and over-the-
counter forms of Chinese medicine are commonly used by Chinese adults as they 
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are considered a more traditional and preferred form of treatment that should be used 
prior to using Western medicines177. It is this preference for using traditional herbal 
treatments over commercial iron supplementation that necessitates the study of the 
efficacy of these treatments in improving iron status using rigorous scientific 
methods.  However, there is currently a paucity of sound scientific evidence on the 
effects of most traditional Chinese herbal medicines83,178, making it difficult to create 
evidence-based recommendations on using them to treat conditions such as iron 
deficiency. To highlight this point, despite the frequency of its use in both China and 
the US, to our knowledge, the research reported in this dissertation is the first study 
in which BaZhen KeLi has been tested in humans for its impacts on either iron status 
or physical performance. 
While this study does not support the use of BZ to treat iron deficiency or its 
consequences on physical performance, it is possible that other formulations of its 
components, such as the four-herb combination called Si Wu Tang, could still 
improve iron status86,149. It is also possible that other traditional herbal treatments 
may impact iron status but have not yet been tested. A 2009 analysis of Cochrane 
reviews concerning varying kinds of Traditional Chinese Medicinal therapies 
concluded that of the 70 Cochrane systematic reviews examined, 27 reviews 
suggested some kind of benefit from the treatments while another 41 reviews 
concluded there was not sufficient, high-quality evidence to determine the efficacy of 
the reviewed treatments179.  This finding supports a recommendation that more 
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research is needed to evaluate the efficacy of using Chinese herbal medicines to 
treat IDNA and/or anemia in humans.   
Additionally, there are several other methods that could be used alone or in 
combination with TCM to address iron deficiency in China. A 2008 review by the 
Chinese Center for Disease Control evaluated the cost-effectiveness of using 
supplements, dietary diversification, food fortification, and biofortification to resolve 
iron deficiency in China81. In 2003, China implemented fortification programs for soy 
sauce and wheat flour. These programs have been successful in the populations that 
have access to or can afford to regularly purchase and consume these products; 
however, the review concluded that no further fortification programs are needed.  The 
publication also concluded that while all of the intervention approaches examined 
have some degree of effectiveness, the most feasible and promising methods at the 
national level are promoting the use of biofortification and dietary diversification. 
However, they recognized the cost limitations for suggesting dietary diversification for 
low-resource subgroups and therefore stressed the importance of biofortification. The 
2009 review by Ma and colleagues, which as of this writing was the most recent 
English-language review addressing this issue in China, made no mention of using 
traditional Chinese medicine to address iron deficiency in the Chinese population. It 
is unclear whether this oversight is because there is currently insufficient scientific 
evidence to make recommendations or because it is not considered a realistic 
method for addressing this issue at the population level. If more evidence on the 
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efficacy of TCM treatments in improving iron status is reported in peer-reviewed 
scientific publications, evaluating the combination of using traditional Chinese 
medicines with methods such as dietary diversification or the cultivation and 
consumption of biofortified crops may become a feasible strategy for addressing iron 
deficiency in the Chinese population. 
6.5: Physical activity, obesity, and iron status in Chinese women 
 
The role of physical activity in the Chinese culture is somewhat different than it 
is in the United States. Voluntary, recreational physical activity is less common in 
China than it is in the U.S., particularly among women175. A 2014 review of physical 
activity in China found that “active leisure” activities do not contribute much to the 
physical activity of Chinese adults158. Rather, the majority of physical activity 
performed by Chinese adults was occupational in nature. Additionally, the amount of 
total daily recreational physical activity performed by the average Chinese woman 
has decreased somewhat over the last two decades158. This decline in physical 
activity, along with a shift from a traditional to “Western” style diet, is cited as one of 
the primary reasons underlying the increasing rates of obesity in the last three 
decades180,181.  
The prevalence of overweight and obesity (BMI > 25 kg/m2) in China has 
increased at an alarming rate since the early 1990’s, affecting 29.2% of Chinese 
adults in 2009181. To prevent the chronic diseases that are associated with 
overweight and obesity, the Chinese Ministry of Health is developing a national 
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framework that includes a physical activity recommendation180. In 2009, the Chinese 
government created national fitness recommendations to help increase daily 
voluntary physical activity in China and in 2010 they released a set of physical activity 
guidelines for Chinese adults180. Understanding the implications that increasing 
general physical activity levels may have for iron status in China is somewhat difficult, 
as it is unclear how effective these new guidelines and programs will be and whether 
the levels of exertion achieved will be high enough to impact, or be impacted by, iron 
nutrition. 
In 2011, the average Chinese female performed less than three MET-hours of 
physical activity per week158. MET-hours reflect the intensity of an exercise and its 
duration, so 3 MET hours per week is the equivalent of doing an activity that requires 
3 times the amount of energy expended at rest for one hour. Examples of this 
intensity of activity include walking at 3 miles per hour or using a stationary bicycle 
with very light effort135.  Accordingly, it may be that the average Chinese woman is 
not currently physically active enough to be at the higher risk of iron deficiency 
associated with regular aerobic activity, such as that which was reported in the 
trained women in this dissertation. However, this means that the current 40% 
prevalence of iron deficiency in Chinese women173 occurred despite the population 
being largely sedentary. The trained women in this study were biking at a speed 
classified as vigorous physical activity (6.5 METs) by the 2011 Compendium of 
Physical Activities135. This equates to 13.5 MET-hours per week, or about 4.5 times 
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the amount of an average Chinese woman. Based on the results reported in Chapter 
3, it is clear that this amount of aerobic training (25 minutes per day at 75-85% of 
maximum heart rate, for an average of 4 days per week) was sufficient to impact 
conventional indicators of iron status and stored liver iron. This amount of exercise 
would not be difficult to achieve over the course of a week. For example, a woman 
who walks for 1 hour at 3 miles per hour 5 days per week would achieve roughly the 
same number of MET-hours per week as the women in the trained group in this 
dissertation. Given the relationship between regular exercise and decreased 
apparent iron status as assessed by sFer, sTfR, and Hb76,117, the prevalence of iron 
deficiency in China could potentially be exacerbated further if there is a significant 
increase in the frequency of leisure-time exercise in the female Chinese population 
because iron requirements would increase with increasing activity levels (though as 
mentioned in Section 6.3, it remains unclear how varying duration and intensity of 
exercise impact this relationship). 
It is important that as the Chinese government and research institutions 
continue to promote physical activity as a means to control obesity and metabolic 
syndrome in the Chinese population, that they also carefully monitor women’s iron 
status. Obesity often has comorbid iron deficiency and anemia, though paradoxically, 
about one-third of patients with metabolic syndrome have elevated ferritin levels182. 
While the relationship between obesity, inflammation, hepcidin, and iron homeostasis 
is still being studied, it is becoming clearer that obesity and metabolic syndrome can 
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negatively impact iron status through inflammation and women with these conditions 
should be monitored closely to prevent iron deficiency183. Further complicating this 
relationship is that women who are iron deficient or anemic are known to be less 
active in free-living physical activity44. Therefore, it is unclear how widely the physical 
activity recommendations will be adopted in populations where iron deficiency and 
anemia are more widely prevalent. 
Based on the collective findings in this dissertation, several general 
recommendations can be made for improving and monitoring iron status in China. 
Chinese health care practitioners should be trained to order tests for sFer and, if 
monetarily feasible as technology progresses, sTfR in addition to Hb to identify iron 
deficiency in its early stages before it progresses to anemia. Additionally, medical 
practitioners and health educators should encourage the use of proven efficacious 
interventions and treatment regimens that use commercial iron supplements, dietary 
diversity, or iron-fortified food products to improve iron status or prevent decrements 
in iron status as women increase their daily physical activity levels. Traditional herbal 
medicine practitioners should be advised that the formulation of BZKL used in this 
dissertation is not known to be effective for treating iron deficiency and should be 
avoided until more conclusive evidence is available for its efficacy in improving iron 
status or physical performance. Finally, as public health researchers develop 
interventions aiming to reduce obesity and metabolic syndrome, they should consider 
the implications that changing physical activity patterns may have on the iron status 
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of their target populations, as well as how iron deficiency may limit women from 
adopting physical performance recommendations, and account for this effect in their 
study designs. Similarly, when designing interventions aiming to improve iron status 
in Chinese women, researchers should be aware of how active their participants are, 
as they may need to adjust their intervention dose as discussed in Section 6.3. 
6.6:  Directions for future research 
 
 This dissertation has helped clarify several aspects of how improved iron 
status and aerobic training interact to affect physical performance and measures of 
iron status in Chinese women. It has also raised several new questions that can help 
guide the future of this field of study.  
First, this study was conducted in a group of IDNA, but otherwise healthy, 
sedentary females, which allowed for the examination of the research questions 
proposed in Aims 1 through 3 of this dissertation. However, the results here may be 
limited in their generalizability to other populations. Future research could examine a 
similar research question in other populations to understand how factors such as 
anemia, level of fitness or regular physical activity at baseline, as well as baseline 
weight/body composition or gender alter the results reported in this dissertation. 
Examining the relationship between aerobic training and changing iron status would 
be particularly interesting, as the added physiological stressor of anemia would likely 
influence the metabolism of supplemental iron. Understanding how iron is 
differentially distributed in the body to support various metabolic adaptations in iron 
 
 
 
 
 
 
 
178 
deficient anemic individuals undergoing aerobic training, compared to IDNA 
individuals undergoing the same training would help clarify the basic mechanism of 
iron metabolism across varying levels of iron status. 
Future research should also address the question of how iron deficiency impacts 
the typical adaptations to aerobic training using methodologies that allow for a more 
detailed examination of energy metabolism and muscle physiology. Of foremost 
interest is elucidating the metabolic changes underlying the observed changes in iron 
status markers and physical performance. As discussed in sections 6.2 and 6.3, 
there are several biomarkers that, if measured, could help understand these 
changes. Future research should be conducted that reproduces the study reported 
here with several added measurements. Specifically, future studies should measure 
a larger number of iron biomarkers including erythropoietin and erythroferrone to 
understand how erythropoiesis is influenced and hepcidin and IL-6 to understand 
how general iron homeostasis and inflammation are altered. Additionally, if possible, 
studies should also try and assess DMT1 and Cytochrome B, perhaps via mRNA 
expression, to clarify whether exercise-induced inflammation is altering iron 
absorption in the trained women.  
Furthermore, future research should examine how aerobic training in the iron 
deficient state impacts muscle metabolism and growth. To address this question, it 
would be particularly promising to measure muscle metabolites and myoglobin during 
exercise before and after the 8-week treatment period used in this dissertation. This 
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could be achieved by taking muscle biopsies from the quadriceps muscle (a muscle 
that is trained heavily in cycling) of the women before and after the 8-week study 
period both at rest and after an exercise test that would achieve both an aerobic 
steady state (to observe endurance capacity) as well as maximal exertion (to allow 
for examination of both VO2max and VO2peak). Muscle biopsies would also allow us 
to examine changes in muscle fiber type and intramuscular fuel stores, which would 
help clarify how iron deficiency impacts the typical adaptations to aerobic training. 
Combining the expanded biomarker collection and muscle biopsies with untargeted 
metabolomics would also further improve the ability of such a study to make 
comprehensive conclusions about the changes in iron homeostasis, muscle 
metabolism before and after exercise, and how these factors interact in response to 
the treatments used in the current research.  
Additionally, it is likely that other biomarkers may be more reflective of general 
iron homeostasis than only examining sFer, Hb, and sTfR. As mentioned previously, 
the use of global metabolomics may help inform the design of a better panel of iron 
biomarkers or even potentially new metabolites altogether for use in future iron 
studies.  
6.7: Conclusions 
 
 To summarize, this 3x2 factorial intervention study helped elucidate the 
relationship between simultaneous improvements in iron status and fitness level and 
how they impact physical performance in Chinese university women. Chapter 3 
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demonstrated that iron deficient, non-anemic women who undergo regular aerobic 
training while taking iron supplements do not improve their estimated iron stores as 
much as women who remain sedentary during supplementation. However, while it is 
clear that iron stores in trained women do not increase as expected, it is unclear how 
the supplemental iron is being used by these women (for example, whether it is being 
shuttled to myoglobin, erythropoiesis, or other unmeasured pathways or storage 
sites) and whether any exercise-induced inflammation is occurring that alters iron 
absorption. 
 Chapter 4 explored the influence that supplemental iron has on physical 
performance and/or the physiological adaptations to aerobic training. Iron 
supplementation improved endurance performance at both maximal and submaximal 
exercise intensities in iron-deficient, non-anemic women. The results suggested that 
iron supplementation alone increased submaximal performance to the same extent 
as training without supplementation. Interestingly, this study also found that taking 
supplemental iron during aerobic training had no additive benefit on physical 
performance compared to either treatment alone. This finding contradicts previous 
studies, which showed an ergogenic effect of supplemental iron above that of training 
alone3.  
Furthermore, though not discussed in detail in Ch. 4, this is the first study to 
separately examine VO2max and VO2peak as markers of different physiological 
states – maximal capacity for oxygen consumption and endurance at near-maximal 
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intensities, respectively. The results of this dissertation agree with previous studies 
that suggest that iron deficiency without anemia should not impact VO2max5, while 
also expanding upon the findings of the Pasricha et al review134 that concluded that 
iron supplementation does improve VO2max, which was measured as a combined 
variable of VO2max and VO2peak together. 
 Finally, Chapter 5 examined the efficacy of using a traditional Chinese herbal 
medicine, BaZhen KeLi, on improving iron status and physical performance in iron-
deficient, non-anemic women. To our knowledge, this was the first time that the 
efficacy of this treatment has been tested in humans, despite its frequent use in both 
China and the United States. This study found that BaZhen KeLi had no impact 
whatsoever on any measure of iron status measured and does not improve maximal 
or submaximal physical performance. Additionally, this treatment did not have any 
ergogenic effect when given during aerobic training. Based on these findings, 
Traditional Chinese Medicine practitioners should be advised not to prescribe this 
treatment for symptoms of iron deficiency or iron deficiency anemia, especially in lieu 
of conventional iron supplements where feasible. Additionally, healthcare 
practitioners in both China and the US should be aware of iron deficient and anemic 
patients’ self-care practices and caution against using this treatment as a home 
remedy to improve iron status in lieu of standard iron supplementation. Based on the 
literature, it is possible that one or more of the components in BaZhen KeLi may 
affect iron status or physical performance, but further research is needed to clarify 
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whether different formulations or dosages of BZKL, or even single active ingredients, 
are effective in increasing iron status or physical performance in women with varying 
degrees of iron deficiency or IDA. 
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150.  Xue J, 薛己, Wilcox L. Xuē Jĭ’s Categorized Essentials of Repairing the Body : 
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Appendix A: Data Collection Forms 
 
A1: Screening Documents (Chinese) 
A1.1: Screening informed consent 
 
知情同意书 1——受试对象筛选过程 
 
我们邀请您参与一项科学研究的筛选过程。表格的设计是为了给您提这项研究有关信
息。我们将为您描述这项研究并对您的任何疑问做出解答。 
 
项目名称：铁在有氧训练和机体性能之间关系的功能和代谢作用。本研究的负责人是
美国康奈尔大学的 Laura Pompano，她的导师是康纳尔大学的 Jere Haas博士和昆明医
科大学的蔡乐博士。 
 
本研究的负责人:  Laura Pompano 硕士 
云南省昆明市呈贡新城雨花街道春融西路 1168 号 650500 
公共卫生学院 
邮箱: lmp262@cornell.edu 
电话: 186-8751-3238  
 
康乃尔倒是    Jere Haas 博士 
    Division of Nutritional Sciences  
220 Savage Hall, Cornell University, Ithaca, NY 14853 USA 
电话: +1-607-255-2665  
邮箱: jdh12@cornell.edu  
 
昆明医科大学的老师  蔡乐博士 
云南省昆明市呈贡新城雨花街道春融西路 1168 号 650500 
公共卫生学院 
邮箱: caile002@hotmail.com 
电话: 871-5922921 (办公室)  
 
研究目的： 
本次调查的目的是决定您是否有资格参与该项研究。这是一项为期 8周的研究，检查
铁缺乏如何影响其他因素以及如何被运动影响。本次研究有两组受试者：铁缺乏非贫
血妇女和健康妇女。我们将基于筛选试验时您体内铁的含量将您分到相应的小组。这
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次研究的主要目的是阐明机体铁缺乏状态，有氧运动和机体性能之间的关系。 
 
研究方法： 
我们希望您能认真审阅参与本次研究所需的一系列标准。如果您符合这些标准，我们
希望您能允许护士使用无菌针管在手臂血管处抽取 4ml的血液。这些血液将会用于实
验室内测量您体内的铁含量。我们还需要通过一个简单的健康问卷和测量您的身高体
重，以便了解您的健康状况。抽血时间不超过 15分钟。 
 
风险和不适： 
从手臂处抽血的并发症包括轻微出血,擦伤或感染。为防止意外,将由一名有经验的护
士进行抽血。如果您确实在抽血后出现出血,擦伤或感染等情况,医生/护士将免费为您
进行治疗。 
 
好处/利益： 
参加本次筛选试验的一个优点是，在筛选试验完成后您将了解自己体内铁状态。 
 
参与成本： 
参加本次筛选试验完全属于自愿、免费的。 
 
参与回报： 
为感谢您的参与，完成筛查的受试者将收到我们提供的小礼物一份。 
 
血液样本的处理： 
在血红蛋白和血清铁蛋白筛选完成后，您的血液样本将会进行卫生处理，不会有样本
会保留用于其它血液分析。 
 
测试结果异常： 
如果我们在抽血或后续分析中得到任何异常结果，我们都会在 10天内通知您这些结果
并建议您联系您的私人医生进行随访。请注意，作为研究者，我们并未经过进行诊断
或治疗的训练。 
 
如果您在本研究中受伤 
在面对任何研究相关活动所导致的伤害时，我们将提供包括急救、应急处理、所需随
访护理等治疗措施。这些治疗费用将通过普通方式由您或您的保险公司支付。如果您
认为您受到了研究相关的损伤，请联系芮溧老师，研究顾问电话为 87165922921。 
 
隐私和保密 
所获得的数据将被安全储存并以匿名形式（没有表示能将您和您的信息联系在一起）
报道。只有负责调查或伦理委员会的成员才可以访问严格保密的原始数据。如果您符
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合资格，我们将邀请您参加本次研究。 
 
自愿参与原则 
作为参与者，你有权在任何时候推出筛选试验，并且不需要说明原因或承担负面后
果。退出时无需退回之前所获得的补偿，也对您和这次试验所在学校间的关系无任何
影响。 
 
研究者、医生或赞助的退出 
研究者、医生或赞助商在任何时候都可能停止研究或将您从研究中剔除。他们应该是
从您的最佳利益判断并做出决定。如果您在相关研究中受伤，如果您需要额外的或不
同的药物/治疗，或者如果您不遵守研究计划。他们可以因为各种行政或医疗原因，未
经您同意而将您从研究中剔除。 
 
若在筛选过程中发现年龄在 18周岁以下或者有严重贫血（血红蛋白<90g/L）的女性将
不能参与本次研究。所有的潜在参与者将由昆明医科大学公共卫生学院的芮溧博士跟
进。 
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Subject Screening ID #: ______ 
 
如果您有以下情况时，请务必说明： 
1、能阻止您在固定自行车上锻炼的身心障碍  
2、去年一年内处于怀孕或哺乳期  
3、吸烟  
4、服用精神药物  
5、最近又发烧、肺部或胃肠道疾病  
6、已知有炎症或慢性炎症疾病  
7、溶血性贫血  
8、肌肉、骨骼问题  
9、目前或过去饮食失调  
        
（在上述的条件里，如果你能满足其中一项，请选择有）      有___     没有
____  
 
 
问题： 
1、近期，你有服用任何药物吗？                              是___      不是
____ 
如果是，请说明： 
 
 
 
 
2、近期，你有服用维生素，矿物质，或营养补充剂吗？          是___      不是
____ 
如果是，请说明：  
 
 
3. 如果你被录取，你愿意遵守全部 8周口服维生素或者中药吗？  是___      不是
____ 
 
 
4. 如果你被录取，你愿意遵守全部 8周的体能训练计划吗？      是___      不是
____ 
 
 
5. 如果参与研究，你愿意遵守全部 8周不放假吗? (包括国庆节)  是___      不是
____ 
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如果您有任何的疑问 
进行此项主要人员为美国康奈尔大学的研究生劳拉。如果您有任何疑问，请在现
场进行咨询。如果你以后有问题，你可以联系公共卫生学院讲师芮溧，电话
13888531601。如果您有任何问题或关心关于作为研究的受试者您的权利，你可以联系
昆明医科大学或康奈尔大学或访问他们的网站的机构审查委员会（IRB）来了解参与人
权利。 
 
同意声明 
我已阅读以上材料，并以了解相关信息。我同意参加本次筛选研究这一阶段。 
 
姓名：              日期：    
 
本研究的负责人：                日期：    
 
本知情同意书将被研究保留至研究结束后至少 5年。 
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A1.2 Screening Physical Activity Questionnaire 
国际身体活动问卷                 Screening ID #:____________ 
我们对找寻人们在他们日常生活中多种的身体活动有兴趣，这个问卷会问你在最近 7
天花在身体活动的时间，请回答每一个问题，甚至如果你想自己是一个没有活动的
人，请想一想你在工作时的活动、像是你在家里或园艺的部份、从一个地方到一个地
方及在你空闲的时间运动或娱乐。 
 
1. 想一想在最近 7 天里你做过所有强而有力的活动，强而有力的身体活动是指以费力的
身体负荷且让你呼吸较正常更为急促的活动，仅回想你所做过每次至少 10 分钟的那些
身体活动。 
 
最近 7 天里，你花多少天做强而有力的身体活动, 像是提重物, 苦力, 有氧运动或快骑脚
踏车？ 
a. _____ 每周几天  
b. _____  没有强而有力的身体活动     跳到问题 2 
 
在参与强有力身体活动的那些天，你通常花多少时间做强而有力的身体活动？  
a. _____ 每天几分钟 
b. _____  不知道/不确定 
 
你是否经常参与类似于足球比赛一类的剧烈运动? 
c. _____ 参加 
d. _____  不参加 
 
2. 想一想最近 7 天你做过所有适度的活动，适度的活动是指以适度的身体负荷并且让你
呼吸比正常费力一些的活动。 
 
最近 7 天里，你花多少时间做适度的身体活动，像是提轻的物品、正常的速度骑脚踏
车或网球双打？不包含走路。 
a. _____ 每周几天 
b. _____  没有适度的身体活动     跳到问题 3 
 
在参与适度身体活动的那些天，通常你花多少时间做适度的身体活动？ 
a. _____  每天几分钟 
b. _____  不知道/不确定 
 
3. 想一想最近 7 天你花多少时间在走路，包含工作、在家、从某地到某地、娱乐、游戏
或休闲时的走路。 最近 7 天里，你花多少天走每次至少 10 分钟的路？ 
a. _____ 每周几天 
b. 沒有走路   跳到问题 4 
 
在走路的那些天，你通常花多少时间在走路？ 
a. _____  每天几分钟 
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b. _____  不知道/不确定  
 
4. 最後的问题是在最近连续 7 个非假日时间（扣除周六与周日）你花多少时间在坐着，
包含花在工作、家里、做作业及休闲时的坐着，这或许可以包含花在书桌、拜访朋
友、读书或看电视的躺着或坐着。 
a. _____ 每天几分钟 
b. _____  不知道/不确定 
問卷最後感謝你的參與! 
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A1.3 Screening Health History Questionnaire 
健康历史调查: 
请您如实回答下面的问题，您的所有信息将会保密。 
1. 姓名: ___________ 
 
2. 年龄: ___________ 
 
3. 专业: ___________ 
 
4. 民族：___________ 
 
5. 最后的月经期：___________ 
 
6. 你每个月抽几支烟？        □ 0      □ 1-5  □ 6-10         □ 10+ 
 
7. 您是否有如下一种或多种情况： □ 是  □ 不是 
a. 近期得感染性疾病 
b. 近期发热 
c. 炎症或慢性炎性疾病 
d. 溶血性贫血 
e. 慢性呼吸系统疾病 
f. 肌肉骨骼系统问题 
g. 进食障碍的历史 
 
8. 您是否有别的问题（例如：发烧、头疼、胃部不适、疲劳等等）？如果有，请具体说
明： 
 
 
9. 您是否: 
a. 怀孕       □ 是 □ 不是 
b. 处于哺乳期      □ 是 □ 不是 
c. 服用精神类药物     □ 是 □ 不是 
d. 服用维生素      □ 是 □ 不是 
e. 如果服用精神类药物或者维生素，请具体说明： 
 
 
10. 您是否会骑自行车?      □ 是 □ 否 
 
11. 您现在能否骑自行车？（是否有身体不适）   □ 能 □ 不能 
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这个页是研究者完成的。 你不要填空。 
Screening Data: 
1. Screening ID: 
 
2. Height: _____________ cm 
 
3. Weight: _____________ kg 
 
4. Hb:  _____________ g/dL   
 
5.  Body fat:  
 
 
6. Gift Received?      
7. Subject signature of gift received: _____________  
 
Lab Test Results: 
1. Hb: __________ 
2. sFer: _________ 
 
 
 
 
 
 
 
 
Site 1st  Measurement (mm) 2nd Measurement (mm) Average (mm) 
Bicep    
Tricep      
Subscapular         
Suprailiac    
MUAC    
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A2: Screening Documents (English) 
A2.1 Screening informed consent 
Screening Session (FORM 1A) 
 
We are asking you to participate in a screening process for a research study. This form is 
designed to give you information about this study.  We will describe this study to you and 
answer any of your questions.   
 
Project Title:   Defining the Functional and Metabolic Role of Iron in the Relationship 
Between Aerobic Training and Physical Performance 
 
Principal Investigator: Laura Pompano 
Division of Nutritional Sciences 
1168 West Chunrong Street, Yuhua Avenue, Chenggong New 
 District 
Kunming, Yunnan Province, China 650500 
Email: lmp262@cornell.edu 
Telephone:  
 
Cornell Faculty Advisor  Dr. Jere Haas 
    Division of Nutritional Sciences  
220 Savage Hall, Cornell University, Ithaca, NY 14853 USA 
Phone: (607) 255-2665  
Fax: (607) 255-1033  
Email: jdh12@cornell.edu  
 
Chinese Faculty Advisor  Dr. Le Cai 
    Department of Nutrition and Food Sciences 
School of Public Health, Kunming Medical University 
1168 West Chunrong Street, Yuhua Avenue, Chenggong New 
District 
Kunming, Yunnan Province, China 650500 
Email: caile002@hotmail.com 
Tel: 86-871-5922921 (office)    
 
What the study is about 
The purpose of this research is to determine if you qualify to be included in this study. The 
study will be an 8-week study examining how iron deficiency affects and is affected by 
exercise. The study will have two groups of participants: iron deficient non-anemic and 
healthy women. You will be assigned to a group based on your body iron status at screening. 
The primary aim of the study is to clarify the relationship between body iron status, aerobic 
exercise training, and physical performance 
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What we will ask you to do  
We will ask you to review a list of criteria for participation. If you meet these criteria, we will 
ask you to allow a nurse to draw 4mL of blood using a sterile needle from a blood vessel in 
your arm. The blood will be taken to the laboratory and it will be used to measure the 
amount of iron in your body. We will also ask simple questions about your general health via 
a general health questionnaire and record your weight and height. The blood draw should 
take no more than 15 minutes. 
 
Risks and discomforts 
The disadvantages/ risks of having blood drawn from the arm are slight bleeding, bruising or 
infection. To prevent these risks, blood will be drawn by an experienced nurse. If you do 
have any bleeding, bruising or infection after the blood draw, you will be cared for by the 
nurse and/or doctor at no cost to you. 
 
Benefits 
An advantage of participating in the screening session is that you will learn your iron status 
after the screening exercise has been completed. 
 
Cost of participating 
Your participation in the screening session is entirely voluntary and free of charge. 
 
Payment for participation 
You will receive a small gift for your participation. 
 
Use of Tissue Samples/DNA for Future Studies  
After screening for hemoglobin and serum ferritin, your blood sample will be disposed of in a 
sanitary way. No samples will be retained for future analysis. 
 
Abnormal Test Results 
In the event that we get back any abnormal results from the blood draw or subsequent 
analyses, we will inform you about these results within 10 days and recommend you contact 
your private medical provider for follow-up. Please be advised that as researchers, we not 
trained to diagnose or treat medical conditions.  
 
If you are injured by this research 
In the event that any research-related activities result in an injury, treatment will be made 
available including first aid, emergency treatment, and follow-up care as needed. Cost for 
such care will be billed in the ordinary manner to you or your insurance company. No 
reimbursement, compensation, or free medical care is offered by Cornell University. If you 
think that you have suffered a research-related injury, contact Dr. Le Cai, the research 
advisor immediately at 87165922911. 
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Privacy/Confidentiality  
The obtained data will be stored safely and reported in an anonymous form with no 
identifiers that can associate you with your data. Only the responsible investigators and/or 
the members of the ethical committee have access to the original data under strict 
confidentiality. If you qualify, you will be invited to join the study. 
 
Taking part is voluntary  
As a participant, you have the right to withdraw from the screening session at any time 
without needing to specify any reasons or facing negative consequences. Withdrawing will 
have no effect on the compensation earned before withdrawing or on your relationship with 
the universities involved with the research. 
 
Withdrawal by investigator, physician, or sponsor 
The investigators, physicians or sponsors may stop the study or take you out of the study at 
any time should they judge that it is in your best interest to do so, if you experience a study-
related injury, if you need additional or different medication/treatment, or if you do not 
comply with the study plan. They may remove you from the study for various other 
administrative and medical reasons. They can do this without your consent. 
 
Women under the age of 18 or found to have severe anemia (Hb<90g/L) in the screening 
process will not be invited to participate in the study. All potential participants will be 
examined by a project physician, Li Rui, M.D. from the public health department at KMU.  
 
Please indicate if you have any of the following conditions: 
  
1. physical/mental disability that prevents you from exercising on a stationary bicycle  
2. pregnancy or lactating within the last year  
3. smoke cigarettes 
4. taking psychoactive drugs 
5. current/recent fever, respiratory, or gastrointestinal illness  
6. known inflammatory or chronic inflammatory disease 
7. hemolytic anemia 
8. musculoskeletal problems 
9. current or past eating disorder 
10. other preexisting medical condition 
 
Yes _____            No  _____        
(If you have one or more of the 10 conditions listed above, please selected YES) 
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Are you taking any kind of medication? Yes___     No____   
If Yes, please explain:  
 
 
 
 
Are you taking any kind of vitamin, mineral, or nutritional supplement? Yes___     No____   
If Yes, please explain: 
 
 
 
 
You must complete a physical activity questionnaire that indicates you currently do not 
participate in regular exercise or organized sports, are interested in increasing their level of 
physical fitness, and willing to comply with the full 8-week training program.  
 
If you have questions 
 
The main researcher conducting this study is Laura Pompano, a graduate student at Cornell 
University in the U.S.A. Please ask any questions you have now. If you have questions later, 
you may contact Laura Pompano at lmp262@cornell.edu or (I will insert my Chinese phone 
number here once I acquire it in China). If you have any questions or concerns regarding 
your rights as a subject in this study, you may contact the Institutional Review Board (IRB) 
for Human Participants at KMU or at Cornell or access their website.  
 
KMU: 
*I will insert this information as soon as Dr. Cai provides it to me. * 
 
Cornell:  
+1-607-255-5138   
http://www.irb.cornell.edu.  
 
You may also report your concerns or complaints anonymously through Ethicspoint online at 
www.hotline.cornell.edu or by calling toll free at +1-866-293-3077. Ethicspoint is an 
independent organization that serves as a liaison between the University and the person 
bringing the complaint so that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
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Statement of Consent 
I have read the above information, and have received answers to any questions I asked. I 
consent to take part in this phase of the study screening.  
 
Your Signature         Date  
  
 
Your Name (printed)          
   
 
Signature of person obtaining consent       Date 
   
 
Printed name of person obtaining consent       
   
 
This consent form will be kept by the researcher for at least five years beyond the end of the 
study. 
  
 
 
 
 
 
 
 
226 
A2.2 Screening Physical Activity Questionnaire 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part of their 
everyday lives.  The questions will ask you about the time you spent being physically active in the last 
7 days.  Please answer each question even if you do not consider yourself to be an active person.  
Please think about the activities you do at work or school, as part of your house and yard work, to get 
from place to place, and in your spare time for recreation, exercise or sport. 
 
1. Think about all the vigorous activities that you did in the last 7 days.  Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
 
During the last 7 days, on how many days did you do vigorous physical activities like heavy 
lifting, running, aerobics, or fast bicycling?  
a. _____  days  
b.  No vigorous physical activities  Skip to question 2 
 
How much time did you usually spend doing vigorous physical activities in a typical day? 
a. _____ Minutes per day 
b. _____   Don’t know/Not sure 
 
 Do you participate in organized sports or regular vigorous physical activity? (Ex: running 
program, organized sports leagues, etc) 
a. _____    Yes 
b. _____    No 
 
2. Think about all the moderate activities that you did in the last 7 days.  Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
 
During the last 7 days, on how many days did you do moderate physical activities like 
carrying light loads, bicycling at a regular pace, or badmitton?  Do not include walking 
a. _____ days  
b. No moderate physical activities Skip to question 3 
 
How much time did you usually spend doing moderate physical in a typical day? 
a. _____ Minutes per day 
b. _____ Don’t know/Not sure 
 
 
 
3. Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you might do solely 
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for recreation, sport, exercise, or leisure.  During the last 7 days, on how many days did you 
walk for at least 10 minutes at a time?   
a. _____  days  
b.  No walking   Skip to question 4 
 
How much time did you usually spend walking in a typical day? 
a. _____ minutes per day 
b. _____ Don’t know/Not sure 
  
4. The last question is about the time you spent sitting on weekdays during the last 7 days.  
Include time spent at work, at home, while doing course work and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television.  
During the last 7 days, how much time did you spend sitting on a week day? 
a. _____ minutes per day 
b. _____ Don’t know/Not sure 
 
This is the end of the questionnaire, thank you for participating. 
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A2.3 Screening Health History Questionnaire 
Health History Form: 
Please answer this form honestly and to the best of your ability. This information will be kept 
private and will only be used for this study by the researchers.  
1. Name: 
 
2. Age: 
 
3. Major: 
 
4. Chinese ethnicity/minority group: _________ 
 
5. Height ____________   m 
 
6. Weight ____________ kg 
 
7. Date of Last Period   ___________ 
 
8. How many cigarettes do you smoke per month?      
  □ 0  □ 1-5  □ 6-10  □ 10+ 
 
9. Do you have one or more of the following health conditions: □ Yes □ No      
a. recent infectious illness 
b. recent fever 
c. current inflammation or chronic inflammatory disease 
d. hemolytic anemia 
e. chronic respiratory disease 
f. musculoskeletal problems 
g. history of eating disorder 
 
10. Do you have any other present health complaints or problems (ex: fever, headache, stomach 
problems, tired, etc.)? If yes, please describe. 
 
11. Are you: 
a. Pregnant      □ Yes □ No      
b. Lactating      □ Yes □ No      
c. Taking any psychoactive medications?   □ Yes □ No      
d. Taking any vitamins?     □ Yes □ No      
e. If yes to C or D: Please list which medications / vitamins you are taking: 
 
12. Do you know how to ride a bicycle?    □ Yes □ No      
Are you currently physically able to ride a bicycle?  □ Yes □ No      
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A3: Main Study Informed Consent (English and Chinese) 
A3.1 Chinese 
知情同意书 2——正式研究 
    我们邀请您参与一项科学研究的筛选过程。以下是这项研究的有关信息，如果有
任何疑问，我们将为您做出解答。 
项目名称：铁在有氧训练和机体性能之间关系的功能和代谢作用。本研究的负责
人是美国康奈尔大学的博士研究生 Laura Pompano，她的导师是康纳尔大学的 Jere 
Haas博士和昆明医科大学的蔡乐博士。 
    研究目的：这是一项为期 8周的研究，检查铁缺乏如何影响其他因素以及如
何被运动因素影响。本次研究有两组受试者：铁缺乏非贫血妇女和健康妇女。我们将
根据筛选试验中您体内铁的含量值将您分到相应的小组。本研究旨在阐明机体铁缺乏
状态，有氧运动和机体功能之间的关系。 
研究步骤 
第 1部分：补充剂： 
    如果您愿意参加该研究，您将被随机分配到三个组（硫酸亚铁补充剂组、八珍颗
粒补充剂组、安慰剂组）中的其中一组，请您连续 8周口服硫酸亚铁补充剂（每天两
次，每次 50mg），或八珍颗粒补充剂（每天两次每次，600mg），或相似的安慰剂（每
日 2次）。为了保证研究的完整性，我们要求您不能与你朋友或同学交换补充剂。我
们要求您一天服药两次，并每周向我们提供您的用药频率记录。为减少胃肠道不适的
风险，我们建议您在用餐时服用补充剂。为了提高营养物质的吸收，我们建议你服用
补充剂的同时服用富含维生素 C的食物，例如柚子、橙子或荔枝等。 
 
第 2部分：运动试验 
        本次研究将在第 0周、4周和 8周各进行一次运动试验，即整个研究过程共进行 3
次运动试验，该运动试验用来评估你的身体状况。 
    每次试验包括两项运动测试。第一项测试是用来测量在运动过程中最大吸收和利
用氧的能力。在测试过程中，我们将采用无菌一次性采血针对手指进行针刺，并收集
一滴血以便观察血乳酸浓度。该检查在第一项测试中将进行多次。第二项测试的目的
是检测机体效率。该测试将根据第一项测试结果确定在三个工作负荷下进行。在第二
和第三的负荷后，会抽取 4ml的臂肘静脉血。 
    每次进行的两项运动测试要间隔两天，每项测试要求在固定脚踏车上踩踏约 15-30
分钟，测试期间要求戴面罩用于呼吸和心率的监测。 
 
第 3部分：抽血 
    所有的静脉抽血将由有资格的执业医师执行。抽血将在研究中以下时间点进行。 
    a.在第 0周，4周和 8周：在非运动、静息状态时收集 4ml臂肘前静脉血。一部分
血用于评估血红蛋白。将剩余的血液向下旋转分离出血清，并收集，冷冻，存储用于
以后的分析。 
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    b.在第 0周，4周，和 8周：如本文第 2部分描述的那样，将于第二个运动试验各
阶段后抽取 4ml血液。将血液旋转到血清分离，并收集，冷冻，存储用于以后的分
析。 
    c.在第 0周，4周和 8周：在第一个运动试验的每次负荷结束后对手指戳刺。需要
对每个手指进行采血。取决于测试期间你的实际情况，将收集 2-5滴血。对这部分不
进行存储。 
 
第 4部分：体力活动评估 
    在研究开始前，我们会要求你完成一个体力活动调查问卷，以便总结您的体力活
动模式。在第 0周，4周和 8周时，要求在腰带上佩戴小型加速度计装置以便测量每天
的体力活动。应佩戴连续 5天（一般选择某一周的星期三至星期天），并且每天都要
求全天佩戴。你可以将其戴在上衣或裤子上，这取决于你的个人喜好。当您睡觉、游
泳、洗澡或做任何需要在水中进行的活动时，应脱去装置。在下雨时您可以佩戴装
置，但在这种情况下，我们要求装置放在衣服里面。 
 
第 5部分：膳食评价 
    在研究过程中的第 0周，4周和 8周，需要完成一个为期 4天的膳食评价。这种评
估需要记录连续 4天的饮食情况。要求这期间保持正常的饮食习惯以便提供准确的能
够代表平时的饮食情况的信息。 
 
第 6部分：有氧锻炼 
随机选取一些参与者进行有氧运动训练。如果选择了这个训练，要求在佩戴心率
监视器的情况下进行骑自行车的训练，总共训练 8周，每周 5天，每天 30分钟。训练
将在昆明医科大学护理学院进行。工作人员将监视训练进程。训练将由负荷为 75%的最
大心率开始（大约每分钟 150次），并在 8周的训练时间内进展到 85%的最大心率（约
每分钟 170次）。 
 
第 7部分：允许储存的血液样本用于未来的分析 
    采集的血液样本（如第三部分描述）将用于分析铁含量、炎症和代谢物的浓度。
研究开始后，对您采集的所有标本及其他登记表，都使用代码，避免您的相关信息被
泄露。 
小结（第 1-6部分）： 
持续 8周给予补充剂。在 3个实验时间点（0周，4周和 8周），评价运动试验 2
天/每个运动测试项目，共计 6个运动试验，每个持续 15-30分钟。第一个运动试验通
过戳手指测量血乳酸浓度。第二运动试验期间，分三次采集静脉血（休息时，负荷 1
后，测试结束后），并存储用于以后的营养分析。体力活动评估将需要在三个不同的
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场合连续 5天佩戴加速度装置器加速度计装置，总共有 15天需佩戴装置。最后，如果
参加运动锻炼，锻炼时间为每周 5天每天 30分钟并持续 8周。 
 
风险和不适 
    第 1部分：有些人可能在服用补充剂后出现胃肠不适（腹痛，腹泻，便秘）的情
况。为了尽量减少这种风险，建议你服用补充剂的同时服用维生素 C片，以便助于提
高补充剂的吸收。 
 
    第 2部分：有些人可能会在运动测试后感到疲倦、疼痛甚至晕厥。测试期间，将
监测心率和身体状况，以便将昏厥发生的风险最小化。如果研究人员认为你处于昏迷
高风险期，我们将停止测试并采取适当的预防措施来降低这种风险。试验完成后将提
供水和零食的，以促进全面恢复。 
 
    第 3部分：从胳膊处抽血的缺点/风险，如轻微出血、擦伤或感染。为了避免这些
风险，由执业医师抽血。如果您确实在抽血后出现出血，擦伤或感染等情况，医生/护
士将免费为您进行治疗。 
 
    第 4-5部分：没有已知的与佩戴加速度计装置或完成相关的膳食评价有关的风
险。 
 
    第 6部分：由于运动试验的风险与日常训练的风险相同，故请参阅第 2部分风
险。 
 
    第 7部分：没有已知的风险是与血液或血清存储相关的。您的个人信息将不会被
储存。样品将被保存只有一个 ID代码，并不能追溯到您。只有主要研究人员有机会接
触这些样本。 
 
优点 
    第 1部分：如果选择接受补铁剂或八珍颗粒，在 8周研究期间您的体内贮存铁量
可能得到改善。 
 
    第 2部分：在运动试验完成后了解您的身体状态。 
 
    第 3部分：在完成血液分析后能了解您的铁含量和炎症状态。 
 
    第 4部分：在日常的基础上了解如何有效的锻炼。 
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    第 5部分：没有已知的对参与者的利益。 
 
    第 6部分：如果选择接受训练，你的身体水平可能在 8个星期的训练期得到提
升。 
 
    第 7部分：没有已知的对参与者的利益。 
 
参与回报 
    在您完成研究要求的所有内容（包括 8周的补充，6次运动试验，3次体育活动评估
以及如果分配到训练组 3次评估饮食和有氧运动训练），为感谢您的参与将送上一份
价值 300人民币的礼物。在研究最后，如果您的血铁水平仍然未达到正常水平，我们
可以为您提供一份研究过程中关于您各种检查结果的报告，以利于您的下一步治疗，
但我们不能再为您提供任何的补充剂。 
 
如果您在本研究中受伤 
在面对任何研究相关活动所导致的伤害时，我们将提供包括急救、应急处理、所
需随访护理等治疗措施。这些治疗费用将通过普通方式由您或您的保险公司支付。如
果您认为您受到了研究相关的损伤，请联系芮溧老师，研究顾问电话为 0871-
65922921。 
 
隐私和保密 
所获得的数据将被安全储存并以匿名形式（没有表示能将您和您的信息联系在一
起）报道。只有负责调查或伦理委员会的成员才可以访问严格保密的原始数据。如果
您符合资格，我们将邀请您参加本次研究。 
 
自愿参与原则 
作为参与者，你有权在任何时候退出筛选试验，并且不需要说明原因或承担负面
后果。退出时无需退回之前所获得的补偿，也对您和这次试验所在学校间的关系无任
何影响。 
 
研究者、医生或赞助的剔出 
研究者、医生或赞助商在任何时候都可能停止研究或将您从研究中剔除。他们应
该是从您的最佳利益判断并做出决定。如果您在相关研究中受伤，如果您需要额外的
或不同的药物/治疗，或者如果您不遵守研究计划。他们可以因为各种行政或医疗原
因，未经您同意而将您从研究中剔除。 
 
如果您有任何的疑问 
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你会得到本知情同意书的复印件。进行此项研究的主要人员为美国康奈尔大学的
研究生劳拉。如果您有任何疑问，请在现场进行咨询。如果你以后有问题，你可以联
系公共卫生学院讲师芮溧，电话 13888531601。如果您有任何问题或关心关于作为研究
的受试者您的权利，你可以联系昆明医科大学或康奈尔大学或访问他们的网站的机构
审查委员会（IRB）来了解参与人权利。 
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您将获得这种形式的副本保存在您的记录。  
 
知情同意书 2 
 
请签字这项研究中，你同意参加的每个部分：  
 
第 1部分 - 补充：____________  
 
第 2部分 - 运动测试：______________  
 
第 3部分 - 抽血：________________  
 
第 4部分 - 身体活动评估：_____________  
 
第 5部分 - 膳食评估：_____________  
 
第 6部分 - 运动训练（如随机分配）：___________  
 
第 7部分 - 多余的血清对未来营养分析存储：____________ 
 
 
同意声明 
我已阅读以上材料，并以了解相关信息。我同意参加本项目的正式研究。 
姓名：           日期：  
  
 
本研究的负责人：                日期：    
 
本知情同意书将被研究保留至研究结束后至少 5年。 
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A3.2 English 
FORM 1B 
We are asking you to participate in a research study. This form is designed to give you 
information about this study.  We will describe this study to you and answer any of your 
questions.   
 
Project Title:   Defining the Functional and Metabolic Role of Iron in the Relationship 
Between Aerobic Training and Physical Performance 
 
Principal Investigator: Laura Pompano 
Division of Nutritional Sciences 
1168 West Chunrong Street, Yuhua Avenue, Chenggong New 
 District 
Kunming, Yunnan Province, China 650500 
Email: lmp262@cornell.edu 
Telephone: (Insert Chinese phone number once acquired)  
 
Cornell Faculty Advisor  Dr. Jere Haas 
    Division of Nutritional Sciences  
220 Savage Hall, Cornell University, Ithaca, NY 14853 USA 
Phone: (607) 255-2665  
Fax: (607) 255-1033  
Email: jdh12@cornell.edu  
 
Chinese Faculty Advisor  Dr. Le Cai 
    Department of Nutrition and Food Sciences 
School of Public Health, Kunming Medical University 
1168 West Chunrong Street, Yuhua Avenue, Chenggong New 
 District 
Kunming, Yunnan Province, China 650500 
Email: caile002@hotmail.com 
Tel: 86-871-5922921 (office)   
 
What the study is about 
The study will be an 8-week study examining how iron deficiency affects and is affected by 
exercise. The study will have two groups of participants: iron deficient non-anemic and 
healthy women. You would be assigned to a group based on your body iron status at 
screening. The primary aim of the study is to clarify the relationship between body iron 
status, aerobic exercise training, and physical performance 
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What we will ask you to do 
Part 1: Supplementation: 
We will ask you to consume either a ferrous sulfate supplement (50mg, twice daily), a Ba 
Zhen Ke Li supplement (600mg, twice daily), or an identical placebo (twice daily) for 8 weeks. 
You will be randomly assigned to one of these three groups. To maintain the integrity of the 
research, we ask that you do not trade supplements with your friends or peers. You will be 
asked to take your given supplement twice daily, and provide records of how often you took 
the supplement each week. To minimize risk of gastrointestinal discomfort, we advise that 
you take your supplements with food. To improve absorption of the nutrients, we advise 
that you consume the supplements with foods containing vitamin C, such as pumelo, 
oranges, or lychee. 
 
Part 2: Exercise testing 
We will assess your physical performance via two exercise tests that will occur at weeks 0, 4, 
and 8 during the study. Each session, the tests will occur over two days. Each test requires 
you to pedal on a stationary cycle ergometer for approximately 15-30 minutes. During the 
tests you will wear a facemask and your heart rate (HR) will be monitored.  
 
The first test is designed to measure your maximum ability to uptake and use oxygen during 
exercise. During the test, we will monitor your blood lactate concentration by collecting a 
small drop of blood from a finger-stick using sterile, disposable lancets. This measurement 
will occur several times during the first test. 
 
The second test is designed to see how efficiently your body is. The test will be conducted at 
three workloads, determined by the results of your first test. After the 2nd and 3rd workloads, 
a licensed phlebotomist will collect 4mL of blood from the antecubital vein in your arm.  
 
Part 3: Blood Draws 
All venous blood draws will be performed by a licensed phlebotomist. Blood will be collected 
at the following points during the study. 
a. At weeks 0, 4, and 8: 4mL of blood will be collected from the antecubital vein in your arm 
while you are in a non-exercised, resting state. A portion of this blood will be used to assess 
hemoglobin. The remainder will be spun down to separate the serum, which will be 
collected, frozen, and stored for later analyses. 
 
b. At weeks 0, 4, and 8: 4mL of blood will be collected after each phase of the 2nd exercise 
test, as described in Part 2 of this document. This blood will be will be spun down to 
separate the serum, which will be collected, frozen, and stored for later analyses. 
 
c. At weeks 0, 4, and 8: several finger sticks will be performed during the first exercise test, 
one at the end of each workload. One drop of blood is needed per finger stick. You will 
receive between 2-5 sticks, depending on your performance during the test. No blood will be 
 
 
 
 
 
 
 
237 
stored from this section. 
 
Part 4: Physical Activity Assessment 
At the beginning of the study, we will ask you to complete a Physical Activity Questionnaire 
that summarizes your typical physical activity patterns.  
 
On three occasions, we will ask you to wear a small accelerometer device on an elastic belt 
around the waist to measure daily physical activity. The device should be worn all day, every 
day for 5 consecutive days including two weekend days. You can wear it under or above the 
clothing, depending on your personal preference.  You should remove the device when you 
go sleep, swim, take a shower, or do any activity that will submerge the device in water. You 
can wear the device if it is raining, but in this situation we request you wear the device under 
your clothing. This assessment will occur once at week 0 and once during weeks 1-8 of the 
study. 
 
Part 5: Dietary Assessment 
At three occasions during the study, you will be asked to complete a 4-day dietary 
assessment. This assessment will require you to record the foods and beverages that you 
consume for a consecutive 4-day period. We request that you maintain your normal dietary 
habits during this period to provide accurate representation of your usual diet.  
 
Part 6: Aerobic training 
Some participants will be randomly selected to participate in aerobic exercise training. If you 
are selected for this training, we will ask you to complete 30 minutes of exercise on a 
training bicycle while wearing a heart rate monitor. Training will occur in the public health 
building of KMU located at: 
 
Department of Nutrition and Food Sciences 
School of Public Health, Kunming Medical University 
1168 West Chunrong Street, Yuhua Avenue, Chenggong New District 
Kunming, Yunnan Province, China 650500 
 
Training will be monitored by our researchers. You will be trained for 8 weeks, 5 days per 
week for 30 minutes each day. The training will begin at a workload equal to 75% of your 
maximum heart rate (approximately 150 beats per minute), and progress in difficulty over 
the 8-week training period up to 85% of your maximum heart rate (approximately 170 beats 
per minute).   
 
Part 7: Permission to store blood samples for future analyses  
The blood samples collected (as described in Part 3) will be analyzed for iron content, 
inflammation, and metabolite concentrations. If you consent, all remaining blood or serum 
samples will be stored at negative 80®C for later nutrient, metabolite, proteome, or genetic 
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analyses in future studies. Stored samples will be de-identified and will have no personal 
information associated with them that could link them to you. 
 
Summary of Requirements (Parts 1-6):  
Supplementation will last for 8 weeks. Assessment of exercise testing will take 2 days per 
session and involve three separate sessions (weeks 0,4, and 8), for a total of 6 exercise tests 
each lasting 15-30 minutes. Finger sticks will be performed during the first exercise test to 
measure blood lactate concentration. Venous blood will be collected three times during the 
second exercise test (at rest, after workload 1, after end of test) and stored for use in later 
nutritional analyses. Physical activity assessment will require wearing an accelerometer 
device for 5 consecutive days on two separate occasions during the study, for a total of 10 
days wearing the device. Finally, if selected for training, training will last 8 weeks and take 
place 5 days a week for 30 minutes each day.  
 
 
 
 
Risks and discomforts 
Part 1: Some subjects may experience gastrointestinal discomfort (cramping, diarrhea, 
constipation) from the supplementation. To minimize this risk, you are advised to consume 
your tablets with meals and vitamin C, which helps improve absorption of the supplement.  
 
Part 2: Some subjects may feel tired, sore, or faint after the exercise tests. During the test, 
we will monitor your heart rate and physical condition to minimize risk of fainting. If the 
researchers consider you at high risk for fainting, we will stop the test and take appropriate 
precautions to minimize this risk. We will provide water and snacks after completion of the 
test to promote full recovery from exercise.  
 
Part 3: The disadvantages/ risks of having blood drawn from the arm are slight bleeding, 
bruising or infection. To prevent these risks, blood will be drawn by a licensed phlebotomist. 
If you do have any bleeding, bruising or infection after the blood draw, you will be cared for 
by the nurse and/or doctor at no cost to you. 
 
Part 4-5: No known risks are associated with wearing the accelerometer device or 
completing the dietary assessment. 
 
Part 6: Please see risks for Part 2, as the risks for exercise testing are the same as the risks of 
daily training. 
 
Part 7: No known risks are associated with storage of blood or serum. Your personal 
information will not be stored. The samples will be stored only with an ID code, which is not 
traceable to you. Only the primary researchers will have access to these samples. 
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Benefits 
Part 1: If selected to receive iron supplementation or Ba Zhen Ke Li supplementation, your 
body iron stores may improve over the 8 week study.  
 
Part 2: You will learn your fitness level after completion of the exercise testing. 
 
Part 3: You will learn your iron and inflammation status after completion of the blood 
analyses. 
 
Part 4: You will learn how physically active you are on a daily basis. 
 
Part 5: No known benefit to participant.  
 
Part 6: If selected to receive exercise training, your fitness level may improve during the 8-
week training period.   
 
Part 7: No known benefit to participant. 
 
Payment for participation 
Upon completion of the study (including the 8 week supplementation, six exercise tests, two 
physical activity assessments, three dietary assessments, and aerobic exercise training if 
assigned to a training group) you will receive a gift for your participation valued at $50 USD, 
or 300元.  
 
Privacy/Confidentiality  
The obtained data will be stored safely and reported in an anonymous form with no 
identifiers that can associate you with your data. Only the responsible investigators will have 
access to the original data under strict confidentiality.  
 
Taking part is voluntary 
As a participant, you have the right to withdraw from the study at any time without needing 
to specify any reasons or facing negative consequences. Withdrawing will have no effect on 
the compensation earned before withdrawing or on your relationship with the universities 
involved with the research. 
 
Withdrawal by investigator, physician, or sponsor 
The investigators or KMU physicians may stop the study or take you out of the study at any 
time should they judge that it is in your best interest to do so, if you experience a study-
related injury, if you need additional or different medication/treatment, or if you do not 
comply with the study plan. They may remove you from the study for various other 
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administrative and medical reasons. They can do this without your consent. 
If you have questions 
The main researcher conducting this study is Laura Pompano, a graduate student at Cornell 
University. Please ask any questions you have now. If you have questions later, you may 
contact Laura Pompano at lmp262@cornell.edu (I will insert my Chinese phone number here 
once I acquire it in China). If you have any questions or concerns regarding your rights as a 
subject in this study, you may contact the KMU or Cornell Institutional Review Board (IRB) 
for Human Participants at: 
 
KMU: 
*I will insert this information as soon as Dr. Cai provides it to me. * 
 
Cornell:  
+1-607-255-5138   
http://www.irb.cornell.edu.  
 
You may also report your concerns or complaints anonymously through Ethicspoint online at 
www.hotline.cornell.edu or by calling toll free at 1-866-293-3077. Ethicspoint is an 
independent organization that serves as a liaison between the University and the person 
bringing the complaint so that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
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Statement of Consent 
I have read the above information, and have received answers to any questions I asked. I 
consent to take part in the study.  
 
Please initial for each part of the study in which you agree to participate: 
 
Part 1 – Supplementation:  ____________ 
 
Part 2 -  Exercise testing: ______________ 
 
Part 3 – Blood draws:  ________________ 
 
Part 4 – Physical Activity Assessment: _____________ 
 
Part 5 – Dietary Assessment: _____________ 
 
Part 6 – Daily exercise training (if randomly assigned): ___________ 
 
Part 7 - Storage of excess blood serum for future nutritional analyses: ____________ 
 
 
Your Signature         Date  
  
 
Your Name (printed)          
   
 
Signature of person obtaining consent       Date 
   
 
Printed name of person obtaining consent       
   
 
This consent form will be kept by the researcher for at least five years beyond the end of the 
study 
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A4: VO2max testing form 
Test Title: VO2max 
 
Subject Name:_____________________    Date:       
 
Height:   (cm)   Weight:   (kg)   Age:   ___        
 
Max HR ______________     MaxHR +/- 10 BPM: ________        
 
Temperature:_________       Barometric Pressure:______       Rel. Humidity:________ 
%  
 
Test Start Time:       
 
Mask Size:   Pet     XS      Sm        
 
Seat Height: _______ 
 
Time 
(min) 
Heart 
Rate 
RPM Work Load 
(kg) 
WL# Legs have 
feeling? 
Breathing 
faster? 
0:00 
(start) 
 Start 
Test 
Start Test Start yes/no yes/no 
1:00   1        kg Warm-up   
2:00   1        kg Warm-up   
3:00   1        kg Warm-up   
4:00   1        kg Warm-up   
5:00             kg WL1   
6:00             kg WL1   
7:00             kg WL2   
8:00             kg WL2   
9:00             kg WL3   
10:00             kg WL3   
11:00             kg WL4   
12:00             kg WL4   
13:00             kg WL5   
14:00             kg WL5   
15:00             kg WL6   
16:00             kg WL6   
17:00             kg WL7   
18:00             kg WL7   
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Post-Test Blood Lactate Level: _____________ mmol 
A5: Daily Log (English and Chinese) 
A5.1 Chinese 
口服补充剂日志 
受试者 # _____             周  _____ 
1 请每天准确记录你是否吃丸剂 
 周一 周二 周三 周四 周五 周六 周日 
 
早上 
 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 
晚上 
 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 
2. 下面每个问题，请你表示是或否  
 周一 周二 周三 周四 周五 周六 周日 
你在来月经吗？  是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
你是否出现胃肠问
题？ 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
 是 
 否 
你是否患其他疾病
或受外伤？如果是
，请简要描述。 
 
 是 
 否 
问题： 
 是 
 否 
问题： 
 是 
 否 
问题： 
 是 
 否 
问题： 
 是 
 否 
问题： 
 
 是 
 否 
问题： 
 
 是 
 否 
问题： 
 
 
你是否吃了别的药
？如果是，请简要
描述。 
 
 是 
 否 
药： 
 是 
 否 
药： 
 是 
 否 
药： 
 是 
 否 
药： 
 是 
 否 
药： 
 是 
 否 
药： 
 是 
 否 
药： 
你是否参与体力活
动？如果是，请简
要描述。 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
 
 是 
 否 
活动： 
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多久？ 
 
多久？ 多久？ 多久？ 多久？ 多久？ 多久？ 
A5.2 English 
Capsule ingestion log  
Subject # _____  Week # _____ 
For each day, please indicate whether you took your pill in the morning and evening. 
 Monday Tuesday Wednesda
y 
Thursday Friday Saturday Sunday 
Morning 
 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
Evening 
 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 
For each question below, please indicate yes or no.  
 Monday Tuesday Wednesd
ay 
Thursday Friday Saturday Sunday 
Are you 
menstruating? 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
Did you have GI 
complaints? 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
Did you have 
other illness or 
injury? If yes, 
please describe. 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
Did you consume 
other 
medications? If 
yes, please 
describe.  
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
Did you engage in 
physical activities? 
If yes, please 
describe. 
 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
 Yes 
 No 
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A6: Four-day Diet Record (English and Chinese) 
 
Instructions for Completing the 4-Day Food Record 
 
It is extremely important that you take this part of the study seriously. We need for you to be 
as complete and specific as possible.  
 
1. Please write down everything you eat or drink as soon as possible after you consume it 
for the next four days.  
2. Include anything you “eat”, including hard candy, gum, etc.  
3. Please fill out each column for each food item  
a. Type of Food—We need to know what types of foods you eat so that we can 
determine the nutrients in your overall diet. 
b. Time – We need this to see if timing of eating makes a difference in the things 
we are measuring 
c. Place –We need to know where you ate the food so that we can use cafeteria 
recipes to figure out what all of the ingredients are. 
d. Amount – We need this to be able to enter your food intake correctly into the 
computer.  
 
Here are some tips for estimating the amount of food you eat.  
• Try to use amounts such as grams, etc. if possible, but just describe the volume if you 
are not sure. 
• If the item is a standard size at a restaurant, you can just say exactly what the item was 
and what size (small/medium/large, 10cm/20cm, single/double, etc.) – remember to 
say WHERE you ate. 
• If you make the food yourself, tell us how many pieces/slices of EACH ingredient in 
stir fry, how much of EACH sauce or topping, etc.  
• For drinks, tell us whether it was regular or diet, sweet or unsweetened, and the SIZE 
(small/medium/large, 500mL/1L), and anything you added (i.e. 珍珠, sugar, etc.)  
• If the item is one “pack” or “package”, please tell us the size of the package – should 
be on the package itself  
• For any foods that you can, especially rice/馒头/面包, etc., please tell us the BRAND 
NAME and PRODUCT NAME of the food you ate. 
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指导完成为期 4天的饮食记录 
 
您采取这部分研究的严重是极其重要的。我们需要你尽可能完整和明确化。 
1. 请写下所有你吃或尽快与您使用它在未来四年天后饮用。  
2. 包括任何你“吃”，包括硬糖，口香糖等。  
3. 请填写各栏每一个食品项目  
a. 类型食品，我们需要知道你吃什么类型的食物，这样我们就可以在你的
整体饮食决定的营养素。  
b. 时间 - 我们需要这个，看看吃的时机使得我们所测量的东西有差别  
c. 地方 - 我们需要知道你在那里吃饭，这样我们就可以使用食堂菜谱找出
所有的成分都是。  
d. 量 - 我们需要这是能够正确输入您的食物摄入到计算机。  
 
下面是估算的食物你吃的量的一些技巧。  
• 尽量使用如克等，如果可能的数量，而只是描述了音量，如果你不能确定。  
• 如果项目是在一家餐厅标准尺寸，你可以说正是这个项目是什么尺寸（小/中/
大，10厘米/ 20厘米，单/双，等） - 记得说你吃了。  
• 如果你自己做的食物，告诉我们有多少个/每种成分的翻炒，多少每个酱或摘心
片等。  
• 适用于饮料，告诉我们，无论是规律或饮食，甜或不甜的，和你增加的大小
（小/中/大，500毫升/公升），和任何东西（即珍珠，糖等）  
• 如果该项目是一“包”或“包”，请告诉我们包的大小 - 应该是在包装本身  
• 对于任何食物，你可以，特别是大米/馒头/面包等，请告诉我们你吃的食物的
品牌名称和产品名称。 
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ID # ___________      第一天 
食物的种类 
你在哪儿吃？ 
（家庭，食堂，
餐厅等） 
什么时候
吃？ 
你吃了多少这种菜？ 
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ID # ___________      第二天 
食物的种类 
你在哪儿吃？ 
（家庭，食堂，
餐厅等） 
什么时候
吃？ 
你吃了多少这种菜？ 
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ID # ___________      第三天 
食物的种类 
你在哪儿吃？ 
（家庭，食堂，
餐厅等） 
什么时候
吃？ 
你吃了多少这种菜？ 
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ID # ___________      第四天 
食物的种类 
你在哪儿吃？ 
（家庭，食堂，
餐厅等） 
什么时候
吃？ 
你吃了多少这种菜？ 
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Appendix B: AJCN Publication Reprint 
 
 
The following 10 pages contain the publication that resulted from the work 
reported in Chapter 3. The citation for this publication is: 
 
Pompano, LM and Haas JD. Efficacy of iron supplementation may be misinterpreted 
using conventional measures of iron status in iron-depleted, nonanemic women 
undergoing aerobic exercise training. Am J Clin Nutr. 2017 Dec;106(6):1529-1538. 
doi: 10.3945/ajcn.117.152777. Epub 2017 Nov 1. 
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